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M alaria immunology 
Aims /  Thesis outline
Chapter 1
Chapter 1
Preface
The focus of this thesis is the regulation of human cellular cytokine responses against 
malaria parasites. To fully appreciate this field and its contribution to the control of 
malaria, in particular malaria vaccine development, some understanding is first helpful 
of the global burden of malaria and issues affecting alternative methods of control. The 
first section of this introductory chapter therefore sets out to cover in overview the most 
essential facets of the global burden of malaria, with reference to the immunological 
implications of each: the bigger picture, so to speak, from a prospective immunologist’s 
perspective. Section two of this introductory chapter then provides a concise synopsis 
of a number of central issues in malaria immunology and malaria vaccine development, 
in the process introducing in more depth the central topic of this thesis: the regulation of 
cellular cytokine responses. This introductory chapter concludes with a summary of the 
aims and outline of this thesis.
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The global burden o f malaria
At the turn of the millennium, the scourge of malaria was seen as a problem of such 
global significance, that its control was enshrined as a specific goal in the United 
Nations’ Millennium Declaration [1]. Partly due to this renewed attention, the first 
decade of the 21st century has witnessed for the first time since the 1980s a reduction in 
malaria transmission in many of the most-effected parts of the world [2]. Despite these 
more than welcome successes, achievement of Millennium Development Goal 6.3 
appears a long way off [3] and malaria today remains responsible for an intolerable 
burden of morbidity and mortality [4].
Aetiology, distribution & epidemiology
Human malaria can be caused by five species of protozoan parasite of the genus 
Plasmodium: P. falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi [5, 6]. 
Global distribution of these species differs, with P. falciparum  being the most widely 
prevalent. Transmission of malaria parasites from one human host to the next requires 
an Anopheline mosquito vector and thus it is the climatic and environmental factors that 
restrict mosquito survival that ultimately determine global malaria distribution. 
Whereas marginal areas of formerly low-transmission in relatively highly developed 
parts of the world, including Europe, North America and Australia have become 
malaria-free over the course of the previous century, the disease is still prevalent 
throughout most of the tropics including Southeast & South Asia, Central & Southern 
America and above all sub-Saharan Africa [7]. As of 2006, 3.3 billion people in 109 
countries lived within the confines of the disease [8] (Fig. 1).
Figure 1. Global malaria distribution
Estimated incidence of malaria per 1000 population (2006). Source: [8]
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However, both transmission pattern and intensity vary enormously throughout this area, 
with zones of perennial transmission around the equator, seasonal transmission in areas 
with a clear-cut rainy season such as the Sahel and peripheral regions with unstable 
epidemiological transmission [9]. These variations in transmission pattern and intensity 
have a crucial effect not only on the magnitude of the disease burden, but also on the 
acquisition of immunological protection in exposed populations and through it on the 
age distribution and clinical manifestation of that burden [10, 11]. Regional differences 
also exist in both parasite species and parasite strains, but to what extent cross-reactive 
(protective) immune responses develop against parasites from other areas remains 
controversial (reviewed in [12]). Finally, the global distribution of malaria overlaps 
with that of many other widely prevalent (tropical) pathogens, including in particular 
helminth infections, which may modulate immune responses to malaria parasites 
(reviewed in [13]).
Global estimates of the annual incidence of malaria infection are difficult to compile 
accurately, but a figure of 250-450 million is estimated [4, 14]. Although the vast 
majority of these cases do not result in life-threatening disease (an interesting 
immunoevolutionary point in its own right [15]), the sheer numbers involved means that 
malaria still remains responsible for an approximated 900,000 deaths a year, 
predominantly due to P. falciparum infection amongst children under five in sub- 
Saharan Africa [4]. Indeed, overall malaria forms the third largest infectious cause of 
death after HIV/AIDS and tuberculosis and ranks fourth after only pneumonia, 
diarrhoea and prematurity in total under five mortality [16].
Malaria life-cycle
Malaria is transmitted to the human host by female mosquitoes of the genus Anopheles, 
when they take a blood meal which they require for egg development (Fig. 2). Invasive 
forms of the parasites, known as sporozoites, reside within the mosquito’s salivary 
glands and are unwittingly introduced into the host’s skin by the probing mosquito. 
These motile sporozoites migrate through the dermal tissue until they enter a blood 
vessel and are carried to the liver. Many sporozoites fail to reach a blood vessel 
however and either perish in the dermal tissue or enter a lymph duct from where they 
are transported to the draining lymph node [18, 19]. These misdirected sporozoites may 
be taken up by antigen-presenting cells and play an important role in priming the 
immune system [20].
Sporozoites that do reach the liver cross the sinusoidal wall by traversing the resident 
phagocytic Kupffer cells without activating them [21] and subsequently traverse several 
hepatocytes [22]. Eventually, the sporozoite chooses a hepatocyte in which to mature 
through trophozoite and schizont stages, meanwhile undergoing multiple mitotic 
divisions. It is possible that this tissue tropism developed in order to exploit the liver’s 
tolerogenic microenvironment [23]. Some 6 days after inoculation, an estimated 40.000 
merozoites per infected hepatocyte are released into the circulation enclosed in a 
temporary membrane (merosome) [24, 25], presumably another strategy to avoid 
immune recognition. The liver-stage infection generally passes asymptomatically.
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Merozoites in circulation rapidly invade erythrocytes (RBC), where they again mature 
through trophozoite to schizont stages and divide, eventually rupturing the erythrocyte 
and releasing 16-32 new merozoites into circulation. These new merozoites again 
invade RBCs, leading to an exponential cyclical increase in parasitaemia. This cycle 
takes approximately 48 hours in most human Plasmodium species and underlies all 
clinical symptoms related to malaria (see also below). The choice of erythrocytes as 
host cell furthermore appears immunologically beneficial to the parasite, since RBCs 
lack the cellular machinery to process and present (non-self) antigen to the immune 
system in MHC context. In P. falciparum, mature parasite-infected erythrocytes 
(PfRBC) express surface proteins which allow adhesion to deep vascular endothelium 
(sequestration). This adaptation is believed to be a parasite strategy to avoid filtration 
through the spleen, and the antigenic diversity and variation in these surface proteins is 
another important immune evasion mechanism employed by the parasite (reviewed in
e.g. [26]).
A small proportion of parasites mature into male or female gametocytes, the only sexual 
stage in the plasmodium life cycle. Sexual stage parasites are in themselves not 
pathogenic and although they induce immune responses in the host [27], such responses 
cannot contribute to clinical protection. These gametocytes may be taken up in the 
blood meal of a new mosquito, where in the mosquito midgut male and female gametes 
fuse to form an ookinete. The ookinete invades the mosquito midgut wall, forming an 
oocyst which eventually releases new sporozoites that migrate to the mosquito salivary 
glands, ready to start a new cycle.
This complicated life-cycle, with multiple stages and rapid multiplication, stage-specific 
antigens and antigenic variation, has generally been considered an obstacle to the 
development of protective immunity through either natural exposure or a vaccination 
strategy, since immunity must be developed to each stage individually. On the other 
hand, the parasite’s life cycle can also be seen as extremely constrained with regards to 
tropism and numerous bottlenecks in development that represent vulnerabilities to be 
exploited [28]. Furthermore, many important antigens are conserved across both stages 
and strains and represent excellent candidates for cross-reactive protective immune 
responses (e.g. [29, 30]).
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Figure 2. Life cycle of Plasmodium parasites in human host and mosquito vector
Reproduced from [17] with permission.
Pathology and symptoms
The symptoms and pathology of malaria infection can all be attributed to the blood- 
stage cyclical multiplication of parasites. Upon rupture of the mature infected 
erythrocyte, debris and toxins are released that induce pro-inflammatory and pyrogenic 
responses by phagocytes [31, 32]. Since most species of malaria have evolved 
synchronous parasite growth, a large a number of simultaneously rupturing infected 
erythrocytes can cause systemic symptoms including the classic triad of chills, fever and 
profuse sweating every 48-72 hours, accompanied by more general flu-like symptoms 
of headache, malaise, myalgia and arthralgia.
Life-threatening manifestations of malaria are almost solely associated with P. 
falciparum  infection, due to the ability of infected erythrocytes (PfRBC) to avoid 
splenic clearance by adhering to deep capillary endothelium, (reviewed in [33]). This 
can result on the one hand in hyperparasitaemia, on the other in local inflammation, 
vascular occlusion and ultimately organ failure. Manifestations of severe malaria tend 
to vary with age, with young children being especially susceptible to severe anaemia,
12
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metabolic acidosis and respiratory distress, whereas older children show the greatest 
burden of cerebral malaria, and ARDS and acute renal failure are almost exclusively 
seen in adults (reviewed in e.g. [34]). Although the pathophysiological processes 
underlying these various manifestations are still not fully understood, immunological 
factors, e.g. prior exposure and maturity of the immune system, are believed to underlie 
the differences observed. In particular, inappropriate pro-inflammatory responses may 
contribute to pathogenesis (reviewed in [35, 36]). A special manifestation of organ- 
related malaria is placental infection in primi- and paucigravid women [37].
Host genetics and susceptibility to malaria
This burden of morbidity and mortality, combined with its target of primarily young, 
pre-pubescent children, means that malaria has exerted a strong selective pressure on 
human populations for at least the last 10.000 years. Such selective pressure is visible 
today in the genetic make-up of humans from malaria-endemic areas [38]. Indeed some 
of the oldest and best-studied human genetic variations, those of the haemoglobin 
genes, including the HbS and HbC variants and a- and p-thalassaemias are found in 
African populations as a result of selection by malaria [39]. Malaria has furthermore 
exerted strong selective pressure on the immune system [40-44]. Nevertheless, 
differences in susceptibility to malaria continue to exist between both individuals and 
populations in endemic areas [45, 46] to which other, as yet undiscovered, genetic 
factors may contribute [47].
The socio-economic context of malaria infection
As can be appreciated from Figure 1, malaria occurs mainly in low-income countries
[48]. Within those countries there furthermore appears to be an inverse relationship, 
although less clear-cut, between malaria burden and household income (reviewed in
[49]). In part this is due to lower uptake of treatment and control measures by poor 
households [49], potentially including use of future malaria vaccines. In any case, this 
association with poverty, in particular poor access to health care, low coverage of 
vaccination, concomitant malnutrition and the overlapping global distribution of other 
(parasitic) infectious diseases and H IV, mean that the immunology of malaria should 
best be studied in the context of general poor health and co-infections [50, 51].
Malaria in turn is itself responsible for an enormous economic burden on both 
individuals and states due to medical expenses, missed education and lost productivity. 
It has been estimated that, corrected for co-variables, the GDP of countries endemic for 
malaria grows at 1.3% per year slower than countries which are malaria-free; this has 
left such endemic countries with GDPs per capita of less than 33% of those of non­
endemic countries [52], even after correction for confounding historical, geographical, 
climatological and socio-cultural factors. Malaria and poverty thus represent partners in 
a vicious cycle and malaria may truly be classified as a poverty-related disease [48].
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Control measures
Not until the turn of the 21st century, following more than 3 decades of disillusionment 
(reviewed in [53]), has the incidence of malaria once again started to drop in many 
regions of Africa [2], facilitated by increased funding for control &  research, e.g. the 
Global Fund to Fight AIDS, Tuberculosis &  Malaria. Indeed, first proposed by the B ill 
&  Melinda Gates Foundation in 2007 [54], a renewed ambition to eliminate malaria has 
since been adopted by the WHO [55, 56]. The recent discovery of primate reservoirs of 
human malaria parasites may yet again complicate this ambition, however [57-60].
Efforts to control or eradicate malaria have traditionally fallen into two main categories: 
vector control and chemoprophylaxis/chemotherapy. The goal of vector control is to 
lim it human exposure to infected mosquito bites, by either eliminating the mosquito 
itself or preventing mosquito-human interaction. Methods have included habitat 
destruction (e.g. swamp drainage), large-scale insecticide spraying (e.g. DDT), small- 
scale insecticide spraying (e.g. indoor residual spraying), biological agents such as 
larvivorous fish and insecticidal fungi, and the distribution of insecticide-impregnated 
bed-nets (reviewed in e.g. [61]).
Anti-malarial drugs can be used to both treat and prevent malaria. Following the failure 
of chloroquine (CQ) and to a lesser extent sulphadoxine-pyrimethamine/amodiaquine as 
effective anti-malarial treatment due to wide-spread parasite resistance, a new class of 
drug, the artemisinin-derivatives, has proved highly efficacious, particularly in 
combination with a longer acting partner-drug (artemisinin combination therapy - ACT) 
[62]. Nevertheless concern has been raised over the possible emergence of resistance to 
artemisinins [63] and hence the need to develop new classes of anti-malarial drugs 
(reviewed in [64, 65]). Whereas continuous mass causal-prophylaxis is not a 
realistically obtainable goal in most endemic areas, intermittent presumptive treatment 
programmes in infants (IPT i) [66] and pregnant women (IPTp) [67] have been 
successful in reducing the burden of malaria in these vulnerable groups.
Both vector control and chemotherapy have in the past raised fears of a rebound-effect, 
i.e. a relative increase in malaria burden following discontinuation of control measures, 
due to lack of acquired protective immunity in individuals shielded from immunological 
exposure [68, 69]. However, meta-analysis of IPT i has since allayed such concern [66]. 
Indeed, although such interventions lead to a delay in the development of immunity and 
a small (non-significant) rise in the cumulative rate of uncomplicated malaria cases, the 
cumulative rate of severe malaria, particularly severe anaemia, actually decreases [70]. 
To what extent the above control measures have contributed to the reduction of malaria 
transmission in many endemic areas in the course of the first decade of the 21st century 
remains controversial (reviewed in [2]). In any case, despite these welcome reductions, 
malaria today still remains widely prevalent in endemic areas and responsible for an 
intolerable burden of morbidity and mortality [3]. Successful control of malaria, as 
enshrined in Millennium Goal 6.3, w ill therefore require continued commitment and 
financial support for existing control strategies, in addition to new control tools, of 
which an effective malaria vaccine w ill be one of the most crucial [71] (Box 1).
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Box 1. M alaria vaccines
A brief history
The prospect of attainable vaccination against malaria was first raised by seminal experiments in 
the ‘60s and ‘70s demonstrating that radiation-attenuated sporozoite infections could induce 
sterile protection against subsequent patent challenge in both mice [72] and humans [73]. 
Dissection of immune responses in these vaccinees and in naturally-exposed populations in search 
of correlates of protection led to the identification of immunodominant parasite antigens and the 
development of sub-unit vaccines, e.g. [74-76]. In the early ‘90s hopes were raised by the success 
of SPf66, a chemically synthesised blood-stage vaccine, which proved itself successful in Latin 
America [77-79]; unfortunately protection could not be reproduced in African and Asian 
populations [80, 81]. Since then many promising vaccine candidates have failed to demonstrate 
protection in field trials, e.g. [82-84]. The only vaccine to have successfully made it into large- 
scale phase III trials in endemic settings is RTS,S, a recombinant product based on the 
circumsporozoite protein (reviewed in [85]); it is currently planned for full licensure in 2012-14. 
The partial protection induced by this vaccine in African children [86, 87] and infants [88-90] is 
encouraging, although the ultimate success of this approach remains to be determined.
Stage-specificity
Malaria vaccines have traditionally been categorised as either pre-erythrocytic, blood-stage or 
transmission-blocking. Pre-erythrocytic vaccines aim to prevent sporozoite invasion of 
hepatocytes and/or liver-stage development [91]. Blood-stage vaccines should interrupt or slow 
asexual parasite multiplication [92] and/or prevent pathology by inhibiting PfRBC sequestration 
or neutralising toxins [93]. Transmission-blocking vaccines may prevent the spread of malaria 
from infected humans to others through mosquitoes [94]. This strict distinction is questionable, 
however, since many prominent vaccine candidate antigens are shared between stages [29, 30].
Vaccine design
Because of seemingly insurmountable logistical hurdles associated with mass-producing an 
irradiated sporozoite vaccine, attention turned to the development of sub-unit vaccines. Various 
approaches have been developed, including synthetic peptide [95], recombinant protein [96] and 
DNA- or (viral) vector-based vaccines [97, 98]. Relative disillusionment with the achievements 
of sub-unit vaccines has however led to renewed interest in attenuated whole-parasite vaccines for 
malaria, which it is hoped will induce broader and more robust immunity. Such attenuation can 
be achieved in sporozoites by radiation [99], chemically [100] or genetically [101], but can also 
be applied to blood-stage parasite vaccines [102].
Current issues
The onus on sub-unit vaccine development in the near future will be to induce sufficiently strong 
and/or broad, long-lasting immune responses to provide robust protection in naturally-exposed 
populations; the development of new adjuvant strategies may be a way forward in this regard 
[103]. Whole-parasite based vaccines in turn still face a number of logistical and regulatory 
hurdles. Ultimately, however, the success of either approach will also require clearer 
understanding of what constitutes protective immunity against malaria in humans.
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M alaria immunology
Despite many years of research and a considerable accumulated knowledge-base 
regarding protective immunity in malaria, a fully effective malaria vaccine is still not 
available [104]. It is believed that further dissection of the precise immunological 
effector mechanisms contributing to protection and their fine-regulation w ill therefore 
first be required. In addition to being a sine qua non for the development of an effective 
malaria vaccine, the holy grail of malaria immunology, the study of immunological 
processes in malaria may help predict and tailor the effect of non-immunological 
malaria control programmes such as bed-net distribution [105-107] and intermittent 
presumptive treatment (reviewed in [108]). Finally, research into this in many ways 
unique host-parasite symbiosis has uncovered a number of novel immunological 
concepts in their own right, e.g. antibody-dependent cellular inhibition (ADCI) [109].
Evidence for induction of protective immunity against malaria in humans
Evidence for protective immunity against malaria in humans, and hence the rationale for 
the development of a malaria vaccine, is derived from both naturally-exposed 
populations and experimental human malaria infections in previously-unexposed 
volunteers.
Naturally acquired immunity - In highly endemic regions, the burden of malaria is not 
equally distributed across age strata, but falls primarily on infants [110]. Whereas in 
less-endemic regions such as Southeast Asia and Latin America adults remain 
susceptible to (severe) clinical malaria, older children and adults in highly endemic 
areas of Africa with time experience fewer and less severe episodes, in other words they 
develop immunity to malaria [111]. The pattern of immunological acquisition is 
particular to malaria and develops in three steps (Fig. 3).
—  Severe
—  Mild
—  Parasite
~ i  . .
50 permission.
Figure 3. Age-dependent 
susceptibility to severe 
malaria, mild malaria and 
asymptomatic parasite 
carriage in an endemic area 
Susceptibility is shown as a 
percentage of maximum 
recorded period prevalence. 
Reproduced from [111], with
0 10 20 30 40
Age
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i. Immunity to severe disease & death. In highly endemic areas, the peak incidence of 
severe malaria and death lies between 2-4 years of age; thereafter, although children still 
regularly develop symptomatic episode, they tend no longer to develop severe 
complications or die. ii. Immunity to symptomatic infection. In older children and 
adults, the incidence of clinical malaria episodes also starts to drop, although adults 
remain susceptible to occasional episodes. iii. Immunity to parasitaemia. Finally, the 
prevalence of asymptomatic infection declines, as determined by detection of blood- 
stage parasites in circulation, although even adults do not achieve continued sterile 
protection. Thus naturally-acquired immunity to malaria exists, but requires repeated 
exposure to develop, continued exposure to sustain, and even then remains incomplete 
(reviewed in [12, 112]).
Figure 4. Stage-specific targets of immunity against malaria parasites
Pre-erythrocytic immunity: A. Inhibition of sporozoite motility or hepatocyte invasion. B. 
Inhibition of intra-hepatic development. Blood-stage immunity: C. Inhibition of RBC 
invasion D. pRBC clearance by the spleen E. Prevention of PfRBC 
adhesion/sequestration F. Neutralisation of parasite-derived toxins Transmission-blocking 
immunity: G. Prevention of gametocyte uptake by mosquito bite H. Inhibition of zygote 
formation or development. Note: E. and F. primarily represent anti-disease immunity. 
For a more extensive review of stage-specific immune effector mechanisms in malaria, 
the reader is referred to e.g. [111]. Figure modified from [17] with permission.
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Experimentally-induced immunity - It has been recognised since the days of malaria 
therapy that partial immunity against malaria can be induced by repeated infection in 
previously unexposed humans [113, 114]. However, fully sterile immunity can also be 
achieved in human volunteers by a number of experimental approaches, the best-known 
of which is inoculation of gamma-irradiated sporozoites by mosquito bite (reviewed in 
[115]). Thus immunity to malaria can also be induced in humans experimentally, 
although the duration of such immunity appears to be of short duration (months-years). 
Since the immunological mechanisms underlying both naturally-acquired and 
experimentally-induced immunity to malaria remain only partially understood, further 
dissection of these mechanisms w ill be required to move forward rational malaria 
vaccine development.
Concepts in malaria immunology
Indeed the immunology of malaria is too complex a subject to discuss in its entirety 
here. Instead, a number of general concepts in malaria immunology w ill first be briefly 
discussed, insofar as they are required for contextualising the research described in this 
thesis. Thereafter the central subject of this thesis, cellular immune responses in 
malaria, w ill be introduced in more detail. It should be noted that the immunology 
described in this thesis focuses exclusively on responses against P. falciparum, which 
forms the most widely prevalent and clinically significant species of human malaria.
Stage-specific immunity - Immune responses against malaria parasites have traditionally 
been categorised as either pre-erythrocytic immunity (against sporozoites and intra- 
hepatic parasites), blood-stage immunity (against free merozoites and intra-erythrocytic 
asexual forms) or transmission-blocking immunity (against gametocytes and gametes), 
for reasons of conceptual functionality (Fig. 4). Pre-erythrocytic immunity in itself 
does not prevent clinical disease unless it is 100.0% effective - even a single merozoite 
emerging from the liver is theoretically sufficient to produce exponential blood-stage 
parasitaemia. On the other hand, the relatively low microbial burden at the pre- 
erythrocytic stage makes such sterile immunity more readily attainable; furthermore, 
even partial pre-erythrocytic immunity may contribute to clinical protection by 
preventing the subsequent overwhelming of blood-stage immunity. Sterile blood-stage 
immunity is harder to achieve due to the rapid and exponential multiplication of intra- 
erythrocytic parasites; however, incomplete asexual immunity still contributes directly 
to clinical protection by slowing or even stalling parasite growth. Transmission- 
blocking immunity prevents successful transmission of sexual-stage parasites to the 
mosquito vector; although beneficial at a community level by reducing malaria 
transmission, it is of no direct (clinical) benefit to the human host and w ill not be 
discussed further here. The targets and mechanisms of stage-specific immunity are 
discussed in detail elsewhere [27, 116, 117]. Although useful from conceptual 
perspective, it is unclear to what extent naturally-induced immune-responses comply 
with this paradigm, since various evidence has been found for stage-transcending 
immune responses [118-121].
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Anti- disease immunity - In addition to direct anti-parasitic effects, immune responses 
may also protect against clinical disease by preventing pathophysiological phenomena 
of infection, e.g. sequestration [122] or toxin release [93]. The what extent the 
prevention of immunopathology and/or the induction of tolerance can also be construed 
as anti-disease immunity, remains a matter of debate [112, 117, 123, 124].
Components o f  immune responses against malaria parasites - Both humoral and 
cellular components of the innate and adaptive branches of the immune system have 
variously been shown to contribute to immunological responses against malaria 
(reviewed in [111, 116, 117, 125]). Figure 5 provides a schematic overview of the most 
important immunological components of those responses and their interactions, insofar 
as they w ill be referred to in this thesis. Central to interactions between cellular 
components of the immune system in general and to immune responses against malaria 
in particular, are cytokines. Table 1 provides a brief overview of the most important 
cytokines in this regard, that pertain to the research described in this thesis.
Table 1. Important cytokines in immune responses against malaria parasites*
Cytokine Cellular source Function
IFNy T cells, NK cells activation of monocytes/macrophages (increased 
phagocytosis, induction of iNOS and MHC-II 
upregulation), activation of NK cells, Th1 differentiation 
by T cells, class-switching by B cells
IL-1(P) monocytes, DCs endogenous pyrogen, master activator of pro- 
inflammatory immune responses
IL-2 T cells activation and proliferation of T cells and NK cells
IL-4 T cells induction of antibody production by B cells
IL -6 monocytes, T cells endogenous pyrogen, both pro- and anti-inflammatory 
characteristics
IL-10 monocytes, T cells anti-inflammatory, suppression of immune responses
IL-12 DCs, monocytes stimulation of Th1 differentiation by T cells, induction of 
IFNy by T cells and NK cells
IL-18 macrophages, DCs similar to IL-12, induction of IFNy by T cells and NK 
cells
TNFa monocytes, T cells, 
NK cells
endogenous pyrogen, pro-inflammatory
* Listed are cytokines that pertain in particular to the research described in this thesis. (IFNy - 
interferon-gamma, iNOS - inducible nitric oxide synthase, IL  - interleukin, MHC-II - major 
histocompatibility complex class II, TNFa - tumor necrosis factor-alpha)
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Figure 5. Key components of the immune response against malaria parasites and 
their interactions
A. Complement, in conjunction with antibodies, lyses or opsonises pRBC [126-128]. B. 
B-cell derived antibodies inhibit sporozoite motility, block parasite invasion of 
hepatocytes or RBC, lyse or opsonise pRBC (in conjunction with complement), induce 
antibody-dependent cellular inhibition (ADCI), prevent pRBC sequestration and 
neutralise toxins (reviewed in e.g. [129]). C. CD8+ T cells attack infected hepatocytes 
(reviewed in [130]). D. CD4+ T cells provide (cytokine) help to B-cells, phagocytes and 
other T cells (reviewed in e.g. [131]). E. NK cells [132] and yST cells [133, 134] 
recognise pRBC directly through invariant receptors. F. Myeloid cells recognise pRBC 
components through pattern-recognition receptors (PRRs) [135]; dendritic cells (DCs) 
present antigen to T cells [136]; monocytes phagocytise opsonised pRBC [137] and 
contribute to ADCI [109]. Note: negative regulators of the immune response, e.g. 
regulatory T cells (Tregs), are not shown.
Evidence for protective cellular immunity to malaria in humans
Whereas the contribution of humoral responses to naturally-acquired immunity against 
malaria was originally demonstrated in seminal passive transfer experiments [138, 139] 
and has since been extensively delineated (reviewed in [111, 117, 140]), the 
contribution of cellular responses to naturally-acquired immunity has been harder to pin 
down (reviewed [129, 131]). However, the central role of cellular immunity to malaria 
has emerged from studies of experimentally-induced protection in both animal models 
and experimental human malaria infections.
In murine malaria models, cellular responses are required for both pre-erythrocytic 
([116]) and blood-stage protection [131, 141]. Sterile protection in human volunteers
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can be induced by either radiation-attenuated sporozoite exposure [115] or repeated 
blood-stage exposure followed by drug cure [142]. The former method induces both 
CD8+ and CD4+ T cell responses against sporozoite and liver-stage antigens [143­
145]. In the latter model, protection was associated with the induction of cellular but 
not antibody responses [142]. Furthermore, although not fully protective, stronger 
cellular responses were associated with tighter control of parasitaemia in naïve 
volunteers undergoing a primary malaria infection [146]. Finally, cellular responses 
have also been associated with protection in more classical vaccine approaches [147]. 
Thus, it appears that the induction of cellular responses is central to the acquisition of 
artificially-induced immunity against malaria, by whatever approach.
Interferon-gamma (IFNy) is a central mediator of cellular responses
The cytokine IFNy forms a central mediator of immune activation and is known to have 
a multitude of different effects on other components the immune system, including 
inducing cell-mediated immunity by promoting Th1 over Th2 differentiation of T cells, 
inducing IgG class-switching to cytophilic isotypes and activating phagocytes (reviewed 
in [148]). Its source consists predominantly of lymphocytes, including natural killer 
(NK) cells , NKT cells, y5T and apT cells, but also cells of the myeloid lineage [149, 
150]. Its induction is largely dependent on IL-12 and IL-18 production by activated 
myeloid APCs [151, 152], in addition to signals directly activating lymphocytes 
themselves.
IFNy has been shown to be a crucial mediator of the immune response against 
intracellular (myco)bacteria and some viruses [153-155], but is also involved in 
protection against both intra- and extracellular protozoan parasites such as Leishmania 
spp [156], T. cruzi [157] and T. gondii [158] (reviewed in [159]). It is the central 
position of IFNy in (pro-inflammatory) immune responses against malaria that forms a 
principle focus of this thesis.
Unresolved issues in cellular cytokine responses against malaria
Despite the accumulated insight into the role of cellular responses in general, and IFNy 
in particular, in protective immunity against malaria, many crucial issues relating to the 
dynamics of such responses remain insufficiently resolved.
Induction - Immune responses against (pathogenic) micro-organisms are initially 
triggered by the recognition of evolutionarily conserved components of those micro­
organisms, known as pathogen-associated molecular patterns (PAMPs), by pattern- 
recognition receptors (PRRs) on cells of the (innate) immune system. The most 
extensively studied of these are the members of the Toll-like receptor (TLR) family 
([160, 161]). Whereas purified Plasmodium-derived TLR ligands such as GPI anchors 
(recognised by TLR-6/TLR-2 and TLR-1/TLR-2 heterodimers and to a lesser extent 
TLR-4 [162]) and haemozoin [163-165], whether or not with associated parasite DNA 
[166] (both recognised by TLR-9), have been identified in artificial in vitro systems, the 
overall importance of these receptors for the recognition of intact Plasmodium parasites
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by human PBMCs and the downstream production of IFNy remains unknown. 
Furthermore, the role of other innate receptors including the nucleotide-binding 
oligomerisation domain containing (NOD) proteins 1 and 2 [167, 168], C-type lectins 
(including mannan-binding lectin [169], the macrophage mannose receptor, DC-SIGN 
and dectin-1 (reviewed in [170]) in the recognition of Plasmodium parasites and the 
downstream IFNy response have remained practically unexplored, as has direct 
recognition by invariant lymphocyte receptors (e.g. the y5T receptor [133, 134], NK 
(KIR)- [132] and the NKT receptor [171]).
Duration and maintenance - Whereas protective immune responses should ideally 
persist throughout the life of the host, immune responses to malaria are commonly 
believed to be short-lived following exposure, based mainly on the half-life of specific 
antibodies [172-174] (reviewed in [175]). Indeed IFNy responses to individual antigens 
are either relatively short-lived, i.e. declining within a few years of exposure [176, 177], 
or unstable [178-180]. However, proliferative responses to crude whole parasite antigen 
have been detected in donors up to 15 years following a single malaria infection [181] 
and undiminished IFNy effector responses have been witnessed 3 months post-infection 
in previously naïve volunteers [182]. Thus, although responses to individual antigens or 
epitopes may be unstable, the total IFNy response to pRBC can remain remarkably 
long-lived. Which lymphocyte subsets are responsible for maintaining this 
immunological memory and its precise rate of attrition remain unknown, however.
An associated puzzle is the finding that adult residents of highly endemic regions 
produce markedly lower IFNy responses against pRBC than residents of low-endemic 
regions or indeed even non-exposed donors [183, 184]. Whether such down-regulation 
of pro-inflammatory responses represents a beneficial adaptation by the host to avoid 
immunopathology due to repeated or chronic malaria infections [185] or a detrimental 
manipulation of its host’s immune system by the parasite for its own survival advantage 
[186] remains an open question with major implications for successful vaccine 
development (reviewed in [187]). Analysis of the dynamics of cellular responses in 
relation to well-defined single and multiple malaria infections may contribute to 
untangling this relationship.
Influence o f  host genetics on cellular responses - Malaria has exerted strong selective 
pressure on genes involved in both the adaptive [40] and innate immune response [41­
43]. Nevertheless, unexplained differences in susceptibility remain between both 
individuals and populations [45, 46] to which as yet undiscovered genetic factors likely 
contribute [47]. Furthermore, few of these studies have investigated functional immune 
responses as intermediaries in the pathway between genetics and susceptibility. 
Combining forward- and functional reverse-genetic approaches can form a powerful 
tool to delineate the role of individual gene products in cellular immunological 
responses, e.g. IFNy production, the effect of genetic polymorphism on those responses 
and ultimately the associations between both and susceptibility to disease.
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Modulation by the malaria parasite - The malaria parasite itself has also evolved 
various mechanisms of immune avoidance (reviewed in [188]). Inhibition of 
(protective) pro-inflammatory responses appears to be an active strategy pursued by 
malaria parasites, since both innate responses [189-191] and IFNy production are 
suppressed by acute malaria infection [192, 193] and chronic parasitaemia [178, 194]. 
On the other hand, inflammation may be beneficial to the parasite under specific 
circumstances, e.g. up-regulation of endothelial adhesion receptors allowing the parasite 
to sequester in the deep peripheral circulation [195-197], avoiding clearance by the 
spleen. The factors determining the parasite’s tendency towards pro- or anti­
inflammatory modulation of its host’s cytokine response remain incompletely 
understood, however, in particular whether these might differ between acute and 
chronic infection.
Immunopathology - Malaria is characterised clinically by high fevers, often in 
synchronised peaks, which form a manifestation of (pro-)inflammatory immune 
responses to parasite antigen released into the bloodstream upon rupture of mature 
parasitised erythrocytes. Such inflammatory responses serve to activate the immune 
system and inhibit parasite multiplication. However, excessive inflammatory immune 
responses, whether or not secondary to a defect in counter-regulatory anti-inflammatory 
responses, have been implicated in the pathophysiology of various forms of severe 
malaria including cerebral malaria (reviewed in [197]), severe anaemia (reviewed in 
[198]) and respiratory distress, as a manifestation of both systemic metabolic acidosis in 
children [199] and adult respiratory distress syndrome (reviewed in [200]). Whereas 
such immunopathology has primarily been ascribed to other cytokines, in particular the 
classic endogenous pyrogens IL-10, IL-6 and TNFa [41, 201-204], concerns have been 
raised that IFNy may indirectly contribute [205-209]. Many other studies, e.g. [210­
212], have failed on the other hand to demonstrate any such association.
Whether or not the latter proves to be an issue of genuine concern, it is clear that a 
better understanding of the induction, source, duration and modulation of cellular 
cytokine responses against malaria w ill contribute not only to better clinical case- 
management but more importantly to the development of an effective, long-lasting, 
broadly implementable and safe malaria vaccine.
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Aims
The overall aim of this thesis is to further characterise the regulation of cellular cytokine 
responses against malaria parasites in humans, with particular focus on interferon­
gamma (IFNy) production. Specifically, we w ill explore:
i) the molecular pathways by which recognition of malaria parasites by human 
PBMCs leads to pro-inflammatory cytokine production (including IFNy) and the 
manipulation of these pathways by the parasite itself
ii) the dynamics, stage-specificity and cellular source of IFNy responses following 
single or multiple malaria infections in humans
iii) correlations between pro-inflammatory cytokine responses, in particular IFNy, 
and protection against malaria in both experimentally infected malaria-naïve 
volunteers and malaria-endemic human populations
Thesis outline
To address these questions, the core chapters of this thesis are grouped into three 
sections. In addition to dealing with separate immunological issues, each section is also 
characterised by the source of the incorporated data. Together these three sections thus 
form a complementary and comprehensive overview of cellular immune responses in 
malaria.
Section 1. Induction & modulation
This section characterises the molecular pathways of pro-inflammatory cytokine 
induction by PfRBC and the modulation of these pathways by the malaria parasite. The 
strength of these studies lies in the ability to isolate and manipulate individual receptors 
in in vitro systems. Chapter 2 explores the role of innate pattern-recognition receptors 
(PRRs), in particular Toll-like receptors (TLRs) in the induction of pro-inflammatory 
cytokine responses, including IFNy production, against whole PfRBC. Chapter 3 
focuses on the pro-inflammatory modulation of such TLR responses by the malaria 
parasite - a feature unique amongst other micro-organisms, which is in turn a direct 
consequence of those same IFNy responses.
Section 2. Dynamics, stage-specificity and cellular source
This section explores the characteristics of IFNy responses induced by precisely defined 
single and multiple malaria infections with regards to duration of recall, antigen 
specificity and cellular source. The collection of these unique data is possible only 
within our centre’s ongoing programme of experimental human malaria infections 
(EHM Is), whereby malaria-naïve volunteers undergo patent P. falciparum infection by 
mosquito bite under highly controlled circumstances and subsequent curative treatment. 
Chapter 4 focuses specifically on the ‘memory-like’ IFNy response by ‘innate’ NK 
cells following exposure and their dependency on T cells for full activation - a case of
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back-to-front immunology. Chapter 5 describes the longevity of IFNy responses 
against malaria parasites following infection, their specificity for the different life-cycle 
stages of the malaria parasite and their respective cellular sources over the course of 
time.
Section 3. Correlations with protection
This section investigates IFNy responses against PfRBC  as correlates of protection, 
specifically the control of parasitaemia, in both malaria-naïve volunteers and semi­
immune African adults. Besides EHM Is, this section incorporates data from ongoing 
field studies examining interethnic differences in susceptibility to malaria amongst 
sympatric semi-immune African populations. Chapter 6 describes a unique model of 
protective immunisation of malaria-naive volunteers by exposure to chemically- 
attenuated whole parasites and the correlation between induced cellular cytokine 
responses and protection in those volunteers. Chapter 7 demonstrates the value of 
early IFNy responses against PfRBC  as a correlate of protection in malaria-endemic 
populations, specifically explaining interethnic differences in susceptibility to 
parasitaemia. Chapter 8 next explores the effect of ethnic polymorphism in caspase- 
12, a gene believed to be important in modulating pro-inflammatory cytokine 
production, on IFNy production against PfRBC  and its subsequent effect on 
susceptibility to malaria.
Discussion & summary
The final chapters of the thesis summarise and bring to a conclusion the previous 
sections. Chapter 9 discusses the results described in this thesis in the light of 
previously published literature on cellular cytokine responses in malaria. In particular, 
it highlights the central role of IFNy in such responses, its association with clinical 
protection and the implications of this for rational malaria vaccine development. 
Chapter 10, finally, summarises the main conclusions of this thesis in English and in 
Dutch.
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Abstract
Blood-stage malaria is characterized by high fevers induced by pro-inflammatory 
cytokines. How Plasmodium falciparum-infected erythrocytes (PfRBC) induce pro- 
inflammatory cytokine responses at a molecular level remains poorly understood, 
however. Toll-like receptors (TLRs) are innate pattern recognition receptors involved 
in the recognition of pathogen-associated molecular patterns and have been implicated 
in the recognition of Plasmodium ligands in in vitro and animal models. Here we 
investigated the role of TLRs in the recognition of intact PfRBC  by human PBMCs and 
downstream cytokine production, using specific inhibitors. We could not find any 
evidence for the role of human TLR-2, TLR-3 or TLR-4 in the recognition of PfRBC. 
However, specific inhibition of TLR-9 signalling reduced the IFNy response by PBM C 
against PfRBC  by up to 60%. Furthermore, we identify a possible role for the mannose 
recognition pathway in the IFNy response against PfRBC. Thus, amongst common 
PRRs, only TLR-9 and possibly the mannose receptor are involved in PfRBC 
recognition. Instead, invariant lymphocyte receptors, e.g. the NK-, NKT- or y5T- 
receptors, may play a more direct role.
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Malaria, a disease still responsible for a huge burden of morbidity and mortality 
worldwide, is caused by protozoan parasites of the genus Plasmodium. Clinically, 
malaria is characterised by high fevers associated with strong pro-inflammatory 
cytokine responses against the intra-erythrocytic stage of the parasite’s life cycle. 
However, the molecular pathways underlying (innate) immune recognition of 
Plasmodium parasites and induction of downstream cytokine responses remain poorly 
understood.
Initial immunological recognition of pathogens takes places through innate pattern- 
recognition receptors (PRRs) expressed on myeloid cells that recognize structures of the 
microorganisms called pathogen-associated molecular patterns (PAMPs). The best 
studied example of this is the recognition of the lipid A component of Gram-negative 
bacterial lipopolysaccharide (LPS) by Toll-like receptor (TLR)-4 [1]. Ligand binding to 
TLR-4, as for most other TLRs, leads via MyD88 (a common adapter molecule shared 
with the IL-ip and IL-18 signalling pathways [2, 3]) to NFkB activation and eventually 
pro-inflammatory cytokine production (e.g. IL-ip, IL-12 and TNFa) by myeloid cells. 
These pro-inflammatory mediators recruit and activate lymphocytes which in turn 
produce Thi-type (e.g. IFNy) or Th2-type (e.g. IL-4) cytokines.
With regards to malaria, glycosylphosphatidylinositol anchors of membrane-bound 
blood-stage P. falciparum proteins were reported to be recognized by TLR-2 and to a 
lesser extent TLR-4 in vitro [4]. Furthermore, TLR-9 has been shown to recognize 
components of Plasmodium-infected red blood cells (pRBC), although some 
controversy exists as to the precise ligand involved, with one group identifying 
haemozoin (a haem-derived by-product of haemoglobin metabolism by the parasite) [5­
7] and another haemozoin-associated parasitic DNA [8]. However, the above in vitro 
studies employed only transfected human embryonic kidney (H EK) cell lines or purified 
murine macrophages and measured upstream cytokines, e.g. TNFa; downstream IFNy 
or even IL-12 production was not assessed. In contrast, in vitro IFNy production by 
murine natural killer (NK) cells in response to PfRBC was inhibited when MyD88-/- or 
IL-18R-/-, but not TLR-1-/-, TLR-2-/- or TLR-9-/- macrophages were used as APCs [9], 
suggesting the requirement of the IL-1/IL-18 signalling pathway, but not individual 
TLRs, for the IFNy response to whole parasites. A similar picture emerges from in vivo 
studies investigating the contribution of TLR-pathways to malaria susceptibility in 
murine models: these tend to show reduced serum or ex vivo IFNy production in 
MyD88-/- or IL-18-/- mice, but not in TLR-2-/-, TLR-4-/- or TLR-9-/- animals [10-12], 
although elsewhere these same authors do report TLR-9-dependency for the ex vivo 
IFNy response to malaria by murine splenocytes [5, 11]. Part of these discrepancies may 
be due to differences in TLR/MyD88 pathway usage between mouse strains used [13]. 
In addition to the TLRs, other PRRs are known to contribute to pathogen recognition, 
including the nucleotide-binding oligomerisation domain containing (NOD) proteins 1
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and 2, and C-type lectins (CLRs) such as mannose receptor, dectin-1 and dectin-2, 
amongst others. Despite the potential importance of all these receptors for recognition 
of malaria parasites, very little is known about the importance of the human 
counterparts of these PRRs in pRBC recognition.
Since clinical malaria is characterised by such strong pro-inflammatory cytokine 
responses, which are believed to contribute partly to the pathophysiology of the disease, 
better understanding of the molecular pathways by which such responses are induced is 
crucial. Here we have studied for the first time the contribution of human PRRs 
families TLRs and CLRs for the recognition of intact P. falciparum-infected 
erythrocytes (PfRBC).
Materials & Methods
Parasites - NF54 strain P. falciparum  asexual parasites were cultured as described 
previously [14]. Briefly, parasites were grown in RPMI-1640 containing 10% human A+ 
serum and a 5% haematocrit erythrocyte suspension in an automated continuous culture 
system, in the absence of antibiotics and regularly screened for mycoplasma 
contamination and other microorganisms. Asynchronous cultures of NF54 strain 
parasites were harvested at a parasitaemia of approximately 10-20% and mature asexual 
stages purified by centrifugation on a 63% Percoll density gradient [15]. This 
purification step results in preparations with a 80-90% parasitaemia, consisting of more 
than 95% schizonts/mature trophozoites. These preparations of parasitized red blood 
cells (PfRBC) were washed twice in PBS and used fresh in stimulation assays. Mock- 
cultured uninfected erythrocytes (uRBC) were obtained similarly and served as control.
CHO cell lines - Chinese hamster ovary (CHO) cell lines transfected with human CD14 
alone, CD14 and human TLR-2, or CD14 and TLR-4, were originally a kind gift from 
dr. D. Golenbock (University of Massachusetts). Cells were cultured at 37°C, 5% CO2 
in 75cm2 flasks in Ham’s F12 medium supplemented with 10% FCS and 50mg/mL 
gentamicin plus 400U/mL hygromycin; culture medium for the TLR-2 expressing CHO 
cell line additionally contained 0.5 mg/mL geniticin (G418) and medium for the TLR-4 
expressing line 50^g/mL puromycine. Cells were passaged 1:5 - 1:10 twice weekly at 
confluency by trypsinisation, up to a maximum of 18 passages. For stimulation 
experiments, cells were transferred to 24-well plates at 105 cells/well in 0.5mL culture 
medium, left to adhere overnight and stimulated for an additional 20 hours with 1^g/mL 
LPS, 10^g/mL peptidoglycan (pepG), 107/mL PfRBC, 107/mL uRBC, or culture 
medium only. Stimulated cells were harvested by trypsinisation, washed once in FACS 
buffer (1% BSA  5mM EDTA in PBS), stained for 30’ with anti-CD25-FITC MAbs (BD 
Biosciences) at pre-titrated dilution, washed once more in FACS buffer and read for 
CD25 expression by flow cytometry (Coulter).
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HEK cell lines - Human embryonic kidney (H EK) cell lines transfected human TLR- 
2/YFP, TLR-3/YFP, TLR-4/YFP+MD2 and TLR-9/YFP constructs, in addition to 
untransfected ‘naked’ control HEKs were a kind gift from dr. D. Golenbock. Cells were 
cultured at 37°C, 5% CO2 in 75cm2 flasks in DM EM  supplemented with 10% FCS and 
10mg/mL ciprofloxacin; culture medium for the TLR expressing HEK cell lines 
additionally contained 0.5 mg/mL geniticin (G418). Cells were passaged 1:4 - 1:8 
twice weekly at confluency by trypsinisation. For stimulation experiments, cells were 
transferred to 96-well plates at 2-4x104 cells/well in 100^L culture medium and left to 
adhere overnight. Cells were then transfected with the reporter plasmids NFkB-Iuc 
(firefly luciferase under control of an NFKB-dependent promoter) and pBIND (Renilla 
luciferase under a constitutatively active hCMV promoter), both kind gifts from F. van 
Kuppeveld, using the FuGeneTM transfection reagent (Roche) in the following 
proportions: 25ng NFkB-Iuc + 25ng pBIND in 0.3 ^L FuGene/4.7 ^L DMEM per well. 
Following another overnight incubation, cells were stimulated for 6 hours with 1^g/mL 
Pam3Cys (P3C), 5^g/mL poly(I:C) (pIC), 10ng/mL LPS, 5^g/mL CpG DNA (ODN 
M362, InvivoGen), 10^g/mL M. tuberculosis (Mtb) lysate, 5x106/m PfRBC, 5x106/mL 
uRBC or culture medium only, washed once in 0.9% NaCl and lysed with 30^L/well 
passive lysis buffer (Promega). Firefly and Renilla luciferase activity were measured 
using the Dual-GloTM kit (Promega) as follows: 5^L cell lysate was added to 10^L LA R  
II (firefly luciferase) substrate and luminescence measured by integration over 5 
seconds on a luminometer; subsequently 10 ^L Stop & Glo (Renilla luciferase) 
substrate was added to the lysate mixture and luminescence was similarly measured. 
Relative NFkB activity in each sample was calculated as firefly luminescence/Renilla 
luminescence.
Peripheral blood mononuclear cells (PBMC) isolation and stimulation - PBMCs from 
malaria-naïve donors were isolated from EDTA anticoagulated venous whole blood by 
density gradient centrifugation on Ficoll-Hypaque. Cells were washed twice in cold 
PBS and resuspended at a final concentration of 2.5x10A6/mL in complete culture 
medium (RPM I 1640 supplemented with 50^g/mL gentamicin, 1mM pyruvate and
2 mM L-glutamine) plus 10% v/v human A+ plasma and plated in U-96 culture plates 
(5x106/well). PBMCs were stimulated with 5x106/mL fresh PfRBC, 5x106/mL control 
uRBC, 1ng/mL LPS, 1|ag/mL Pam3Cys or RPM I, or RPM I control. Cells were 
incubated for 24 hours at 37°C in 5% CO2, following which cell supernatants were 
collected & stored at -20°C for subsequent cytokine measurement by ELISA .
Field studies - PBMCs were also collected from naturally exposed, semi-immune 
African populations, as part of an ongoing investigation into inter-ethnic differences in 
susceptibility to malaria in Koro district of Mali, West Africa [16, 17]. Briefly, samples 
for this study were collected during the 2006 rainy (=transmission) season and the 2007 
dry (=non-transmission) season. The original study included both healthy adult male 
Dogon and Fulani volunteers and patients presenting to the local health centre with 
symptoms of uncomplicated malaria (fever or history of fever); here we present only
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Dogon data, since the prevalence of TLR-4 polymorphisms in Fulani is low. A thick 
smear was made from each volunteer and examined microscopically for the presence of 
P. falciparum  parasites; patients with clinical symptoms but a negative slide were 
excluded from the study. After community and individual written informed consent 
was obtained, 10mL lithium heparin venous whole blood was collected and PBMCs 
were isolated, washed and cultured as described above. In addition, stimulations were 
performed with whole blood diluted 1:5 in RPM I using 10ng/mL LPS, 10yg/mL 
Pam3Cys or RPM I control. Approval for the study was provided by the institutional 
review boards of the University of Stockholm (National Ethical Committee no. 03 536) 
and the University of Bamako (N°0527/FMPOS).
TLR-4 polymorphisms - DNA was extracted from whole blood by using the isolation kit 
Puregene (Gentra Sytems, Minneapolis, MN). PCR conditions, concentrations, and 
determinations of the Asp299Gly allele (rs4986790 G) and Thr399Ile (rs4986791 T) 
polymorphisms were performed as described by previously [18].
Cytokine measurements - PBM C and 1:5 whole blood supernatants were analysed for 
cytokine production by commercially available EL ISA  kits (IFNy & IL-6: Sanquin, 
Nijmegen) or by a specific immunoassay as previously described (TNFa: [19]).
Statistical analysis - Data analysed in SPSS; differences in responses between 
conditions were analysed by paired (Wilcoxon signed-rank) or unpaired (Mann­
Whitney U ) non-parametric tests as appropriate; p-values <0.05 were considered 
statistically significant.
Results
Human TLR-expressing cell lines
Recognition of intact PfRBC was initially assessed in a model in vitro system 
employing CHO cell lines expressing human TLR-2 or -4 in addition to CD14. When 
this cell line is immunologically activated, it expresses the IL-2 receptor CD25, which 
can be detected by flow cytometry (Supplementary fig. 1). Whereas petidoglycan 
(pepG) and LPS activated respectively TLR-2 and TLR-4 transfected cells, neither 
PfRBC nor uRBC activated either cell line (Fig. 1.A-C). It should be noted that non­
transfected CHO cells naturally express low levels of hamster TLR-4, thus explaining 
the background LPS response in non-transfected cells.
Recognition of PfRBC  was also tested using HEK cells expressing human TLR-2, -3, - 
4/MD2 or -9. Untransfected cells showed no response to PfRBC or most control stimuli 
(Fig. 1.D). TLR-2 transfected cell responded to Pam3Cys (P3C) and Mycobacterium  
tuberculosis (Mtb) extract (known to contain TLR-2 stimulating ligands [20]), but not to 
PfRBC (Fig. 1.E). TLR-3 similarly responded to poly(I:C) (pIC), but not PfRBC (Fig. 
1.F). Notably, non-TLR-3-transfected cells also responded to poly(I:C), albeit less
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strongly than TLR-3-transfected cells (Fig. 1.D-H); presumably these cells responded 
via other cytoplasmic dsDNA receptors, such as retinoic acid-inducible gene I (RIG-I) 
[21]. TLR-4/MD2 transfected cells consistently failed to thrive in culture and did not 
respond to any stimuli, including LPS (Fig. 1.G). TLR-9 transfected cells performed 
erratically, responding to CpG DNA, but not PfRBC, in only one third of the 
experiments (not shown).
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Figure 1. Recognition of PfRBC by human Toll-like receptors on transfected cell 
lines
A-C. Chinese hamster ovary (CHO) cell lines transfected with human CD14 only (A), 
with CD14+hTLR2 (B) or with CD14+hTLR4 (C) were stimulated with medium only, 
1^ g/mL LPS, 10^ g/mL peptidoglycan (pepG), 107/mL PfRBC or 107/mL uRBC. 
Percentage of cells expressing CD25 following stimulation was measured by flow 
cytometry. Data represent mean+SEM of three similar experiments.
D-G. Untransfected human embryonic kidney (HEK) cells (D), or HEK cells transfected 
with human TLR2 (E), hTLR3 (F) or hTLR4/MD2 (G) were transfected with a N F kB- 
dependent firefly luciferase reporter plasmid and a constitutively active Renilla luciferase 
reporter plasmid and stimulated with 1^ g/mL Pam3Cys (P3C), 5^ g/mL poly(I:C) (pIC), 
10ng/mL LPS, 5^ g/mL CpG DNA, 10^ g/mL M. tuberculosis (Mtb) lysate, 5x106/mL 
PfRBC, 5x106/mL uRBC or culture medium only. Firefly and Renilla luciferase activity 
were measured by luminometer and relative N F kB  activation was calculated as 
firefly/Renilla luciferase activity. Data represent mean+SEM of duplicate wells in one 
out of three representative experiments.
«) x 100 100-
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PBMC experiments
In order to explore PfRBC  recognition by primary human immune cells, fresh human 
PBMCs were incubated with PfRBC  in the presence or absence of various (specific) 
TLR-antagonists. W ith no specific anti-TLR-2 antibody available, supposedly TLR-2- 
inhibitory peptides [22] were tested. However, in vitro these peptides proved not only 
stimulatory in a dose-dependent fashion, but also co-stimulatory with other TLR-ligands 
(data not shown).
A TLR-4 inhibitory MAb (HTA-125) [23] was tested, but repeatedly achieved only 
marginal, albeit statistically significant, inhibition of LPS recognition (Fig. 2.A); 
nevertheless, it had no significant effect on PfRBC recognition (Fig. 2.A+B). Recently, 
however, we demonstrated the TLR-4 inhibitory capacity of LPS derived from another 
Gram-negative bacterium, Bartonella quintana [23, 24]. Whereas Bartonella LPS 
convincingly inhibited E. coli LPS recognition, it had no demonstrable effect on the 
recognition of PfRBC  (Fig. 2.C+D).
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Figure 2. Role of TLR-4 and 
TLR-9 in cytokine response 
by human PBMCs against 
PfRBC
PBMC of malaria-naïve 
donors were stimulated with 
1ng/mL LPS, 1Q^ g/mL 
Pam3Cys, 5x1Q6/mL PfRBC, 
5x1Q6/mL uRBC or medium 
control in the presence or 
absence of 2Q g^/mL anti- 
TLR4 MAb (A+B), 1QQng/mL 
Bartonella LPS (C+D), 1Q^ M 
CQ (E+F) or inhibitory ODN 
DNA (G). IL -6 (A,C, E ) and 
IFNy (B, D, F, G) responses in 
culture supernatants were 
measured by ELISA. Data 
represent mean+SEM of 1Q 
(A+B), 6 (C+D), 5 (E+F) and 
3 (G) volunteers. *p<Q.Q5, 
***p<Q.QQ1 vs RPMI 
respectively; ND - not 
determined.
ND ND
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Chloroquine (CQ) is a non-specific inhibitor of TLR-9 responses, partly through 
interfering with endosome acidification [25]. Whereas CQ indeed inhibited CpG and 
PfRBC signalling in PBMCs, it also inhibited LPS signalling (Fig. 2.E+F), as has been 
shown previously (e.g. [26]). In order to confirm the role of TLR9 for the recognition of 
PfRBC, we also employed inhibitory CpG sequences (hinhODN) that are a more 
specific inhibitor of TLR-9 signalling (e.g. [27]). Importantly, hinhODN clearly 
inhibited cytokine responses to PfRBC in a dose-dependent manner (Fig. 2.G).
TLR4 polymorphisms and the cytokine response
In addition to using specific inhibitors, we attempted another approach to study TLR- 
involvement in PfRBC recognition, by making use of naturally occurring variants in 
human TLRs. Two SNPs in the TLR-4 gene, Asp299Gly allele (rs4986790 G) and 
Thr399Ile (rs4986791 T) are known to affect LPS recognition [28, 29]. We tested 
responses to LPS and PfRBC in West African donors, a region known for a high 
prevalence of TLR-4 SNPs. Whereas pro-inflammatory responses to LPS were clearly 
augmented in donors carrying the TLR-4-299G variant (Fig. 3.A), these donors did not 
differ in their response to PfRBC (Fig. 3.B).
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Figure 3. Cytokine responses to PiRBC or controls in African donors with WT and 
polymorphic TLR-4
Whole blood (A) or PBMC (B) from Malian donors homozygous for WT TLR-4 (white 
bars) or heterozygous for TLR-4-299G (grey bars) were stimulated with respectively 
10ng/mL LPS, 10^ g/mL Pam3Cys, 5x106/mL PfRBC, 5x106/mL uRBC, or RPMI only. 
TNFa (A) and IFNy (B) were measured in culture supernatant by ELISA. Data represent 
median+IQR (n=41 asymptomatic WT, n=8 asymptomatic HTZ, n=13 symptomatic WT, 
n=7 symptomatic HTZ); *p<0.05 for HTZ vs. WT by Wilcoxon signed-rank test.
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The role of CLRs for PfRBC-induced cytokines
Finally, we explored the role of other PRR pathways including the mannose-recognition 
pathway, the glucan-recognition pathway and the chitin-recognition pathway. Pre­
incubation with either S. cerevisiae or C. albicans mannan inhibited PfRBC recognition 
by up to 80% in all donors tested, indicating involvement of the mannose recognition 
pathways in PfRBC  recognition (Fig. 4). Pre-incubation with either laminarin or chitin, 
on the other hand, inhibited PfRBC responses in only 50% of donors (Fig. 4).
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Figure 4. Role of non-TLR recognition pathways in IFNy response by PBMCs 
against PfRBC
PBMC of malaria-naive donors were stimulated 5x106/mL PfRBC, 5x106/mL uRBC or 
medium control in the presence of 50 g^/mL S. cerevisiae mannan, 200^ g/mL C. albicans 
mannan, 50^ g/mL laminarin 20 g^/mL chitin or RPMI control and IFNy responses in 
culture supernatants were measured by ELISA. Data represent mean+SEM of 4 
volunteers over 2 independent experiments.
0
Discussion
In this paper we have assessed the role of human Toll-like receptor pathways in the 
recognition of PfRBC. Using specific inhibitors for TLRs or C-type lectin receptors, as 
well as cell lines transfected with various TLRs, we demonstrate recognition of P. 
falciparum-infected RBC  via TLR-9, while little role was suggested for TLR-2 or TLR-
3 recognition. Using both inhibition assays, tranfection studies and an immunogenetic 
approach, we show that TLR4 is unlikely to play a major role in the induction of a 
cytokine response by PfRBC. Interestingly, preliminary results suggest that while the 
C-type lectin dectin-1 is unlikely to play an important role in recognition of PfRBC, the 
mannan recognition pathway may be involved.
Work in murine models has already suggested that, whereas the IL-1/IL-18 signalling 
pathway is clearly involved, individual TLRs (with the possible exception of TLR-9 [5, 
11]) appear to play little role in the induction of IFNy responses by pRBC [10-12].
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However, known discrepancies between individual murine models, and between mice 
and humans, made it imperative to test these pathways in primary human cells. For lack 
of specific inhibitors, we have as yet been unable to test the role of all 10 human TLRs. 
However, TLR-1 and TLR-6 necessarily form heterodimers with TLR-2 [30] and our 
data suggest TLR-2 itself is not involved in PfRBC  recognition. Furthermore, although 
we thus cannot theoretically exclude a role of e.g. TLR-7 and TLR-8, the known ligand- 
specificity of these receptors in the form of intracellular viral ssRNA [31], would make 
this unlikely.
The role of other PRRs has been little explored. It was recently shown that NOD-1 and 
NOD-2 contribute to cytokine production, including IFNy, in a murine malaria model 
[32]. It has furthermore been suggested that haemozoin is recognized via the NALP-3 
inflammasome and uric acid production [33-35]. Finally, the scavenger receptor CD36 
has been implicated in the binding to, and recognition of, PfRBC  by APCs [36-38]. 
Here we have shown for the first time that another PRR pathway, the mannose 
recognition pathway, appears also to be involved in immune activation by whole 
PfRBC. This is interesting considering the presence of mannan-like structures in 
glycosylphosphatidylinositol (G PI) anchors of P. falciparum  proteins and free parasitic 
GPI moieties [39]. These tetra-mannose glycan cores induces TNFa responses in 
murine macrophages in combination with the GPI lipid tail [40], but are no longer 
stimulatory after the terminal mannose residu is cleaved; furthermore, the inflammatory 
effect of GPI can be blocked by free mannan [41]. However, although soluble human 
mannan-binding lectin (M BL) is capable of recognising glycosilated blood-stage P. 
falciparum  proteins [42], possibly functioning as an opsonin [43], a cellular recognition 
receptor for Plasmodium GPIs has not yet been proposed. One interesting candidate in 
this regard must be the macrophage mannose receptor [44].
Discrepancy between our findings and a previously published study with regards the 
role of TLR-2 and TLR-4 in the recognition of P. falciparum  ligands, i.e. GPI [4], may 
reflect in vitro artefacts in the latter model, e.g. unnatural receptor-cell combinations, 
receptor over-expression, or super-physiological ligand concentrations. Alternatively, it 
may suggest potentially inflammatory parasite ligands on intact PfRBC remain 
stereotactically hidden from (innate) immune receptors. The latter explanation might 
even represent a deliberate (masking) strategy by Plasmodium parasites in order to 
avoid immune activation. One approach to solving this question would be to compare 
receptor requirements for PfRBC lysate with that of whole intact PfRBC. In contrast to 
TLR2 and TLR4, one receptor that appears to be consistently involved in the 
recognition of PfRBC  is TLR9. These data are in line with previous reports of malaria 
PAMPs recognized by TLR9 [5-8]. In addition, polymorphisms in TLR9 have also been 
suggested to influence IFNy responses in children with malaria [45], as well as 
susceptibility to malaria in some [46], though not all studies [47].
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An interesting coincidental observation in our studies is that IFNy forms a good read­
out for the PBM C response to PfRBC, giving a better signal-to-background ratio than 
either IL-6 (Fig. 2), TNFa or IL-12 (not shown). This is remarkable, considering that 
IFNy is normally considered a down-stream cytokine [48] and may suggest direct 
recognition of PfRBC by (innate) lymphocytes through invariant receptors such as NK 
(KIR)- [49], NKT- [50] or y5T- [51, 52] receptors, rather than classical myeloid 
recognition and presentation. Such pathways w ill require further exploration.
Thus, we report the involvement of TLR9 and mannose-recognition pathways that 
underlie the IFNy response to blood-stage malaria parasites. However, many parts of 
the overall picture remain to be elucidated. Finally, to our knowledge no studies have 
yet described the recognition of other parasite life-stages, e.g. sporozoites and 
gametocytes, by PRRs. Although these stages are not in themselves considered 
pathogenic, effective immunological recognition and elimination of these parasites 
could assist in interrupting the malaria life cycle. Furthermore, the study of the 
molecular pathways involved in the recognition of all parasite stages, and possible 
manipulation of these by the parasite itself, remains of considerable interest.
Acknowledgments
We are grateful to the participants in the Mali study for their time, cooperation & 
enthusiasm and we thank the members of the study team involved in collecting the 
samples for their collaboration. We are indebted to M. v.d. Vegte-Bolmer, R. Siebelink- 
Stoter and Henry Witteveen for culturing P. falciparum-infected erythrocytes.
This work was supported by a FP6 European Network of Excellence (BioMalPar) 
fellowship (to M .B.B.M .) and a V ici grant of the Netherlands Organisation for 
Scientific Research (to M.G.N.).
52
PRRs and P. falciparum
1. Poltorak, A., He, X., Smirnova, I., Liu, M. Y., Van, H. C., Du, X., Birdwell, D., Alejos, E., 
Silva, M., Galanos, C., Freudenberg, M., Ricciardi-Castagnoli, P., Layton, B., Beutler, B. 
(1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 
gene. Science 282, 2085-2088.
2. Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., Nakanishi, 
K., Akira, S. (1998) Targeted disruption of the MyD88 gene results in loss of IL-1- and IL- 
18-mediated function. Immunity. 9, 143-150.
3. Janssens, S., Beyaert, R. (2002) A universal role for MyD88 in TLR/IL-1R-mediated 
signaling. Trends Biochem. Sci. 27, 474-482.
4. Krishnegowda, G., Hajjar, A. M., Zhu, J., Douglass, E. J., Uematsu, S., Akira, S., Woods, A.
S., Gowda, D. C. (2005) Induction of proinflammatory responses in macrophages by the 
glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, 
glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. J  
Biol Chem 280, 8606-16.
5. Coban, C., Igari, Y., Yagi, M., Reimer, T., Koyama, S., Aoshi, T., Ohata, K., Tsukui, T., 
Takeshita, F., Sakurai, K., Ikegami, T., Nakagawa, A., Horii, T., Nunez, G., Ishii, K. J., 
Akira, S. (2010) Immunogenicity of Whole-Parasite Vaccines against Plasmodium 
falciparum Involves Malarial Hemozoin and Host TLR9. Cell Host. Microbe 7, 50-61.
6. Pichyangkul, S., Yongvanitchit, K., Kum-arb, U., Hemmi, H., Akira, S., Krieg, A. M., 
Heppner, D. G., Stewart, V. A., Hasegawa, H., Looareesuwan, S., Shanks, G. D., Miller, R.
S. (2004) Malaria blood stage parasites activate human plasmacytoid dendritic cells and 
murine dendritic cells through a Toll-like receptor 9-dependent pathway. J. Immunol. 172, 
4926-4933.
7. Coban, C., Ishii, K. J., Kawai, T., Hemmi, H., Sato, S., Uematsu, S., Yamamoto, M., 
Takeuchi, O., Itagaki, S., Kumar, N., Horii, T., Akira, S. (2005) Toll-like receptor 9 mediates 
innate immune activation by the malaria pigment hemozoin. J  Exp Med 201, 19-25.
8. Parroche, P., Lauw, F. N., Goutagny, N., Latz, E., Monks, B. G., Visintin, A., Halmen, K. 
A., Lamphier, M., Olivier, M., Bartholomeu, D. C., Gazzinelli, R. T., Golenbock, D. T.
(2007) Malaria hemozoin is immunologically inert but radically enhances innate responses 
by presenting malaria DNA to Toll-like receptor 9. Proc. Natl. Acad. Sci. U. S. A 104, 1919­
1924.
9. Baratin, M., Roetynck, S., Lepolard, C., Falk, C., Sawadogo, S., Uematsu, S., Akira, S., 
Ryffel, B., Tiraby, J. G., Alexopoulou, L., Kirschning, C. J., Gysin, J., Vivier, E., Ugolini, S.
(2005) Natural killer cell and macrophage cooperation in MyD88-dependent innate 
responses to Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A 102, 14747-14752.
10. Coban, C., Ishii, K. J., Uematsu, S., Arisue, N., Sato, S., Yamamoto, M., Kawai, T., 
Takeuchi, O., Hisaeda, H., Horii, T., Akira, S. (2007) Pathological role of Toll-like receptor 
signaling in cerebral malaria. Int. Immunol. 19, 67-79.
11. Franklin, B. S., Rodrigues, S. O., Antonelli, L. R., Oliveira, R. V., Goncalves, A. M., Sales­
Junior, P. A., Valente, E. P., varez-Leite, J. I., Ropert, C., Golenbock, D. T., Gazzinelli, R. T.
(2007) MyD88-dependent activation of dendritic cells and CD4(+) T lymphocytes mediates 
symptoms, but is not required for the immunological control of parasites during rodent 
malaria. Microbes. Infect. 9, 881-890.
References
53
Chapter 2
12. Cramer, J. P., Lepenies, B., Kamena, F., Holscher, C., Freudenberg, M. A., Burchard, G. D., 
Wagner, H., Kirschning, C. J., Liu, X., Seeberger, P. H., Jacobs, T. (2008) MyD88/IL-18- 
dependent pathways rather than TLRs control early parasitaemia in non-lethal Plasmodium 
yoelii infection. Microbes. Infect. 10, 1259-1265.
13. Griffith, J. W., O'Connor, C., Bernard, K., Town, T., Goldstein, D. R., Bucala, R. (2007) 
Toll-like receptor modulation of murine cerebral malaria is dependent on the genetic 
background of the host. J. Infect. Dis. 196, 1553-1564.
14. Ponnudurai, T., Lensen, A. H., van Gemert, G. J., Bensink, M. P., Bolmer, M., Meuwissen, 
J. H. (1989) Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes. 
Parasitology 98 Pt 2, 165-173.
15. Rivadeneira, E. M., Wasserman, M., Espinal, C. T. (1983) Separation and concentration of 
schizonts of Plasmodium falciparum by Percoll gradients. J. Protozool. 30, 367-370.
16. Dolo, A., Modiano, D., Maiga, B., Daou, M., Dolo, G., Guindo, H., Ba, M., Maiga, H., 
Coulibaly, D., Perlman, H., Blomberg, M. T., Toure, Y. T., Coluzzi, M., Doumbo, O. (2005) 
Difference in susceptibility to malaria between two sympatric ethnic groups in Mali. Am. J. 
Trop. Med. Hyg. 72, 243-248.
17. McCall, M. B., Hopman, J., Daou, M., Maiga, B., Dara, V., Ploemen, I., Nganou- 
Makamdop, K., Niangaly, A., Tolo, Y., Arama, C., Bousema, J. T., van der Meer, J. W., van, 
d., V, Troye-Blomberg, M., Dolo, A., Doumbo, O. K., Sauerwein, R. W. (2010) Early 
interferon-gamma response against Plasmodium falciparum correlates with interethnic 
differences in susceptibility to parasitemia between sympatric Fulani and Dogon in Mali. J. 
Infect. Dis. 201, 142-152.
18. Van der Graaf, C. A., Netea, M. G., Morre, S. A., Den, H. M., Verweij, P. E., van der Meer, 
J. W., Kullberg, B. J. (2006) Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a 
risk factor for Candida bloodstream infection. Eur. Cytokine Netw. 17, 29-34.
19. Grebenchtchikov, N., van, d., V, Pesman, G. J., Geurts-Moespot, A., van der Meer, J. W., 
Sweep, F. C. (2005) Development of a sensitive ELISA for the quantification of human 
tumour necrosis factor-alpha using 4 polyclonal antibodies. Eur. Cytokine Netw. 16, 215­
222.
20. Tsuji, S., Matsumoto, M., Takeuchi, O., Akira, S., Azuma, I., Hayashi, A., Toyoshima, K., 
Seya, T. (2000) Maturation of human dendritic cells by cell wall skeleton of Mycobacterium 
bovis bacillus Calmette-Guerin: involvement of toll-like receptors. Infect. Immun. 68, 6883­
6890.
21. Li, K., Chen, Z., Kato, N., Gale, M., Jr., Lemon, S. M. (2005) Distinct poly(I-C) and virus- 
activated signaling pathways leading to interferon-beta production in hepatocytes. J. Biol. 
Chem. 280, 16739-16747.
22. Sing, A., Reithmeier-Rost, D., Granfors, K., Hill, J., Roggenkamp, A., Heesemann, J. (2005) 
A hypervariable N-terminal region of Yersinia LcrV determines Toll-like receptor 2- 
mediated IL-10 induction and mouse virulence. Proc. Natl. Acad. Sci. U. S. A 102, 16049­
16054.
23. Tabeta, K., Yamazaki, K., Akashi, S., Miyake, K., Kumada, H., Umemoto, T., Yoshie, H. 
(2000) Toll-like receptors confer responsiveness to lipopolysaccharide from Porphyromonas 
gingivalis in human gingival fibroblasts. Infect. Immun. 68, 3731-3735.
24. Popa, C., bdollahi-Roodsaz, S., Joosten, L. A., Takahashi, N., Sprong, T., Matera, G., 
Liberto, M. C., Foca, A., van, D. M., Kullberg, B. J., van den Berg, W. B., van der Meer, J.
54
PRRs and P. falciparum
W., Netea, M. G. (2007) Bartonella quintana lipopoly saccharide is a natural antagonist of 
Toll-like receptor 4. Infect. Immun. 75, 4831-4837.
25. Yi, A. K., Tuetken, R., Redford, T., Waldschmidt, M., Kirsch, J., Krieg, A. M. (1998) CpG 
motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive 
oxygen species. J. Immunol. 160, 4755-4761.
26. Picot, S., Peyron, F., Donadille, A., Vuillez, J. P., Barbe, G., mbroise-Thomas, P. (1993) 
Chloroquine-induced inhibition of the production of TNF, but not of IL-6, is affected by 
disruption of iron metabolism. Immunology 80, 127-133.
27. Stunz, L. L., Lenert, P., Peckham, D., Yi, A. K., Haxhinasto, S., Chang, M., Krieg, A. M., 
Ashman, R. F. (2002) Inhibitory oligonucleotides specifically block effects of stimulatory 
CpG oligonucleotides in B cells. Eur. J. Immunol. 32, 1212-1222.
28. Arbour, N. C., Lorenz, E., Schutte, B. C., Zabner, J., Kline, J. N., Jones, M., Frees, K., Watt, 
J. L., Schwartz, D. A. (2000) TLR4 mutations are associated with endotoxin 
hyporesponsiveness in humans. Nat. Genet. 25, 187-191.
29. Ferwerda, B., McCall, M. B., Alonso, S., Giamarellos-Bourboulis, E. J., Mouktaroudi, M., 
Izagirre, N., Syafruddin, D., Kibiki, G., Cristea, T., Hijmans, A., Hamann, L., Israel, S., 
ElGhazali, G., Troye-Blomberg, M., Kumpf, O., Maiga, B., Dolo, A., Doumbo, O., 
Hermsen, C. C., Stalenhoef, A. F., van Crevel, R., Brunner, H. G., Oh, D. Y., Schumann, R. 
R., de la Rúa, C., Sauerwein, R., Kullberg, B. J., van der Ven, A. J. A. M., van der Meer, J. 
W., Netea, M. G. (2007) TLR4 polymorphisms, infectious diseases, and evolutionary 
pressure during migration of modern humans. Proc. Natl. Acad. Sci. U. S. A 104, 16645­
16650.
30. Ozinsky, A., Underhill, D. M., Fontenot, J. D., Hajjar, A. M., Smith, K. D., Wilson, C. B., 
Schroeder, L., Aderem, A. (2000) The repertoire for pattern recognition of pathogens by the 
innate immune system is defined by cooperation between toll-like receptors. Proc. Natl. 
Acad. Sci. U. S. A 97, 13766-13771.
31. Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., 
Wagner, H., Bauer, S. (2004) Species-specific recognition of single-stranded RNA via toll­
like receptor 7 and 8. Science 303, 1526-1529.
32. Finney, C. A., Lu, Z., LeBourhis, L., Philpott, D. J., Kain, K. C. (2009) Disruption of Nod­
like receptors alters inflammatory response to infection but does not confer protection in 
experimental cerebral malaria. Am. J. Trop. Med. Hyg. 80, 718-722.
33. Griffith, J. W., Sun, T., McIntosh, M. T., Bucala, R. (2009) Pure Hemozoin is inflammatory 
in vivo and activates the NALP3 inflammasome via release of uric acid. J. Immunol. 183, 
5208-5220.
34. Shio, M. T., Eisenbarth, S. C., Savaria, M., Vinet, A. F., Bellemare, M. J., Harder, K. W., 
Sutterwala, F. S., Bohle, D. S., Descoteaux, A., Flavell, R. A., Olivier, M. (2009) Malarial 
hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases. PLoS. Pathog.
5, e1000559.
35. Dostert, C., Guarda, G., Romero, J. F., Menu, P., Gross, O., Tardivel, A., Suva, M. L., 
Stehle, J. C., Kopf, M., Stamenkovic, I., Corradin, G., Tschopp, J. (2009) Malarial hemozoin 
is a Nalp3 inflammasome activating danger signal. PLoS. ONE. 4, e6510.
36. Ockenhouse, C. F., Klotz, F. W., Tandon, N. N., Jamieson, G. A. (1991) Sequestrin, a CD36 
recognition protein on Plasmodium falciparum malaria-infected erythrocytes identified by 
anti-idiotype antibodies. Proc. Natl. Acad. Sci. U. S. A 88, 3175-3179.
55
Chapter 2
37. Ndungu, F. M., Sanni, L., Urban, B., Stephens, R., Newbold, C. I., Marsh, K., Langhorne, J.
(2006) CD4 T cells from malaria-nonexposed individuals respond to the CD36-Binding 
Domain of Plasmodium falciparum erythrocyte membrane protein-1 via an MHC class II- 
TCR-independent pathway. J. Immunol. 176, 5504-5512.
38. Roberts, D. J., Craig, A. G., Berendt, A. R., Pinches, R., Nash, G., Marsh, K., Newbold, C. I.
(1992) Rapid switching to multiple antigenic and adhesive phenotypes in malaria. Nature 
357, 689-692.
39. Channe Gowda, D. (2002) Structure and activity of glycosylphosphatidylinositol anchors of 
Plasmodium falciparum. Microbes. Infect. 4, 983-990.
40. Tachado, S. D., Gerold, P., Schwarz, R., Novakovic, S., McConville, M., Schofield, L.
(1997) Signal transduction in macrophages by glycosylphosphatidylinositols of Plasmodium, 
Trypanosoma, and Leishmania: activation of protein tyrosine kinases and protein kinase C 
by inositolglycan and diacylglycerol moieties. Proc. Natl. Acad. Sci. U. S. A 94, 4022-4027.
41. Vijaykumar, M., Naik, R. S., Gowda, D. C. (2001) Plasmodium falciparum 
glycosylphosphatidylinositol-induced TNF-alpha secretion by macrophages is mediated 
without membrane insertion or endocytosis. J. Biol. Chem. 276, 6909-6912.
42. Klabunde, J., Uhlemann, A. C., Tebo, A. E., Kimmel, J., Schwarz, R. T., Kremsner, P. G., 
Kun, J. F. (2002) Recognition of plasmodium falciparum proteins by mannan-binding lectin, 
a component of the human innate immune system. Parasitol. Res. 88, 113-117.
43. Garred, P., Nielsen, M. A., Kurtzhals, J. A., Malhotra, R., Madsen, H. O., Goka, B. Q., 
Akanmori, B. D., Sim, R. B., Hviid, L. (2003) Mannose-binding lectin is a disease modifier 
in clinical malaria and may function as opsonin for Plasmodium falciparum-infected 
erythrocytes. Infect. Immun. 71, 5245-5253.
44. Wileman, T. E., Lennartz, M. R., Stahl, P. D. (1986) Identification of the macrophage 
mannose receptor as a 175-kDa membrane protein. Proc. Natl. Acad. Sci. U. S. A 83, 2501­
2505.
45. Sam-Agudu, N. A., Greene, J. A., Opoka, R. O., Kazura, J. W., Boivin, M. J., Zimmerman, 
P. A., Riedesel, M. A., Bergemann, T. L., Schimmenti, L. A., John, C. C. (2010) TLR9 
polymorphisms are associated with altered IFN-gamma levels in children with Cerebral 
Malaria. Am. J. Trop. Med. Hyg. 82, 548-555.
46. Mockenhaupt, F. P., Hamann, L., von, G. C., Bedu-Addo, G., von, K. C., Schumann, R. R., 
Bienzle, U. (2006) Common polymorphisms of toll-like receptors 4 and 9 are associated with 
the clinical manifestation of malaria during pregnancy. J. Infect. Dis. 194, 184-188.
47. Campino, S., Forton, J., Auburn, S., Fry, A., Diakite, M., Richardson, A., Hull, J., Jallow, 
M., Sisay-Joof, F., Pinder, M., Molyneux, M. E., Taylor, T. E., Rockett, K., Clark, T. G., 
Kwiatkowski, D. P. (2009) TLR9 polymorphisms in African populations: no association 
with severe malaria, but evidence of cis-variants acting on gene expression. Malar. J. 8, 44.
48. Munder, M., Mallo, M., Eichmann, K., Modolell, M. (1998) Murine macrophages secrete 
interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: A novel 
pathway of autocrine macrophage activation. J. Exp. Med. 187, 2103-2108.
49. Artavanis-Tsakonas, K., Eleme, K., McQueen, K. L., Cheng, N. W., Parham, P., Davis, D. 
M., Riley, E. M. (2003) Activation of a subset of human NK cells upon contact with 
Plasmodium falciparum-infected erythrocytes. J. Immunol. 171, 5396-5405.
50. Schofield, L., McConville, M. J., Hansen, D., Campbell, A. S., Fraser-Reid, B., Grusby, M. 
J., Tachado, S. D. (1999) CD1d-restricted immunoglobulin G formation to GPI-anchored 
antigens mediated by NKT cells. Science 283, 225-229.
56
PRRs and P. falciparum
51. Behr, C., Poupot, R., Peyrat, M. A., Poquet, Y., Constant, P., Dubois, P., Bonneville, M., 
Fournie, J. J. (1996) Plasmodium falciparum stimuli for human gammadelta T cells are 
related to phosphorylated antigens of mycobacteria. Infect. Immun. 64, 2892-2896.
52. Pichyangkul, S., Saengkrai, P., Yongvanitchit, K., Stewart, A., Heppner, D. G. (1997) 
Activation of gammadelta T cells in malaria: interaction of cytokines and a schizont- 
associated Plasmodium falciparum antigen. J. Infect. Dis. 176, 233-241.
57
Chapter 2
Supplementary figure 1. CD25 expression by CHO cell lines following stimulation with 
PfRBC or controls
Chinese hamster ovary (CHO) cell lines transfected with human CD14 only (‘naked’), with 
hCD14 + human TLR2 or with hCD14 + hTLR4, were stimulated with medium only, 1|ig/mL 
LPS, 10|ig/mL peptidoglycan (pepG), 107/mL PfRBC or 107/mL uRBC. The percentage of cells 
expressing CD25 following stimulation was measured by flow cytometry. Shown is one out of 
three similar experiments.
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Abstract
Toll-like receptors (TLRs) are a major group of pattern recognition receptors that are 
crucial in initiating innate immune responses and are capable of recognizing 
Plasmodium ligands. We have investigated Toll-like receptor responses during acute 
experimental P. falciparum (P.f.) infection in 15 malaria-naïve volunteers. TLR-4 
responses in whole blood ex vivo stimulations were characterized by significantly 
(p<0 .01) up-regulated pro-inflammatory cytokine production during infection compared 
to baseline, whereas TLR-2/TLR-1 responses demonstrated increases in both pro- 
inflammatory and anti-inflammatory cytokine production. Responses through other 
TLRs were less obviously modified by malaria infection. The degree to which pro- 
inflammatory TLR responses were boosted early in infection was partially prognostic of 
clinical inflammatory parameters during the subsequent clinical course. Although 
simultaneous co-stimulation of human PBMCs with P .f lysate and specific TLR stimuli 
in vitro did not induce synergistic effects on cytokine synthesis, PBMCs started to 
respond to subsequent TLR-4 and TLR-2 stimulation with significantly (p<0.05) 
increased TNFa and reduced IL-10 production following increasing periods of pre­
incubation with P.f. antigen. In contrast, pre-incubation with preparations derived from 
other parasitic, bacterial and fungal pathogens strongly suppressed subsequent TLR 
responses. Taken together, P. falciparum  primes human Toll-like receptor responses 
towards a more pro-inflammatory cytokine profile both in vitro and in vivo, a 
characteristic exceptional amongst micro-organisms.
The fu ll text o f  this article is available online at the Journal o f  Immunology website 
(http://www.jimmunol.ors/content/179/1/162.lons).
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Summary
Natural killer (NK) cells are rapid IFN-y responders to Plasmodium falciparum-infected 
erythrocytes (PfRBC ) in vitro and are involved in controlling early parasitaemia in 
murine models, yet it remains that little is known about their contribution to immune 
responses following malaria infection in humans. Here we studied the dynamics of and 
requirements for in vitro NK responses to PfRBC in malaria-naïve volunteers 
undergoing a single experimental malaria infection under highly controlled 
circumstances, and in naturally exposed individuals. NK-specific IFN-y responses to 
PfRBC  following exposure resembled an immunological recall pattern and were tightly 
correlated with T cell responses. However, whereas PBM C depleted of CD56+ cells 
retained 20-55% of their total IFN-y response to PfRBC, depletion of CD3+ cells 
completely abrogated the ability of remaining PBM C, including NK cells, to produce 
IFN-y. Whereas NK responses to PfRBC  were partially dependent on endogenous IL-2 
signalling and could be augmented by exogenous IL-2 in whole PBM C populations, this 
factor alone was insufficient to rescue NK responses in the absence of T cells. Thus, 
NK cells make a significant contribution to total IFN-y production in response to 
PfRBC as a consequence of their dependency on (memory) T-cell help, with likely 
positive implications for malaria vaccine development.
Copyright Wiley-VCH Verlag GmbH & Co. KGaA. Reproduced with permission. 
Abbreviations
PfRBC - Plasmodium falciparum-infected erythrocytes 
uRBC - uninfected erythrocytes
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Natural killer (NK) cells are lymphocytes belonging to the innate immune system 
whose hallmark is their potent activity against altered self cells, such as tumour cells 
and virus-infected cells [1], but are also capable of responding against extracellular 
protozoan pathogens [2, 3], including Plasmodia. Both in vitro [4, 5] and in vivo [6], 
human NK cells are amongst the first lymphocytes to respond with IFN-y production to 
Plasmodium falciparum-infected erythrocytes (PfRBC). The importance of NK cells in 
the control of early parasitaemia has been demonstrated in murine malaria models [7]. 
NK cells directly recognize PfRBC  [8-10], but also crucially require multiple soluble 
(e.g. IL-12 and IL-18) and contact-dependent signals from myeloid accessory cells for 
full activation, including IFN-y production [10, 11]. Deep-rooted innate heterogeneity 
appears to exist between donors with regards to NK responses against PfRBC  [5, 8].
In this study we investigated the dynamics of and requirements for ex vivo IFN-y 
responses by NK cells against PfRBC  in malaria-naïve volunteers over a 20 week 
period following a single experimental malaria infection and in naturally exposed 
individuals.
Introduction
Results and Discussion
NK responses to P. falciparum resemble an immunological re-call pattern
In a strictly controlled setting and following a previously described clinical protocol 
[12, 13], 5 healthy malaria-naïve Dutch volunteers participated in an experimental 
human malaria infection by exposure to bites of Plasmodium falciparum  infected 
mosquitoes (Fig. 1.A). In vitro lymphocyte IFN-y responses against P. falciparum  
demonstrated a classical re-call pattern following volunteers’ exposure to malaria (Fig.
1.B, representative FACS plots shown in supplementary figure 1.A). Whereas only 
low responses above background could be detected in volunteers at inclusion (day C-1, 
0.14±0.17% IFN-y+ lymphocytes [mean±SD]) or during challenge (day C+9,
0.05±0.03%), IFN-y responses against PfRBC  became clearly detectable following 
challenge (day C+35, 1.53±0.74%) and remained high when re-tested more than 4 
months post-infection (day C+140, 0.87±0.57%).
T cell responses, as expected, exhibited the typical dynamics of immunological memory 
in relation to exposure (Fig. 1.C). Interestingly for an ‘innate’ lymphocyte sub-set, NK 
cell responses to PfRBC  closely resembled the recall-like response seen in T cells (Fig.
1.E). In fact this pattern was even more marked for NK cells, increasing in some cases 
to over 12%  following challenge, albeit with considerable inter-individual variation. 
NKT cell responses similarly mirrored the T cell pattern (Fig. 1.D). Further analysis of 
NK cell subsets revealed similar response patterns in both the CD56dim and CD56bright 
populations (Fig. 1.F+G). Thus exposure to a single malaria infection induces robust 
and long-lived cellular responses to P. falciparum  in previously naïve volunteers by not 
only T cells, but also NK cells.
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Figure 1. In vitro IFN-y responses against PfRBC by various PBMC subsets in 
volunteers undergoing malaria infection.
A. Schematic representation of experimental human malaria infection. Diagonal striping 
represents anti-malarial treatment directly following a positive blood smear for P. 
falciparum. The bar below days 7 to 11 indicates actual presentation of patent 
parasitaemia in volunteers and the thick arrow heads indicate time points of 
immunological assessment, namely prior to challenge (day C-1), during blood-stage 
parasitaemia (day C+9), three weeks after treatment (day C+35) and 20 weeks after 
challenge (day C+140). Thin arrows indicate key stages in the protocol. B-G: Percentage 
of (B) all lymphocytes, (C) T cells, (D) NKT cells, (E) total NK cells, (F) CD56dim NK 
cells and (G) CD56bnght NK cells staining positive for IFN-y production after in vitro 
stimulation with PfRBC (squares, solid lines) and uRBC (circles, dashed lines) at each 
time point. Data show mean ± SEM of responses by n=5 volunteers. All time points per 
volunteer were measured in a single experiment; individual volunteers were measured in 
separate experiments. H. Pie charts show the mean contribution of T cells (vertical 
striping), NKT cells (hashed), NK cells (horizontal striping) and other lymphocytes 
(blank) to the total number of IFN-y+ cells responding to PfRBC at different time points
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(corrected for uRBC background); pie chart surface areas directly correlate with the 
magnitude of the (total) IFN-y+ response. I. Correlation between percentages of 
responding T cells and NK cells within volunteers at each time point. Symbols represent 
individual samples for which paired data were available.
Memory-like responses by supposedly innate NK cells have previously been 
demonstrated following influenza vaccination, although no mechanism was sought or 
proposed [14]. Furthermore, T-cell independent NK-mediated immunological memory 
responses have been described in a murine model of hapten-induced delayed-type 
contact hypersensitivity [15]. In other models, proliferation of specific NK subsets 
following ‘priming’ by a pathogen has been shown [16], which may subsequently 
contribute toward control of infection [17]. We therefore next assessed the relative 
contribution of NK and T cells to total IFN-y responses following exposure.
Relative contribution of NK cells to total IFN-y response wanes slowly 
following exposure
Proportions of total T cells and NK cell numbers within the PBM C population did not 
vary greatly between the time points (Supplementary table 1). Prior to challenge (day 
C-1), NK cells made up on average 14% of total IFN-y+ lymphocytes responding to 
PfRBC, with T cells making up 71% (Fig 1.H). Despite the overall increase in 
responding cell numbers following challenge, relative contributions by NK cells and T 
cells to the IFN-y+ response did not differ much immediately following exposure (17% 
and 68% , respectively, on day C+35). However, thereafter the relative contribution of 
IFN-y-producing T cells over NK cells increased slightly with time, with NK cells 
making up only 7% of IFN-y+ lymphocytes 20 weeks after challenge and T cells 83% 
(Fig 1.H), perhaps indicating a maturation of the immune response. Within the NK 
population, the relative proportion of responding CD56dim cells to responding CD56bright 
cells remained roughly constant over time (not shown).
Notably, the proportions of responding T cells and NK cells appeared to be correlated 
within volunteers at all time points (Fig 1.I). Thus, although the relative contribution of 
T cells over NK cells increases somewhat in relation to exposure, in vitro T cell and NK 
cell responses to PfRBC are closely linked within donors.
NK cells are dependent on T cell help for IFN-y response to PfRBC in vitro 
Since both T cells and NK cells showed such parallel IFN-y responses to stimulation 
with P. falciparum in vitro, we next investigated reciprocal interactions between these 
cell types using magnetic bead depletion assays (representative FACS plots shown in 
supplementary figure 1.B). In the absence of NK and NKT cells depleted with anti- 
CD56 beads, the capacity of T cells to respond to PfRBC was slightly reduced (Fig.
2.A). However, depletion of CD3+ T and NKT cells completely abrogated the ability of 
remaining NK cells to produce IFN-y against PfRBC  (Fig. 2.B). Notably, this effect 
must be largely due to T cells bearing an apT cell receptor, since the depletion of y5T
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cells had little effect on NK cell responses (not shown). The requirement of T cells for 
NK cell IFN-y production has been described previously for NK responses to influenza 
virus [18] and H IV  [19], but it remains unclear if this represents a ubiquitous 
requirement for NK cell activation.
Interestingly, NK cells still retained some responsiveness against PfRBC even in the 
absence of T cells, as evidenced by partial up-regulation of the IL-2 receptor CD25 
(Fig. 2.C+D). Since IL-2 is produced by activated T cells post-exposure 
(Supplementary figure 1.g) and IL-2 signalling contributes to PfRBC-induced IFN-y 
production by NK cells (Fig. 2.E+F and [11]), we investigated whether IL-2 might form 
the critical link between T cell and NK cell activation, as it does in the influenza model 
[18]. Addition of exogenous IL-2, as expected, increased IFN-y production to PfRBC 
by both T cells and NK cells in whole PBM C populations (Fig. 2.G+H).
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PBMC from study volunteers post­
challenge were mock depleted 
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& NKT cells (‘-CD56’) o r T &  
NKT cells (‘-CD3’) by magnetic 
beads and were subsequently 
stimulated in vitro with (A-D) 
PfRBC alone, (E, F) PfRBC in the 
presence of 50^ g/mL of an 
inhibitory anti-IL-2 receptor-a 
monoclonal antibody or an isotype 
control and (G, H) PfRBC in the 
presence or absence of 100 IU/mL 
recombinant IL-2. The percentage 
of (A, B, E-H) IFN-Y+ and (C, D) 
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determined. Data are combined 
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However, in the absence of T cells, addition of exogenous IL-2 up to 100 IU/mL was 
unable to rescue IFN-y production by NK cells (Fig. 2.H). Thus IL-2 contributes to, but 
alone is insufficient for NK IFN-y production against PfRBC. Possibly the unique 
immunological characteristics of PfRBC, i.e. a protozoan pathogen residing within a 
host cell without MHC class-I molecules, might explain the requirement of further 
activation signals. One potentially interesting candidate in this regard might be the IL-2 
family member IL-21, which is produced by activated T cells [20] and enhances IFN-y 
production by NK cells [21]. Nonetheless, if T cell help is required for NK cell 
activation, this clearly suggests that it is in fact the immunological memory residing 
within the T cell population, rather than intrinsic NK memory, that underlies the 
observed re-call responses by NK cells against PfRBC.
T cells, but not NK cells, are indispensable for IFN-y production to PfRBC
Finally we investigated the relative contribution of different lymphocyte subpopulations 
to the total IFN-y production by PfRBC (Fig. 3.A). Depletion of NK and NKT cells 
from PBM C with anti-CD56 beads prior to stimulation with PfRBC resulted in a 
reduction of IFN-y production by approximately 60%. Thus, although these two cell 
types together form only around 20% of IFN-y-producing cells following exposure (Fig. 
1.H), their contribution to total cytokine secretion is much greater, presumably in part 
due to a positive feedback effect on T cells (Fig. 2.A). Once more, however, anti-CD3 
depletion of all T cells resulted in the total abrogation of IFN-y secretion into the 
supernatant by remaining PBM C, including NKs (Fig. 3.A). Thus NK cells are 
incapable of producing even small amounts of IFN-y in response to PfRBC  in the 
absence of T cells.
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In order to understand whether such patterns are representative of naturally acquired 
immunity to malaria, we performed similar experiments with PBM C from 
representative samples of three other groups: unexposed Caucasian donors (Fig. 3.B), 
Caucasians exposed by visiting malaria-endemic areas (Fig. 3.C) and semi-immune 
African adults living in an area of intense seasonal transmission (Fig. 3.D). Although 
relative contributions of CD56+ cells varied slightly between individual volunteers, the 
overall pattern was remarkably similar in all, confirming the generality of our findings. 
Of particular note, two out of six malaria-naïve donors responded to PfRBC with 
considerable IFN-y production (Fig. 3.B), a well-known phenomenon [4, 22-24], yet 
even in these ‘innate’ responders depletion of CD3+ cells but not CD56+ cells resulted in 
total abrogation of IFN-y production. In these donors, ‘memory’ is presumably 
provided by cross-reacting T cells [22, 23, 25].
Concluding Remarks
Far from representing an unchanging innate reaction, the IFN-y response by NK cells 
against PfRBC is thus dynamic and exposure-related, but wholly dependent on 
accessory T cell help. Indeed, their immunologically ‘innate’ status needs to be 
questioned if NK cells are incapable of independently responding to PfRBC in the 
absence of ‘adaptive’ T cells. However, the insights presented do provide encouraging 
implications for malaria vaccine development, since they suggest that by inducing 
classical memory T cell responses vaccination w ill simultaneously achieve enhanced 
NK responses ‘into the bargain’.
Materials & methods
Human infections - Protocols for and clinical course of stringently controlled 
experimental human malaria infections at our centre have been described in detail 
before [12, 13]. Briefly, after providing written informed consent, 5 healthy malaria- 
naïve Dutch volunteers were infected with malaria by exposure to the bites of 5 P. 
falciparum-infected mosquitoes and followed-up closely for symptoms and signs of 
malaria. As soon as a standard microscopic thick smear of peripheral blood became 
positive for malaria parasites, volunteers were treated with a standard curative regimen 
of the anti-malarial drug artemether-lumefantrine. The study was approved by the 
Institutional Review Board of the Radboud University Nijmegen Medical Centre (CMO 
2006/207).
Parasites - Preparations of mature parasitized red blood cells (PfRBC ) and mock- 
cultured uninfected erythrocytes (uRBC) were obtained by routine methods as described 
previously [12] and cryopreserved at 150x106/mL in 15% glycerol/PBS in aliquots for 
use in stimulation assays. Cryopreserved PfRBC  form almost as strong a stimulus as
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fresh PfRBC and have identical stimulatory characteristics (Supplementary figure 2). 
Their use in large experiments has logistical advantages, in addition to reducing 
confounding due to inter-batch variation. One single large batch of cryopreserved 
PfRBC was used for the entire follow-up study described above.
PBMC stimulations - Venous whole blood was collected into citrated CPT vacutainers 
(Becton and Dickinson, Basel) prior to challenge (day C-1), during blood-stage malaria 
infection (day C+9), three weeks after treatment (day C+35) and again 20 weeks after 
challenge (day C+140). Peripheral Blood Mononuclear Cells (PBM C) were obtained 
by density gradient centrifugation, washed 3x in cold PBS, enumerated, frozen down in 
10%DMS0/FBS and stored in liquid nitrogen.
Immediately prior to use, cells were thawed, washed twice in RPM I and resuspended in 
complete culture medium (RPM I 1640 containing 2mM glutamine, 1mM pyruvate, 
50^g/mL gentamicine and 10% v/v human A+ serum, Sanquin, Nijmegen) for a final 
concentration of 2.5x106/mL. PBM C were transferred into 96-well round-bottom plates 
and were stimulated in duplo wells with either 5x106/mL cryopreserved PfRBC or 
uRBC. PBM C were stimulated for 24 hours at 37°C/5%C02; 4 hours prior to cell 
harvest, 100^L/well supernatant was collected and stored at -80°C for subsequent 
cytokine measurement and replaced with 100^L/well fresh culture medium containing 
brefeldin A (Sigma) for a final concentration of 10^g/mL.
In some experiments, IL-2 signalling was blocked immediately prior to stimulation by 
the addition of an inhibitory anti-IL-2Ra monoclonal antibody, or isotype control (both 
from R&D Systems, Abingdon, UK), at a final concentration of 50^g/mL based on 
titration experiments. In other experiments whole PBM C were depleted of individual 
leukocyte sub-populations by magnetic beads specific for CD3e, ySTCR or CD56 
(Miltenyi Biotech, Utrecht, N L) according to the manufacturer’s instructions. Depleted 
PBM C were cultured at a concentration equating to 2.5x106 whole PBMC/mL. 
Undepleted control PBM C in these experiments were treated similarly, i.e. also passed 
over a magnetic column. Efficiency of depletion was assessed in a subset of donors by 
flow cytometry and was consistently >90%, >90% and >95%, respectively. In a subset 
of these experiments exogenous recombinant human IL-2 was added immediately prior 
to stimulation at final concentrations up to 100IU/mL.
As a control, similar depletion experiments were performed on PBM C from a 
representative sample of malaria-naïve Caucasian donors, Caucasians who have 
regularly visited malaria-endemic areas under chemoprophylaxis and semi-immune 
African adults. For the latter group, PBM C were collected from healthy adult male 
volunteers in the Koro district of Mali as part of ongoing investigational studies into 
interethnic differences in susceptibility to malaria [26]. Samples for which data is 
presented here were collected during the 2008 dry season (April). Approval for the 
study was provided by the institutional review board of the University of Bamako 
(N°0527/FMPOS).
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Intracellular staining fo r  flow  cytometry - Following 24 hour in vitro stimulation (last 4 
hours with 10^g/mL brefeldin A), PBM C were stained for surface markers and 
intracellular IFN-y using Fix &  Perm reagents (Caltag Laboratories, Carlsbad CA) 
according the manufacturer’s instructions and read on a FACScalibur flow-cytometer. 
The following fluorescent MAbs were used: CD3-PerCP, CD25-APC (BD, San Jose 
CA), IFN-y-FITC, mouse IgG1 isotype-FITC, IL-2-APC, CD56-PE & CD56-APC (all 
Ebioscience, Uithoorn, NL).
Cytokine ELISA - IFN-y production in supernatant was measured by sandwich EL ISA  
(Sanquin, Amsterdam, NL), according to the manufacturer’s instructions.
Statistical analysis - Non-parametric tests (Wilcoxon, Spearman, Friedman) were used 
in all analyses; p-values <0.05 were considered statistically significant.
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Supplementary table 1: Lymphocyte subset compostition*
Time
point
T cells NKT cells NK cells CD56dim
NKs
CD56bright
NKs
other
C-1 78.7 0.7 3.2 2.8 0.2 17.3
(78.1-82.6) (0.4-0.8) (2.3-4) (2.1-3.9) (0.2-0.4) (10.5-17.5)
C+9 79.5 0.8 3.1 2.6 0.3 16.4
(76.4-84.7) (0.5-0.8) (2.4-4) (2.2-3.7) (0.2-0.4) (11.7-17.3)
C+35 82.1 1.2 4.0 3.5 0.4 12.2
(78.0-85.5) (0.8-3.2) (3.7-4.3) (3.2-3.9) (0.4-0.5) (9.8-14.2)
C+140 79.9 1.2 4.6 4.3 0.3 12.8
(78.4-82.6) (1.2-1.3) (3.6-6.8) (3.4-6.4) (0.3-0.4) (10.8-14.5)
p-value 0.24 0.15 0.31 0.31 0.39 0.19
* Data represent median (IQR) percentage of lymphocytes (n=5). P-values by Friedman’s non- 
parametric test for multiple related samples.
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Supplementary figure 1. Representative FACS plots showing cellular responses in whole or 
depleted PBMC
A. Representative FACS plots of lymphocyte phenotypes (a) and IFNy (b-e) or IL-2 (f+g) 
production in response to PfRBC (b+c, f+g) or uRBC (d+e) in one volunteer pre-exposure (b, d, 
f) and post-challenge (c, e, g). B. Undepleted PBMCs (left column), or PBMCs depleted of CD3+ 
cells (middle column) or of CD56+ cells (right column), were stimulated in vitro with PfRBC (h-j, 
n-p) or uRBC (k-m, q-s). Shown are representative FACS plots of IFNy production (h-m) and 
CD25 up-regulation (n-s) in a volunteer post-challenge. Inlays represent percentage of 
lymphocytes within each quadrant.
PfRBC: cryo fresh cryo fresh cryo fresh
undepleted undepleted - CD3
Supplementary figure 2. IFNy responses by PBMC following in vitro stimulation with 
cryopreserved or fresh PfRBC
Whole PBMC or PBMC depleted of CD3+ cells were stimulated for 24 hours in vitro in the 
presence of either cryopreserved or freshly isolated PfRBC. Cells were subsequently stained for 
phenotype and intracellular IFNy production and analyzed by flow cytometry. Box & whisker 
plots represent respectively median, quartiles & range of A. T cells and B. NK cells staining 
positive for IFNy from study volunteers post-challenge. Dotted lines represent median responses 
to uRBC. *p<0.05 for differences in response between depleted vs undepleted PBMC by 
Wilcoxon paired sample signed-rank test.
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Abstract
Cellular responses against Plasmodium parasites, in particular IFNy production, form an 
important contribution to malarial immunity. However, they are commonly held to be 
difficult to induce and/or quick to wane, although the dynamics of cellular responses in 
relation to exposure have proven difficult to study and hard data are lacking.
Here we have explored in detail cellular responses against both pre-erythrocytic and 
blood-stage malaria parasites in previously-naive human volunteers undergoing single 
or multiple experimental P. falciparum infections under highly controlled conditions. 
In vitro IFNy responses by PBMCs were measured by flow cytometry prior to, during 
and up to 13 months post-infection. We show that cellular responses against both 
sporozoites and PfRBC  are not only readily induced following even a single infection, 
but also remarkably long-lived, remaining almost undiminished at least a year post­
infection. Various lymphocyte subsets contribute to the overall increase in IFNy 
response against PfRBC, including not only ‘adaptive’ apT cells, but also ‘semi-innate’ 
y5T and ‘innate’ NK cells. Amongst T cells, CD4+ cells outnumber CD8+ cells in 
responses against both PfRBC  and particularly sporozoites. Moreover, the majority of 
responding cells express an effector memory phenotype both early and late post­
infection. Whereas y5T cells also express such memory markers, we show through 
depletion and autologous recombination that apT cells are the primary vehicles of this 
immunological memory, to which y5T cells also independently contribute. Finally we 
show that infection induces and maintains pluripotent (IFNy+IL-2+) effector memory 
responses against both PfRBC and sporozoites, but that only anti-sporozoite responses, 
although lower in absolute terms, appear to mature in functionality following infection. 
These data demonstrate unequivocally that cellular responses are readily induced and 
long-lived following infection and suggest continued interdependence between adaptive 
and (semi-)innate lymphocyte subsets for executing memory responses against malaria. 
The implications hereof are positive for malaria vaccine development in general and 
whole parasite-based vaccines in particular.
Abbreviations
PfRBC - Plasmodium falciparum-infected erythrocytes 
uRBC - uninfected erythrocytes
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Introduction
Malaria is caused by parasites of the genus Plasmodium, which are transmitted from 
host to host by Anopheline mosquitoes, within whose habitat range reside 3.3 billion of 
the world’s human population [1]. Upon inoculation, sporozoite-stage parasites initiate 
an asymptomatic liver infection, following which blood-stage forms invade and 
multiply exponentially within erythrocytes, the latter process underlying the full 
spectrum of morbidity and mortality associated with clinical malaria. Compounding 
this global burden is the fact that malaria infection, in contrast to many common 
paediatric infectious diseases, does not immediately confer immunity but leaves victims 
susceptible to multiple new symptomatic infections throughout childhood and early 
adulthood; indeed, in endemic areas even adults are found to harbour sub-clinical 
parasitaemia (reviewed in e.g. [2, 3]). Attempts to explain this immunological 
shortcoming have included both the poor induction (priming) of immune responses by 
malaria and the rapid attrition of such responses, although the validity of both 
hypotheses has been brought into question (discussed in e.g. [4, 5]) .
Direct immunological evidence in humans to support or reject both explanations is 
limited, however. Immune responses against malaria are commonly believed to be 
short-lived following exposure, based mainly on the short half-life of specific antibodies 
[6-8] (reviewed in [9]). It would appear that cellular responses to individual antigens 
are also either relatively short-lived, i.e. declining within a few years of exposure [10, 
11], or at least unstable [12-16], but may occasionally persist in areas of unstable 
transmission [17]. However, field studies in endemic areas attempting to answer these 
questions suffer from a profound difficulty in controlling for exposure amongst study 
subjects. Anecdotal evidence from malaria-therapy studies suggests that cellular 
proliferative responses to crude whole parasite antigen can be detected in donors several 
years following a single malaria infection [18] and more recently robust cellular 
cytokine responses were detected at 3 months post-infection in previously naïve 
volunteers [19]. Thus, although responses to individual antigens or epitopes may be 
unstable, the overall cellular response against whole parasites may remain longer-lived.
Experimental human malaria infections are a safe and well-established model, 
performed on hundreds of volunteers over the past two decades, for assessing the 
efficacy of candidate malaria vaccines [20], but also provide a powerful tool for 
exploring basic immunology. Here we have compiled a comprehensive longitudinal 
assessment of cellular responses, in particular IFNy production, against both pre- 
erythrocytic (sporozoite) and blood-stage (PfRBC) parasites in malaria-naïve volunteers 
undergoing single or multiple experimentally induced infections with P. falciparum. 
Interferon-gamma (IFNy) forms a central mediator of cellular immunological responses 
against malaria (reviewed in [21]). In vitro IFNy responses against malaria parasites 
have been shown to correlate with protection against malaria both amongst volunteers 
undergoing experimentally induced infection [22, 23] and naturally-exposed human 
populations [24-27]. Whereas the cellular source of cytokine responses against
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sporozoites has received little attention, phenotypic characterization the in vitro IFNy 
response against whole blood-stage parasites (PfRBC) in malaria-naive donors has 
implicated variously ‘innate’ natural killer (NK) cells [28, 29], ‘semi-innate’ y5T cells 
[30] (including intriguing NK-like y5T cells [31]) and ‘adaptive’ apT cells [32-34]. 
However, it remains unknown how these intrinsic responses develop and mature in the 
course of actual malaria infection and how (long) cellular memory is maintained.
The highly controlled measure of exposure in our volunteer studies allows for the first 
time a detailed insight into the development of cellular immunological memory 
following malaria infection in humans. We show that, in contrast to prevailing opinion, 
even a single patent episode induces robust cellular re-call responses against both 
parasite stages, lasting almost undiminished at least 13 months post-infection, but that 
the execution of full immunological memory responses against malaria requires 
continued interaction between innate and adaptive lymphocytes.
Materials &  Methods
Parasites - NF54 strain P. falciparum  parasites were grown in RPMI-1640 containing 
10% human A+ serum and a 5% haematocrit erythrocyte suspension in a semi­
automated culture system, in the absence of antibiotics and regularly screened for 
mycoplasma contamination. For in vitro stimulation experiments, asynchronous 
asexual-stage cultures of NF54 strain parasites were harvested at a parasitaemia of 
approximately 10-20% and mature asexual stages purified by centrifugation on a 63% 
Percoll density gradient [35]. This purification step results in preparations of 80-90% 
parasitaemia, consisting of more than 95% schizonts/mature trophozoites. Preparations 
of parasitized red blood cells (PfRBC ) were washed twice in PBS and cryopreserved at 
150x106/mL in 15% glycerol/PBS in aliquots for use in individual stimulation assays. 
Cryopreserved PfRBC  form almost as strong a stimulus as fresh PfRBC and have 
identical stimulatory characteristics (Supplementary figure 1); their use in large 
experiments has logistical advantages, in addition to reducing confounding due to inter­
batch variation. Mock-cultured uninfected erythrocytes (uRBC) were obtained similarly 
and served as control.
Sporozoites were obtained from Anopheles stephensi mosquitoes that were reared 
according to standard procedures at our insectary. Infected mosquitoes were obtained 
by feeding on gametocytes cultures of NF54 strain P. falciparum, as described 
previously [36]. On day 21-28 after infection, the salivary glands of the mosquitoes 
were collected by hand-dissection. Salivary glands were collected in DM EM  and 
homogenized in a custom glass grinder. Free sporozoites were counted in a Burker-Turk 
counting chamber using phase-contrast microscopy. Sporozoites were cryopreserved at 
16x106/ml in 15% glycerol/PBS in aliquots for use in individual stimulation assays. 
Sporozoites that had undergone one freeze-thaw cycle were microscopically still intact, 
but were no longer able to glide (assay described in [37]). Salivary glands from an
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equal number of uninfected mosquitoes were obtained similarly and served as a 
background control.
Human infections - The basic design and outcome of experimental human malaria 
infections at our centre has been described before [38]. For the study presented here 
[23], 15 healthy malaria naïve Dutch volunteers were recruited after giving written 
informed consent and randomized double blind to either Group A (n=10) or Group B 
(n=5). Group A volunteers were exposed on three occasions, at monthly intervals, to the 
bites of 12-15 NF54 strain P. falciparum-infected mosquitoes, whilst continuously 
taking a standard prophylactic regimen of chloroquine (300mg base per week). Group B 
volunteers similarly took chloroquine and were exposed to the same number of bites but 
from uninfected mosquitoes. Two months after the final exposure and one month after 
discontinuation of chloroquine prophylaxis, all 15 volunteers were challenged by 
exposure to the bites of 5 P. falciparum-infected mosquitoes and followed-up closely 
for symptoms and signs of malaria. As soon as thick smear positive, volunteers were 
treated with a standard curative regimen of artemether-lumefantrine (6 doses of 
80/480mg over 3 days). The study was approved by the Institutional Review Board of 
the Radboud University Nijmegen Medical Centre (CMO 2006/207).
Cellular immunology - Venous whole blood was collected into citrated CPT vacutainers 
(Becton and Dickinson, Basel) at inclusion (day I-1), following discontinuation of 
prophylaxis and immediately prior to challenge (day C-1), during blood-stage malaria 
infection (day C+9), roughly two weeks after treatment with AL (day C+35) and again 
20 weeks (day C+140) and 13 months (day C+400) after challenge (Fig. 1). Peripheral 
Blood Mononuclear Cells (PBMCs) were obtained by density gradient centrifugation, 
washed 3x in cold PBS, enumerated, frozen down in 10%DMS0/FCS and stored in 
liquid nitrogen. Immediately prior to use, cells were thawed, washed twice in RPM I 
and resuspended in complete culture medium (RPM I 1640 containing 2mM glutamine, 
1mM pyruvate, 50^g/mL gentamicin and 10% human A+ serum, Sanquin, Nijmegen) 
for a final concentration of 2.5x106/mL. PBMCs were transferred into 96-well round- 
bottom plates and were stimulated in duplo wells with either 5x106/mL cryopreserved 
PfRBC  or uRBC, or 5.6x105/mL cryopreserved sporozoites or the extract of an 
equivalent number of uninfected mosquito salivary glands. In a subset of experiments 
PBMCs were instead stimulated with pools of individual purified sporozoite-stage (CSP 
and TRAP), liver-stage (LSA-1 or Exp-1) or blood-stage (AMA-1, MSP-2, MSP-3 and 
GLURP) antigens at concentrations up to 30 ^g/mL per antigen; in these experiments 
60 IU  recombinant IL-2 was added to culture medium for optimal cellular responses. 
A ll PBMCs were stimulated for 24 hours at 37°C/5%C02; 4 hours prior to cell harvest, 
100^L/well supernatant was collected and stored at -80°C for subsequent cytokine 
measurement and replaced with 100^L/well fresh culture medium containing brefeldin 
A (Sigma) for a final concentration of 10^g/mL.
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Depletion/recombination - For recombination experiments, PBMCs collected at 
inclusion (I) or post-challenge (C) were divided into two aliquots. One aliquot was 
depleted of y5T cells by magnetic beads and untouched y5Tpos cells were isolated from 
the second aliquot by negative selection, using magnetic beads (Anti-TCR y/5 
MicroBead K it and TCRy/5+T Cell Isolation Kit, respectively, both from Miltenyi 
Biotech), according to the manufacturer’s instructions. Following separation, 
autologous I/C ySTneg and ySTpos cells were recombined at their original ratios. Purity 
of depletion was consistently >90%, whereas purity of negative selection varied 
between 40-80%; the majority of contaminating non-y5T cells in these negatively 
selected populations consisted of NK and other non-T lymphocytes.
Intracellular staining fo r  flow  cytometry - CD3-CD56-y8T stain - Following 24 hour in 
vitro stimulation, PBMCs were harvested and transferred to FACS tubes (250,000 
cells/tube), washed once in FACS buffer (0.5% BSA/PBS) and incubated for 15’ with 
fluorescent MAbs against cell surface markers. Cells were washed again in FACS 
buffer and incubated for 15’ in fixation medium A (Caltag Laboratories, Carlsbad CA) 
according the manufacturer’s instructions, washed again and incubated for 15’ with 
fluorescent MAbs against intracellular cytokines in permeabilisation medium B. After a 
final wash step, cells were resuspended in FACS buffer and read on a FACScalibur flow 
cytometer (Becton Dickenson). The following fluorescent mAbs were used: CD3- 
PerCP (clone CK7, BD Biosciences), CD56- APC & IFNy-FITC (clones MEM188 & 
4S.B3 respectively, both from Ebioscience) and TCR Pan y/5-PE (clone IMMU510, 
Beckman Coulter).
T cell phenotype stain - Following 24 hour in vitro stimulation, PBMCs were harvested 
and transferred to 96 wells V-plate (250,000 cells/tube), washed once in PBS and 
incubated with live/dead fixable dead cell stain kits Aqua (Invitrogen, Carlsbad, CA, 
USA) for 30 min on 4°C. Cells were washed in PBS and for a second time with FACS 
buffer (PBS containing 0.5% albumin for bovine serum (Sigma Chemical Co.)), and 
stained with IOTest anti-TCR Pan y/5-PE (Beckman-Coulter, Fullerton, CA, USA), 
IOTest CD45RO-phycoerythrin Texas Red (Beckman-Coulter), PerCP anti-human CD3 
(BioLegend, San Diego, CA, USA), PE-Cy7 anti-human CD62L (eBioscience, San 
Diego, CA, USA), Pacific Blue anti-human CD4 (eBioscience) for 20 min on 4°C, and 
Alexa-fluor 700 anti-human CD8 (BioLegend). After washing, cells were incubated 
with fixation Medium A (Caltag, S. San Francisco, CA, USA) and subsequently, 
incubated with FITC anti-human IFN- y (eBioscience) and APC anti-human IL-2 
(eBioscience) in permeabilisation Medium B (Caltag) for 20 min on 4°C. Cells 
(100,000) gated on a lymphocyte gate by forward- and side-scatter were acquired on a 
CyAn ADP 9 colour flow cytometer (Beckman- Coulter).
Statistical analysis - Flow cytometry analysis was performed using Cell Quest and 
FlowJo V9.1 software, and statistical analysis performed in SPSS 16.0. Differences in 
responses within volunteers between time points or between conditions were analyzed 
by non-parametric Wilcoxon signed rank test. Unless otherwise stated, statistical
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analyses were performed on data corrected for background, i.e. responses to PfRBC 
subtracted by responses to uRBC; negative values were set to zero. P-values <0.05 
were considered statistically significant in all analyses.
Results
Cellular recall responses against both pre-erythrocytic and blood-stage 
parasites are readily induced and long-lived following malaria infection
In vitro responses against malaria parasites were measured in PBMCs isolated from two 
sets of human volunteers before and at several time points after exposure to P. 
falciparum  infection under highly controlled circumstances. Group A volunteers (n=10) 
were exposed thrice over to immunizing bites of infected mosquitoes whilst under 
chloroquine prophylaxis and subsequently infected with patent parasites; group B 
volunteers (n=5) received only one patent infection (Fig. 1).
Group A(n=10)
Group B (n=5)
Time (days) 0 7 35 63 119 154 259 519
Immunological day day day day day day
assessment I-1 C-1 C+9 C+35 C+140 C+400
Figure 1. Flowchart of Experimental Human Malaria Infection study
Mosquito symbols indicate exposure to infectious bites. Development of patent blood- 
stage parasitaemia following the first three inoculations in Group A volunteers was 
prevented by prophylactic chloroquine treatment. Arrow heads indicate time points of 
immunological assessment: prior to immunization (I-1), prior to patent challenge (C-1), 
during blood-stage infection (C+9) and 2 weeks (C+35), 17 weeks (C+140) and 13 
months (C+400) post-treatment.
Responses against neither pre-erythrocytic stage sporozoites nor blood-stage PfRBC 
were detectable prior to exposure (day I-1) in either group of volunteers (Fig. 2.A+C). 
Recall responses by PBMCs against both sporozoites and PfRBC, as measured by IFNy 
production, first became visible in Group A volunteers following exposure to 
immunizing bites (day C+1) and increased further in magnitude following patent 
infection (day C+35) for anti-PfRBC responses (Fig. 2.A) and to a lesser extent for anti- 
sporozoite responses (Fig. 2.C). Recall responses against PfRBC and to a lesser extent 
also sporozoites became similarly detectable in group B volunteers following their 
primary patent infection (Fig. 2.A+C). Cellular responses were also assessed against 
pools of individual sporozoite-stage (CSP and TRAP), liver-stage (LSA-1 or Exp-1) and 
blood-stage (AMA-1, MSP-2, MSP-3 and GLURP) antigens (all leading malaria
101
Chapter 5
vaccine candidates), but no such responses could be detected above background in any 
of the volunteers at any time point (data not shown). Nevertheless, cellular immune 
responses against whole pre-eythrocytic and blood-stage malaria parasites are thus 
readily inducible in previously-naïve donors following a small number of, or even a 
single malaria infection.
Most remarkably, cellular responses against malaria parasites did not wane after 
exposure, but rather remained robust 20 weeks and even over a year post-challenge. 
Indeed, cellular re-call responses against sporozoites and PfRBC appeared even to 
intensify with time post-exposure in previously immunized volunteers (Fig. 2.A+C). 
Thus cellular responses induced by malaria infections in previously naïve humans 
remain long-lived at least 1 year post-exposure.
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Figure 2. Induction and 
persistence of IFNy 
responses to PfRBC and 
sporozoites in volunteers 
undergoing experimental 
malaria infection 
PBMC were isolated from 
volunteers prior to inclusion 
(day I-1), immediately prior 
to patent challenge (day C-
1), during expected blood- 
stage malaria infection (day 
C+9), 2 weeks after 
treatment (day C+35), 20 
weeks post-challenge (day 
C+140) and again 13 
months post-challenge (day 
C+400). Note: Group A, 
but not Group B, volunteers 
were exposed to thrice over 
to immunising sub-patent 
infections between day I-1 
and C-1 (Fig. 1). PBMCs
were stimulated in vitro for 24 hours with PfRBC (A) or sporozoites (B) (both represented by 
squares) or their respective uRBC or MSG controls (circles), then stained for intracellular IFNy 
production and analysed by flow cytometry. Shown are the percentage of total lymphocytes 
staining positive for IFNy production at each time point. Data represents median±IQR responses 
by Group A volunteers (filled symbols, n=10) and Group B volunteers (open symbols, n=5).
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T cells are the main in vitro IFNy-producers in response to PfRBC 
following infection
Since many different lymphocyte subsets, including (aP)T cells, y5T cells and NK cells, 
have variously been shown capable of responding to PfRBC, we next assessed the 
contribution of these and other lymphocyte sub-populations to the overall IFNy 
response against PfRBC prior to and post-exposure (flow cytometry gating strategy 
illustrated in Supplementary figure 2). Total numbers of lymphocytes and most of 
their sub-populations did not differ markedly at the various time points assessed, the 
only exception being y5T cells, whose relative numbers in the peripheral lymphocyte 
population almost doubled post-exposure in both groups of volunteers (Supplementary 
table 1).
I-1 C-1 C+35 C+400
0 y5T cells 
□ T cells 
B NK cells
SySNKT cells 
a NKT cells 
□ other lymphocytes
Figure 3. Contribution of innate, semi-innate and adaptive lymphocyte subsets to 
total IFNy+ response against PfRBC
PBMCs isolated from volunteers at the respective study time points were stimulated with 
PfRBC or uRBC and stained for intracellular IFNy production and surface expression of 
CD3, yST and CD56 (gating strategy shown in Supplementary figure 2). Pie charts show 
the relative contributions of apT cells (CD3+yS'CD56‘), yST cells (CD3+yS+CD56‘), NK 
cells (CD3yS'CD56+), NKT cells (CD3+yS'CD56+), ‘ySNKT’ cells (CD3+yS+CD56+) and 
other lymphocytes to the total number of IFNy+ cells responding to PfRBC (corrected for 
uRBC background). Data represent median values for Group A (above, n=10) and Group 
B (below, n=5) volunteers; pie chart surface areas correlate with total IFNy+ response.
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Response patterns in most lymphocyte subsets, including (aP)T, NKT and NK cells, 
mirrored the dynamics of the total PBM C response in relation to exposure; that is, 
whereas almost no responses above background could be detected in volunteers at 
inclusion, IFNy responses to PfRBC became clearly detectable following challenge 
(Supplementary figure 3). In contrast, a significant proportion (around 4%) of y5T 
cells demonstrated the capacity to respond to PfRBC even prior to exposure and this 
percentage increased further following infection (Supplementary figure 3.C). 
Responses in ‘y5NKT’ cells, relatively infrequent in total number (Supplementary 
table 1), resembled the pattern in regular y5T cells (Supplementary figure 3.F).
Figure 3 shows the relative contribution of different lymphocyte subsets to the total 
IFNy response over time. Relative values varied considerably between donors, but of 
the few lymphocytes producing IFNy in response to PfRBC prior to exposure, overall 
60% [43-74%] (median [IQ R]) were y5T cells, with apT cells comprising 18 [0.0-36%], 
y5NKT 9.9% [6.9-17%] and NK cells 3.4% [0.4-6.6%] making up most of the rest. 
Interestingly, despite an increase in overall numbers of responding cells, these relative 
contributions remained more or less stable following repeated exposure in group A 
volunteers (57% [50-63%], 25% [15-30%], 6.7% [5.1-10%] & 3.6% [2.8-5.0%], 
respectively), whereas in group B volunteers following malaria infection there was an 
increase in apT and NK relative to y5T responses (28% [26-32%], 37% [37-38%], 3.1% 
[3.0-3.4%] &  19% [15-21%]). By day 400, the contribution of y5T cells had dropped, 
but was still substantial, in both group A (35% [29-44%], 25% [20-28%],11% [8.0­
16%] &  17% [12-25%]) and group B (18% [18-23%], 41% [36-45%], 6.2% [6.1-7.5%] 
& 27% [20-27%]). Nevertheless, clearly not only ‘adaptive’ apT cells and ‘semi­
innate’ y5T cells, but also ‘innate’ NK cell contribute to the overall increase in IFNy+ 
lymphocytes responding to P. falciparum  following malaria infection (Figure 3).
CD4+ T cells predominate over CD8+ T cells in recall responses against 
both PfRBC and sporozoites
Further analysis of IFNy producing T cells revealed that CD4+ T cells markedly 
outnumbered CD8+ T cells in response to both pre-erythrocytic and blood-stage 
parasites post-challenge. Following in vitro stimulation with PfRBC, 16% [13-22%] 
(median [IQ R]) and 26% [20-32%] of IFNy-producing T cells were CD4+CD8- in 
Group A and B volunteers, respectively; in contrast only 4.5% [3.1-5.6%] and 7.3% 
[4.7-8.8%] were CD4-CD8hlgh (day C+400, not shown). This difference was even more 
marked for anti-sporozoite responses, with 56% [49-83%] and 81% [70-90%] of IFNy+ 
T cells being CD4+CD8- in Group A and B volunteers, respectively, and 8.4% [1.9­
10%] and 0.0% [0.0-1.7%] CD4-CD8high (day C+400, data not shown). It should be 
noted that CD4-CD8high cells represent ‘true’ CD8+ T cells (CTLs), whereas y5T and 
NKT cells both also express CD8, but at lower levels (CD4-CD8intermediate). Thus 
whereas y5T cells and CD4+ (aP)T cells appear to be the predominant responders to 
PfRBC, the IFNy response against sporozoites is primarily mediated by CD4+ T cells. 
In contrast, CD8+ T cells appear hardly to contribute to in vitro recall responses against 
either PfRBC  or sporozoites following experimental human malaria infections.
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In vitro IFNy recall responses against malaria parasites are predominantly 
derived from effector memory cells both early and late after infection
Early following treatment (day C+35) 84% [80-87%] and 0.1% [0.0 -0.4%] of IFNy- 
producing lymphocytes following 24-hour in vitro PfRBC stimulation in Group A 
volunteers displayed effector (CD45RO+CD62L-) and central (CD45RO+CD62L-) 
memory phenotypes, respectively. Remarkably, despite an overall increase in response 
against PfRBC in group A volunteers by day C+400, relative contributions by effector 
and central memory cells did not change markedly: 72% [67-76%] and 0.6% [0.6-0.8], 
respectively (Fig. 4.A). Corresponding values for group B volunteers at day C+35 were 
76% [74-80] and 0.5% [0.3-1.1] and remained constant over time, both in terms of total 
cell numbers and in effector/central memory distribution (Fig. 4.B). Responses to 
sporozoite stimulation showed a similar effector/central memory pattern to PfRBC 
responses (Fig. 4.C+D). Note that y5T-cells also display an ‘effector memory’ 
phenotype (CD45RO+ CD62L-). Thus in vitro recall responses against malaria parasites 
remain primarily derived from the effector memory population, which includes both 
(aP)T and y5T cells, whereas central memory (CD45RO+CD62L-) cells contribute only 
a tiny fraction of the total recall response, even months after infection.
A Group A B Group B
CD45RO-
CD45RO+ CD62L+ 
CD45RO+ CD62L-
Figure 4. Contribution of effector and central memory cells to the total IFNy recall 
response against PfRBC and sporozoites
PBMCs isolated from volunteers at various study time points were stimulated in vitro for 
24 hours with PfRBC (A+B) or sporozoites (C+D) and stained for memory markers 
CD45RO and CD62L. Cake charts show the contributions of effector memory 
(CD45RO+CD62L"), central memory (CD45RO+CD62L+) and naive lymphocytes 
(CD45RO-) to total IFNy-producing cells over time. Data represent median values for 
Group A (A+C, n=10) and Group B (B+D, n=5) volunteers.
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Both aPT cells and y8T cells independently carry immunological memory 
for PfRBC
Since both aPT cells and y5T display memory phenotypes and can mount adaptive 
responses, we first investigated whether aPT cells, y5T cells, or both, are capable of 
carrying immunological memory for PfRBC.
We separated and re-combined ySTpos cells and ySTneg PBMCs (consisting of 
approximately 80% aPT cells and 5% NK cells) from both the time point of inclusion 
(‘Pf-naive’) and post-challenge (‘Pf-exposed’) (Fig. 5). The most important factor 
contributing to the total number of PfRBC-responding IFNy+ lymphocytes was ‘Pf- 
exposed’ ySTneg cells, i.e. largely aPT cells (Fig. 5.A). However, ‘Pf-exposed’ ySTpos 
cells also increased total responses when combined with either ‘Pf-naive’ or ‘Pf- 
exposed’ ySTneg PBMCs. Furthermore, removal of all ySTpos cells reduced total 
numbers of IFNy+ lymphocytes by approximately 50% in both ‘Pf-naive’ and ‘Pf- 
exposed’ ySTneg PBMCs (Fig. 5.A), in accordance with the results in figure 3. Factors 
determining the proportion of responding aPT cells were similar to those for all 
lymphocytes as a whole, i.e. most ‘memory’ was carried within their own population, 
with a small increase in responding aPT cells numbers when co-incubated with ‘Pf- 
exposed’ ySTpos cells (Fig. 5.B). ‘Pf-exposed’ ySTpos cells to an extent carried their 
own intrinsic ‘memory’, particularly in some donors. However, the most important 
factor determining numbers of responding ySTpos cells was co-incubation with ‘Pf- 
exposed’ ySTneg PBMCs (Fig. 5.C). Thus in particular aPT cells, but to a lesser extent 
also y5T cells, independently and intrinsically carry immunological memory for PfRBC. 
Of note, NK cells in ‘Pf-naive’ PBM C populations did not respond intrinsically to 
PfRBC, but reacted robustly within ‘Pf-exposed’ ySTneg populations, suggesting either 
intrinsic memory within the NK population or dependency on aPT cells (Fig. 5.D).
Induction and maturation of pluripotent memory responses against 
malaria parasites
Whereas IFNy has many direct effector functions, the cytokine IL-2 is important for T 
cell proliferation and the induction of cellular memory responses. In a final set of 
experiments, we therefore explored the dynamics of effector memory cells producing 
either IL-2 or IFNy alone, or both cytokines simultaneously (pluripotent lymphocytes), 
in response to PfRBC and sporozoites (Fig. 6). In line with the increase in IFNy 
responses against PfRBC over time in Group A volunteers, the percentage of IL-2+ 
effector memory cells, although low in absolute numbers, increased from 0.22% [0.19­
0.33%] (median [IQR] of total lymphocytes) at day C+35 to 0.34% [0.28-0.38%] at day 
C+400; similarly the percentage of IFNy+IL-2+ cells increased from 0.13% [0.10­
0.15%] to 0.22% [0.19-0.22%]. However the contribution of such pluripotent cells to 
the overall response decreased from 4.6% [3.0-6.4%] day C+35 to 3.4% [2.5-4.3%] at 
day C+400 (Fig. 6.A). In Group B volunteers, the relative contribution of pluripotent 
cells to the PfRBC  responses did increase marginally (2.7% [2.0-3.7%] to 4.9% [3.9­
5.8%]) although in absolute terms these numbers remained low (0.18% [0.15-0.22%] at 
day C+400, Fig. 6.B).
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Figure 5. Immunolo-gical 
memory carriage by yôT 
cells vs. other PBMCs
Cryopreserved PBMCs 
isolated from volunteers at 
inclusion (I) or post­
challenge (C), were thawed 
and separated by magnetic 
beads into yôTpos 
lymphocytes (white) and 
remaining yôTneg PBMCs 
(shades of grey, e.g. T 
cells, B cells and NK cells). 
Following autologous re­
combination at original 
ratios (above), PBMCs 
were stimulated, stained 
and measured as for Figure
2. Shown are the 
percentage of total 
lymphocytes (A), apT cells 
(B), yST cells (C) and NK 
cells (D) staining IFNy+ 
following incubation with 
PfRBC (corrected for 
responses against uRBC). 
Data represent mean+SEM 
of 6 volunteers.
In contrast, although again low in absolute numbers, both IL-2+ and IFNy+IL-2+ 
responses against sporozoites increased markedly in group A volunteers, with relative 
the contribution of pluripotent cells to such responses rising from 5.9% [5.4-19%] to 
18% [16-27%] between day C+35 and day C+400 (Fig. 6.C). For group B volunteers, 
the increase in IL-2 response was even more noticeable (0.03% [0.02-0.05%] to 0.14% 
[0.12-0.16%], Fig. 6.D). Thus although infrequent in total number, pluripotent effector 
memory cells against both PfRBC and sporozoites are induced by and increase 
following infection. However, whereas cellular responses against PfRBC do not appear 
to ‘mature’, such responses against sporozoites increase in functionality as well as 
magnitude.
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Figure 6. IFNy and IL-2 production by uni- and pluripotent effector memory T cells
Data represent median percentage of effector memory (EM) T cells producing either IFNy 
alone, IFNy plus IL-2, or IL-2 alone, following 24 hours in vitro stimulation with PfRBC 
(A+B) or sporozoites (C+D) at various time points before and after infection for group A 
(A+C) and group B (B+D) volunteers.
Discussion
In this study we have delineated in detail the dynamics of cellular immune responses 
against P. falciparum  parasites following malaria infection in previously-naive 
individuals. We demonstrate unequivocally, and in contrast to popularly held belief, 
that IFNy responses against malaria parasites are not only readily induced following 
infection, but also persist more or less undiminished over at least 13 months in the 
absence of further exposure. Importantly, we find responses not only against blood- 
stage PfRBC, but also against pre-erythrocytic stage sporozoites. Both responses 
appear to be either conformation-dependent or at least antigenically broad, since 
responses against individual pre-erythrocytic or blood-stage antigens are hardly 
detectable above background. The main contributors to these IFNy responses consist of 
y5T cells and effector memory CD4+ (aP)T cells, with NK cells making up a small 
fraction of responding cells. We show that not only adaptive, but also semi-innate and 
innate lymphocytes responses exhibit an immunological re-call pattern and that 
immunological memory for PfRBC is independently carried by both ap- and y5T cells.
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Furthermore we show that infection induces persisting pluripotent IFNy+IL-2+ 
responses, that at least against sporozoites appear to further mature functionally 
following exposure.
Consistent with findings by others [30, 31], we show that ‘semi-innate’ y5T cells form 
the majority of IFNy+ lymphocytes responding to PfRBC in malaria-naïve donors. 
Interestingly, this remains largely true following exposure, despite the obvious increase 
in ‘adaptive’ responses. Two factors contribute to the overall increase in responding 
y5T numbers: i) The overall proportion of y5T cells in the PBM C pool of donors 
increase roughly 2-fold following exposure to malaria parasites and persist for many 
weeks (Supplementary table 1). A transient dip in circulating y5T cells during infection, 
followed by reactive increase afterwards, has been observed before in primary [39, 40] 
but not repeated malaria infections [41]. ii) A slightly larger proportion of these y5T 
cells shows reactivity against PfRBC. However, it remains unclear whether this 
increase represents the recruitment of PfRBC-specific y5T clones to the peripheral 
circulation or a non-specific in vitro bystander effect. In support of the latter, it has 
been shown previously that y5T cells readily respond to P. falciparum  lysate by 
proliferation in a polyclonal fashion, as to a superantigen [42, 43]. Whatever the 
underlying mechanism, we show here for the first time that the y5T compartment also 
contributes to responses up to 13 months post-infection, although to a lesser extent than 
the apT compartment. As for NK cells, we and others have recently shown their 
dependency on (aP)T cells for full activation by PfRBC  (Chapter 4, [44]), potentially 
explaining the ‘recall-like’ response in this supposedly innate population.
These data can be combined into a model in which ‘semi-innate’ y5T cells, ‘adaptive’ 
apT cells and ‘innate’ NK cells all contribute significantly to a robust and long-lived 
IFNy effector response following malaria infection, but that it is largely apT cells and to 
a lesser extent y5T cells that independently carry the immunological memory (Fig. 7). 
Thus, in ‘Pf-naïve’ PBMCs a substantial proportion of y5T cells, but very few apT cells 
and consequently few NK cells respond to PfRBC. In ‘Pf-exposed’ PBMCs, all three 
subpopulations contribute to the total increase in IFNy -producing cells, but through 
different mechanisms. For y5T cells this is largely through an overall expansion of this 
compartment in peripheral blood, in addition to a minor increase in the proportion of 
responding cells. For apT cells this increase is also relatively small, but in absolute 
terms these lymphocytes already make up the vast majority of PBM C populations. NK 
cells finally, although fewer in absolute terms, show a much larger proportional increase 
in response, albeit dependent on the increase in T cell responses (Chapter 4). This 
model furthermore has positive implications for malaria vaccine development, since 
vaccine strategies aimed primarily at inducing apT cell memory should have the 
additional effect of amplifying critical y5T and NK effector responses.
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Figure 7. Proposed interdependence of lymphocyte subsets for IFNy response to 
PfRBC
Overall IFNy production to PfRBC in vitro is increased in /¡/-exposed donors (B) 
compared to //-naïve donors (A). (AP)T, yST and NK lymphocyte sub-sets all contribute 
to this increased IFNy response to PfRBC in //-exposed donors and their relative 
contribution remains more or less constant. However, only T cells carry intrinsic 
immunological memory, whereas NK cell reponses are absolutely dependent on T cell 
help; in return, NK cells provide some reciprocal feed-back to T cells (Chapter 4). 
Darker cell colours indicate intrinsic immunological memory; line thickness correlates 
with relative strength of relationship; APC - antigen presenting cell.
We recently showed the development of sterile protection against malaria infection in 
human volunteers to be associated with the induction of pluripotent effector memory T 
cells [23]. Interestingly, these responses were measured against blood-stage parasites, 
whereas protection appeared to be mainly pre-erythrocytic. The importance of 
pluripotent lymphocytes in immunological protection is believed to derive on the one 
hand from their potent effector capability [45] and on the other hand from their role in 
the induction and persistence ofT cell memory [46]. Here we therefore explored the 
dynamics of pluripotent effector memory responses against both PfRBC  and sporozoites 
in our volunteers in relation following infection. Remarkably, despite an overall 
increase in the number of lymphocytes responding to PfRBC up to a year post-infection, 
the relative proportion of pluripotent-responding cells remained roughly constant, 
suggesting no functional maturation had taken place. In contrast, the proportion of 
lymphocytes producing both IFNy and IL-2 in response to sporozoite stimulation 
increased markedly in both groups of volunteers. It w ill be of great interest to 
determine whether these novel responses represent genuine protective immunity against 
(re-) infection in future human malaria trials.
Having conclusively demonstrated that there is no intrinsic deficit in either the 
induction or persistence of cellular responses against P. falciparum, the obvious 
question arises why cellular responses against P. falciparum antigens in naturally 
exposed populations are so transient/unstable [10-16] and tend in fact to be lower than
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in non-exposed donors [47, 48]. Underlying differences in the status of the immune 
system of inhabitants of the rural tropics, due to e.g. malnutrition [49] or helminth co­
infections [50] may affect the induction of robust Thl-type cellular immune responses, 
including IFNy production. Furthermore, inherent immaturity in the immune systems of 
infants and young children [51, 52], the age at which malaria infection is generally first 
contracted, may predispose to tolerant as opposed to sterilizing immune responses [53]. 
Indeed IFNy responses to P. falciparum  antigens in children tend to be weaker than in 
adults [16, 54-57], although of course the effect of prior exposure in these studies 
cannot be distinguished from that of age per se.
Alternatively, the finding both that the deficit in cellular responses is antigen-specific 
[47, 48] and that Pf-specific cellular responses are reduced following repeated or 
chronic infection [14, 58], would tend to suggest active suppression or elimination of 
responding T cells [59, 60]. Obvious accomplices in this process are regulatory T cells 
[61, 62], although why these should necessarily accumulate under conditions of natural 
exposure remains unclear. In this regard, a comparison of the dynamics of regulatory T 
cells in experimentally induced versus naturally acquired infection would be 
informative.
Despite these caveats in extrapolating our findings to the ‘field’, it is now clear that, 
under the right conditions at least, robust long-lasting cellular immune responses against 
malaria parasites can be readily induced. These results lend further support to the 
development of attenuated whole-parasite-based malaria vaccines [63-65]. Most 
importantly, these findings significantly extend our understanding of how cellular 
immunological memory to P. falciparum  develops and is maintained following 
exposure.
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Supplementary table 1. Lymphocyte subset compostition in volunteers prior to, 
during and post-infectionA_____________________________________________________
time
point
yôT
cells
yôNKT
cells
(aP)T
cells
(aP)NKT
cells
NK
cells
other
lymphocytes
group A I-1 2.4 0.4 77.4 0.8 4.6 14.1
(n=10) (1.6-3.3) (0.2-0.5) (76.4-80.3) (0.6-1.2) (3.5-7.1) (11.6-15.3)
C-1 3.0 0.3 77.4 0.7 2.7 13.3
(2.3-4.3) (0.2-0.5) (76.6-80.4) (0.4-1.1) (19-5) (12.9-16)
C+9 3.5 0.3 77.4 0.7 2.8 14.4
(3-4.1) (0.3-0.8) (75.2-79) (0.4-1) (2.5-5.4) (11.9-16.2)
C+35 4.3 0.6 75.2 0.8 4.9 12.2
(3.8-5.5) (0.4-0.8) (72.9-79) (0.6-1.2) (2.4-7.9) (11.6-14.6)
C+140 4.3 0.6 73.7 1.0 3.6 13.2
(2.7-6.2) (0.5-1.1) (69.1-76.2) (0.8-2.6) (2.8-7.2) (12.7-15.9)
C+400 3.7 1.2 74.4 1.2 6.4 11.4
(3.6-4.5) (0.9-1.6) (71.8-75.5) (0.8-2.1) (5.2-9.8) (9.9-13.2)
group B 
(n=5)
I-1 1.2
(0.8-1.4)
0.1
(0.1-0.2)
80.9
(80-82.1)
0.6
(0.6-0.8)
2.6
(2.6-2.9)
13.4
(10.6-14.4)
C-1 0.8
(0.6-1.3)
0.1
(0-0.2)
78.0
(77.3-81.1)
0.4
(0.3-0.6)
3.2
(2.3-4)
17.3
(10.5-17.5)
C+9 0.7
(0.6-0.9)
0.1
(0.1-0.2)
79.0
(75.1-83.8)
0.6
(0.3-0.7)
3.1
(2.4-4)
16.4
(11.7-17.3)
C+35 2.2
(19-3)
0.3
(0.3-0.4)
79.8
(76-82.5)
0.8
(0.5-2.8)
4.0
(3.7-4.3)
12.2
(9.8-14.2)
C+140 2.8
(2.8-3.5)
0.5
(0.5-0.6)
77.1
(75.5-79.2)
0.8
(0.7-0.8)
4.6
(3.6-6.8)
12.8
(10.8-14.5)
C+400 2.3
(2-2 .6)
0.5
(0.5-0.8)
77.0
(76.1-78.7)
1.0
(0.8-1.3)
5.5
(4.5-6.7)
12.7
(10.8-14.1)
A All data represent median (IQR).
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Supplementary figure 1. IFNy responses by PBMC following in vitro stimulation with 
cryopreserved or fresh PfRBC
A-F. PBMC were stimulated for 24 hours in vitro in the presence of 5x106/mL either freshly 
isolated or cryopreserved PfRBC from the same batch, equivalent numbers of uRBC, 10^ g/mL 
PHA or RPMI only. IL-1P (A), IL-2 (B), IL-10 (C), IL-12p70 (D), IFNy (E) and TNFa (F) 
production in the supernatant were detected by commercially available microbead array according 
to the manufacturer’s instructions (Bio-Rad, Veenendaal, The Netherlands). Data represent 
mean+SEM for 5 donors.
Supplementary figure 2. Representative flow cytometry plots
A. Following 24-hour in vitro stimulation, live PBMC were gated based on CD3-expression and 
sub-populations subsequently further gated based on yST and CD56 expression. B. Intracellular 
IFNy expression following incubation with PfRBC (above) or uRBC (below), in lymphocytes 
obtained from a volunteer post-challenge.
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Supplementary figure 3. IFNy responses in PBMC measured by flow cytometry following in 
vitro stimulation with PfRBC
PBMC were isolated from volunteers prior to immunisation (day I-1), immediately prior to patent 
challenge (day C-1), during expected blood-stage malaria infection (day C+9), 2 weeks (day 
C+35), 17 weeks (C+140) and 13 months (C+400) post-challenge. Cells were stimulated in vitro 
for 24 hours with PfRBC or controls, then stained for phenotype and intracellular IFNy 
production and analyzed by flow cytometry (gating strategy illustrated in Supplementary figure
2). Shown are the percentage of total lymphocytes (A), apT cells (B - CD3+yS'CD56'), yST cells 
(C - CD3+yS+CD56'), NK cells (D - CD3yS'CD56+), NKT cells (E - CD3+yS'CD56+) and 
‘ySNKT’ cells (F - CD3+yS+CD56+) staining positive for IFNy production at each time point. 
Data represents mean±SEM responses by Group A volunteers (filled symbols, n=10) and Group 
B volunteers (open symbols, n=5) to PfRBC (squares, solid lines) and uRBC (circles, dashed 
lines). Asterisks indicate significant responses (*p<0.05, **p<0.01) to PfRBC above background 
(uRBC) by Wilcoxon.
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Abstract
Background - The burden of malaria is a global public health priority and an effective 
vaccine is urgently required. Naturally acquired immunity to malaria develops slowly 
and artificial induction of protection in humans has only been achieved by inoculating 
radiation-attenuated sporozoites through >1000 infective mosquito bites. Furthermore, 
malaria vaccine development is hampered by limited knowledge of correlates of 
protection.
Methods - Two sets of healthy volunteers (10 vera and 5 controls) were exposed three 
times, at monthly intervals, to bites of 15 P. falciparum-infected and uninfected 
mosquitoes, respectively, while taking a prophylactic regimen of chloroquine (CQ). One 
month after CQ discontinuation, protection was assessed by homologous challenge with
5 //-infected mosquitoes. Humoral and cellular responses were assessed prior to 
vaccination and prior to challenge to investigate correlates of protection.
Results - A ll 10 vera demonstrated protection against challenge with //-infected 
mosquitoes. In contrast, all 5 control volunteers developed patent malaria. Adverse 
events were mainly reported by vera after first immunization and by control volunteers 
after challenge; no serious adverse events occurred. We identified the induction of 
parasite-specific pluripotent effector memory T-cells producing IFNy, TNFa and IL-2 
as a promising immunological associate of protection.
Conclusions - Protection against homologous malaria challenge is induced by 
inoculation of intact sporozoites.
Reproduced with permission from  the Massachusetts M edical Society.
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Protection against malaria by sporozoite inoculation
Malaria is responsible for a significant burden of morbidity and mortality in the 
developing world and an effective vaccine against this disease is urgently required [1]. 
Despite decades of research a licensed vaccine is still not available, largely because 
immunity to Plasmodium falciparum  malaria is considered difficult to acquire, whether 
through natural exposure or artificially through vaccination. A  further critical factor is 
our incomplete understanding of precisely what constitutes protective anti-malarial 
immunity in humans.
The possibility of vaccinating humans against P. falciparum  malaria was raised 
originally by the success of the radiation-attenuated sporozoite model developed several 
decades ago [2, 3]. Irradiation of infectious mosquitoes disrupts the gene expression of 
sporozoites, which remain capable of hepatocyte invasion but no longer of complete 
liver-stage maturation or progression to the pathogenic blood-stage [4]. Infection of 
human volunteers with irradiated sporozoites thus exposes them to liver-stage antigens 
and generates pre-erythrocytic immunity. However, the requirement of a minimum of 
one thousand bites by irradiated mosquitoes, over five or more immunization sessions, 
in order to successfully induce sterile immunity in humans [5], precludes this method 
for routine immunization.
Research turned thus to developing a subunit vaccine based on antigens expressed by 
pre-erythrocytic, intra-erythrocytic or sexual stages of the parasite. Unfortunately, 
results of many such subunit vaccines in humans have been disappointing and to date 
only one candidate, based on the circum-sporozoite protein (CSP) and known as RTS,S, 
has progressed to phase III field trials. The protection induced by this vaccine is 
encouraging but the ultimate success of this approach remains to be determined [6-9].
It has been shown that, in rodent models, sterile protection against malaria can also be 
achieved by inoculation of intact sporozoites whilst treating the animals concomitantly 
with chloroquine (CQ) [10], a drug that kills asexual blood-stage but not pre- 
erythrocytic parasites [11], with an efficacy significantly higher than that of the 
radiation-attenuated sporozoite model [12]. We therefore designed a proof-of-concept 
study in malaria-naive volunteers to investigate whether protection can be equally 
effectively induced by this approach in humans and to explore the immune responses 
elicited.
Methods
Volunteers - Fifteen healthy volunteers were recruited, aged 18-45 years old, without 
history of malaria or of residence in a malaria endemic area in the six months prior to 
the trial onset. Only one volunteer had ever been in an endemic area, several years 
earlier. A ll volunteers underwent routine physical examination, haematology and 
biochemistry screening at the Clinical Research Centre Nijmegen. Serology for H IV, 
hepatitis B and C and asexual P. falciparum  parasites was negative in all volunteers. A ll 
volunteers gave written informed consent prior to inclusion. The trial was approved by
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the Institutional Review Board of the Radboud University Nijmegen Medical Centre 
(CMO 2006/207). Clinicaltrials.gov identifier: NCT00442377.
Protocol - Volunteers were randomized double blind into two groups (Fig. 1), 10 vera 
and 5 controls. Chloroquine was provided to all volunteers in a standard prophylactic 
regimen of 300mg base weekly, starting with 600mg in two days, for a total duration of 
13 weeks. Whilst under CQ prophylaxis, vera were exposed on three occasions, at four­
weekly intervals, to bites of 12-15 P. falciparum-infected mosquitoes per session, for a 
total exposure of 36-45 infected mosquitoes per volunteer. Controls received bites from 
an equal number of uninfected mosquitoes on the same occasions. Anopheles stephensi 
mosquitoes were reared according to standard procedures at our insectary. Infected 
mosquitoes were obtained by feeding on gametocytes of NF54, a chloroquine sensitive 
strain o f  P. falciparum, as described previously [13]. NF54 is genetically homogeneous, 
but has not been formally cloned. Only the insectary technicians preparing the 
mosquitoes were aware of the infectivity status of the mosquitoes allocated to the 
volunteers. Blood-engorged mosquitoes were dissected to confirm the presence of 
sporozoites. If  necessary, feeding sessions were repeated until precisely the predefined 
number of infected mosquitoes had fed. However, a single feeding session was 
sufficient in 49/60 of all instances of immunization or challenge, whereas a second 
session was required in just 10 instances and a third session in only 1 instance.
From day 6-10 after each mosquito exposure, all volunteers were followed on an 
outpatient basis and blood was drawn for standard whole blood counts and daily thick 
smears. Any signs and symptoms were recorded by the attending physician as follows: 
mild (easily tolerated), moderate (interferes with normal activity), or severe (prevents 
normal activity).
Eight weeks after the last immunization dose and 4 weeks after discontinuation of CQ 
prophylaxis, all 15 volunteers were challenged by exposure to the bites of five 
homologous NF54 strain P. falciparum-infected mosquitoes. This period was 
considered to be sufficient for CQ levels to drop below levels which might be inhibitory 
to parasite multiplication [14]. Volunteers were checked daily on an outpatient basis 
from day 5 to day 21 for symptoms and signs of malaria, haematological parameters and 
thick smears.
As soon as thick smear positive, volunteers were treated with a standard curative 
regimen of artemether/lumefantrine (starting dose of 80/480 mg, followed by five 
identical doses at 8, 24, 36, 48 and 60 hours) and followed closely for three days. 
Complete cure was confirmed by thick blood smears. A ll volunteers still negative by 
day 21 post-challenge were presumptively treated with artemether/lumefantrine. 
Haematological and biochemical parameters were determined in routine fashion at the 
hospital’s central clinical laboratory. Nucleic Acid Sequence Base Amplification 
(NASBA) and real-time QT-PCR to determine the densities of P. falciparum  parasites 
have been described in detail [15, 16]. Chloroquine levels were measured by liquid 
chromatography as previously described [17, 18]. Minimum therapeutic concentrations
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for plasma chloroquine levels maintained by the laboratory were 30 ^g/l, in accordance 
with Rombo et al. [14].
Immunological analysis - Venous whole blood was collected into CPT vacutainers 
(Becton and Dickinson, Basel) prior to first immunization and again prior to challenge. 
Plasma was collected and stored at -70 °C. Peripheral Blood Mononuclear Cells 
(PBM Cs) were isolated by density gradient centrifugation, frozen down in 10% 
DMSO/FCS and stored in liquid nitrogen. Antibody titres were assessed by EL ISA  and 
immunofluorescence assay according standard protocols as previously described [19­
21]. Cellular responses to cryopreserved asexual parasites were assessed by 24-hour in 
vitro PBM C cell stimulation assays as previously described [22], followed by 
intracellular cytokine staining (Fix & Perm kit, Caltag Laboratories) and flow 
cytometry. A more detailed description of these immunological assays is provided in 
the web-only supplementary methods.
Statistical analysis -  Flow cytometric analysis was performed using CellQuest and data 
analyzed in SPSS; differences in responses within volunteers between time points and 
between vera and control volunteers were analyzed by non-parametric tests (Wilcoxon 
and Mann-Whitney-U, respectively), two-sided p-values <0.05 were considered 
statistically significant.
Results
A ll 15 included volunteers completed the immunization phase of the study, during 
which they were exposed thrice to infected- (‘vera’, n=10) or uninfected mosquitoes 
(‘controls’, n=5) under CQ prophylaxis and were subsequently challenged (Fig. 1).
No parasites were seen in the thick blood-smears of any of the 10 vera following each of 
the three immunization sessions under CQ prophylaxis, but after the first immunization 
a brief sub-microscopic parasitaemic episode was detected in all vera (Fig. 2.a). This 
was not unexpected, since CQ has no effect against either sporozoites, liver-stage 
parasites, or the early ring forms of the first generation of blood-stage parasites caused 
by merozoites released from mature hepatic schizonts [11]. Following each of the 
subsequent two immunizations, a progressively reduced incidence and burden of sub- 
microscopic parasitaemia was seen.
In line with these findings, all vera reported solicited or unsolicited adverse events at 
least once during the immunization phase. When excluding local itching after the 
mosquito bites, adverse events were most commonly reported after the first 
immunization (9/10 volunteers), with headache being the most frequent (7/10) (Table 
1). Only few adverse events occurred subsequently (0/10 and 2/10 volunteers after the 
second and third immunization respectively). Severe adverse events were reported by 
three vera: two experienced fever above 39°C after the first immunization, one reported 
severe malaise after the last immunization.
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Figure 1. Study flow chart and demographics
Immunological assessment was performed 1 day prior to 1st immunization (day I-1) and 1 
day prior to challenge infection (day C-1).
Following challenge with homologous NF54 strain of P. falciparum, asexual blood- 
stage parasites were detected in thick blood smears of all 5 control volunteers between 
days 7 and 10.6 post-exposure (mean pre-patent period 9.2 days). Real-time PCR 
analyses revealed the expected cyclical multiplication of blood-stage parasites (Fig.
2.b). Clinical course and kinetics of parasite multiplication were identical to those in 
previous studies involving naive volunteers [23, 24], with all controls reporting severe 
events, in particular fever above 39°C and malaise (Table 1). In marked contrast, there 
was no evidence of blood-stage parasites in any of the vera at any time during the post­
challenge follow-up period till day 20 , either by repeated microscopy of thick blood 
smears or by real-time PCR analyses (Fig. 2.b). Interestingly, 9/10 vera did report mild 
to moderate events in the week following challenge. No serious adverse events 
occurred during any part of the trial and all 15 volunteers completed follow-up 
according to protocol.
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a  Immunisation phase
Figure 2. Parasitaemia in vera and 
controls
a. Number of P. falciparum 
parasites/ml (measured by NASBA) 
after the first (I), second (II) and third 
(III) immunization at days before (-1) 
infection and during expected blood 
stage parasitaemia (days 6-10) in vera 
(mean ± S.E.M.). The number of 
volunteers who became thick smear 
(MPS) and NASBA positive are 
indicated. b. Kinetics of P. falciparum 
parasitaemia (mean ± S.E.M.) from 
data of 5 control (open triangle) and 
10 vera (filled diamonds) as 
determined by qPCR before treatment 
with artemether/lume-fantrine.
Mean peak chloroquine and desbutyl-chloroquine levels measured 24 hours after 
administration were 76 ^g/l (range 58-104 ^g/l) and 13 ^g/l (5-33 ^g/l) respectively and 
did not differ between control and vera. The day before challenge plasma levels had 
dropped to 8 ^g/l (range <5-14 ^g/l) and <5 ^g/l, which is below the minimum 
therapeutic concentrations in vivo [14]. Furthermore, blood-stage parasite multiplication 
kinetics in the controls were identical to those found in previous studies [24], affirming 
that any residual CQ levels had no measurable parasitocidal effect.
Following immunization, vera but not controls developed antibody responses to both 
sporozoites and blood-stage parasites, as shown by EL ISA  (Table 2) and 
immunofluorescence assay (Supplementary figure 1). The majority (8/10) of vera 
seroconverted to the (NANP)6 central repeat peptide of the circumsporozoite protein 
(CSP), an immunodominant sporozoite- and liver-stage antigen. In contrast, only 3/10 
seroconverted to crude asexual-stage antigen. Antibodies to two predominantly asexual 
antigens (AMA-1 and GLURP), both leading vaccine candidates, were undetectable. 
These data are consistent with the relatively low dose exposure to asexual blood-stage 
antigens in the vera.
MPS+ 0/10 0/10 0/10
PCR+ 10/10 6/10 3/10
b Challenge phase
Days post infection
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Table 1. Number of volunteers reporting solicited or unsolicited adverse events1 
after the first, second and third exposure to immunizing mosquito bites under 
chloroquine prophylaxis and after challenge with infectious mosquito bites in the
vera and control groups. No serious adverse events occurred.____________________
Vera (n=10) Controls (n=5)
post
immunization
post
chall.
post
immunization
post
chall.
I I I I I I I  I I  I I I
Abdominal mild 2
pain moderate
severe
Fatigue mild 1 1 7 1 2
moderate 2 1 1 2
severe 1
Fever mild
moderate
severe
2
1
2 5
Headache mild 4 7 2 3 2
moderate 2 1 1 1 1 3
severe 1 1
Loss of mild 1
appetite moderate
severe
Malaise mild 1 1 1
moderate 2 1
severe 1 1 5
Myalgia mild
moderate
severe
1
2
1
2
1
3
4
Nausea mild 3 1 1 1 1
moderate 1 1 1 1
severe 1
Vomiting mild
moderate
severe
1
1
Overall2 mild 4
(40%)
1
(10% )
8
(80%)
1 3 
(20% ) (60%)
moderate 3 1 1 2  1
(30%) (10%) (20%) (40%) (20%) 
severe 2 1 1 5  
____________________ (20% )_________ (10% )_________________________(20% ) (100% )
'Subjects could have more than one adverse event. Only adverse events possibly or probably 
related to the study are listed.
2Highest grade event listed per volunteer per infection.
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Table 2. Antibody reactivity in vera and controls by E L ISA
Day I-11 Day C-1
vera controls vera controls
CSP 0/102 0/5 8/10 0/5
[< 12]3 [< 12] [33 (21-210)] [< 12]
AMA1 ND ND 0/10 0/5
[< 5.8] [< 5.8]
GLURP ND ND 0/10 0/5
[< 42] [< 42]
asexual 0/10 0/5 3/10 0/5
[< 0.6] [< 0.6] [1.7 (1.5-2.0)] [< 0.6]
‘Plasma was collected prior to immunization (day I-1) and prior to challenge (day C-1).
2Number of volunteers with detectable responses (> mean + 3SD of naive donor pool); ND = not 
done
3Antibody titre in responders in arbitrary units (AU) [median(range)]. (Response of Tanzanian 
semi-immune adult pool was set at 100 AU; thresholds for CSP, AMA1, GLURP and asexual 
positivity as defined in 2 equated to 12, 5.8, 42 and 0.6 AU, respectively.)
Cellular immune responses were assessed by enumerating cytokine producing cells 
within the PBM C populations of volunteers by intra-cellular cytokine staining and flow 
cytometry after 24 hour in vitro stimulation with homologous strain P. falciparum- 
infected erythrocytes (PfRBC) or controls (Fig. 3 and supplementary figures 2+3). 
Whereas cellular responses to uninfected erythrocytes (uRBC) never differed in any 
experiment from those to culture medium alone, stimulation with PfRBC elicited small 
percentages of lymphocytes producing IFNy or TNFa, but not IL-2, in both groups of 
volunteers prior to immunization (day I-1, Supplementary figure 2). Although no 
statistically significant increment was seen in the overall percentage of cells producing 
individual cytokines (IFNy+ or TNFa+) in either group following immunization (day C- 
1), a marked and significant increase was observed in the percentages of cells producing 
multiple cytokines in response to PfRBC in vera (IFNy+IL-2+ p=0.026, Fig. 3.a; 
TNFa+IL-2+ p=0.046, Fig. 3.b; IFNy+TNFa+IL-2+ p=0.032, Fig. 3.c). The importance of 
these pluripotent lymphocytes in acquired immune protection is suggested by their 
higher cytokine content and possibly as a consequence a better effector function (Fig.
3.d-f). The major contributors to this increase in PfRBC-responding pluripotent 
lymphocytes were (CD3+CD45RO+) memory-like T cells (p=0.025 vs. day I-1, Fig. 3.g 
and supplementary figure 3), in particular CD4+CD8- cells (p=0.005 vs. day I-1, Fig.
3.h). Most noticeably, these new pluripotent lymphocytes were predominantly of the 
effector memory (CD62L-CD45RO+) phenotype (p=0.005 vs. day I-1), although there 
was also a small but significant (p=0.017) increase in the numbers of responding central 
memory (CD62L+CD45RO+) cells in vera (Fig. 3.i).
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Figure 3. In vitro pluripotent cytokine responses to P. falciparum parasites by flow 
cytometry
a-c: Percentage of vera (shaded grey) and control (unshaded) lymphocytes collected prior 
to immunization (day I-1) and prior to challenge (day C-1) producing IFNy+IL-2 (a), 
TNFa+IL-2 (b) and IFNy+TNFa+IL-2 (c), respectively, following in vitro stimulation 
with PfRBC, uRBC or PHA. Dotted lines represent the percentage of positive cells in 
unstimulated wells (culture medium only). d-f: Geometric mean fluorescence intensity of 
cells producing respectively IFNy (d), TNFa (e) and IL-2 (f) isolated from vera prior to 
challenge (day C-1) and stimulated in vitro with PfRBC. Cells are grouped according to 
their positivity or negativity for each of the other two cytokines. g-i: Number of cells 
within specific lymphocyte sub-populations producing IFNy+IL-2 in response to PfRBC 
as a percentage of total lymphocytes; total numbers of IFNy+IL-2+ lymphocytes following 
stimulation with uRBC were below 0.005% (not shown). g. Lymphocyte phenotypes: 
naïve T cells (CD3+CD45RO-, vertically lined bars), memory T-cells (CD3+CD45RO+, 
hashed bars) and non-T-lymphocytes (CD3‘CD45RO‘, plain bars). h. T-cell phenotypes: 
T-helper cells (CD4+CD8- vertically lined bars), cytotoxic T-cells (CD4-CD8+, 
horizontally lined bars) and other lymphocytes (CD4-CD8-, plain bars). i. Memory 
phenotypes: naïve T-cells (CD62L+CD45RO-, vertically lined bars), central memory T - 
cells (CD62L+CD45RO+, hashed bars), effector memory T-cells (CD62L-CD45RO+, 
horizontally lined bars) and other lymphocytes (CD62L-CD45RO-, plain bars). Data 
represent mean + SEM of vera (n=10) and control (n=5) volunteers; p-values represent 
differences between vera and controls by Mann-Whitney. Representative FACS plots are 
shown in supplementary fig. 2+3. Relative proportions of lymphocyte sub-populations 
remained constant between time-points in both vera and controls (Suppl. fig. 3).
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Discussion
Our study shows that sterile protection to an homologous challenge with P. falciparum  
malaria can be much more efficiently induced in comparison to irradiation-attenuated 
sporozoite immunization. In the endemic situation, non-sterile semi-immunity is 
acquired only after years of repeated natural exposure. The improved efficiency of our 
approach we believe to be due to a critical balance of exposure to pre- and intra- 
erythrocytic antigens. In contrast to irradiated sporozoites that arrest early during liver- 
stage development [4], intact sporozoites under CQ cover mature fully and develop into 
a first generation of blood-stage parasites [11], thus presenting to the host’s immune 
system a markedly broader palette of pre-erythrocytic and additionally, albeit at 
relatively low-dose, erythrocytic-stage antigens. The contribution of intra-erythrocytic 
antigens to the development of protective immunity is suggested by Pombo et al., who 
reported that repeated intravenous injection of ultra-low densities of blood-stage 
parasites followed by drug-cure with atovaquon/proguanil induced protection in human 
volunteers against a similarly low-dose blood-stage challenge [25]. However, caution 
needs to be exercised when interpreting the latter results, since residual anti-malarial 
drug concentrations may partially or even fully have accounted for the observed 
protection [26].
In the field, in contrast, patent parasitaemia typically develops before patients seek 
treatment. In these individuals, acute blood-stage infection may suppress the induction 
of protective pre-erythrocytic immunity, as has been shown in rodent models [27]. 
Indeed, parasitaemic episodes or febrile malaria attacks in Kenyan children are 
prospectively associated with a poorer induction and more rapid attrition of cellular ex 
vivo and memory responses to a pre-erythrocytic P. falciparum  antigen [28]. Thus, 
patent parasitaemia and probably also chronic sub-patent parasitaemia, as are 
experienced regularly by children in endemic areas, appear to induce inhibitory 
mechanisms that delay the generation of protective anti-parasite immunity. Meta­
analysis of intermittent preventative therapy in infancy (IPT i) studies has decreased 
concerns of a rebound-effect and in some cases even indicates sustained protection 
following discontinuation of prophylaxis [29], thus further indicating that the 
acquisition and maintenance of protective immunity is not dependent on chronic blood- 
stage exposure. The salient feature of our approach we believe therefore to be the 
exposure of the immune system to the full palette of pre-and intra-erythrocytic antigens, 
whilst restricting the development of symptomatic and potentially immunosuppressive 
parasitaemia [30]. Since NF54 is known to be a CQ-sensitive strain in vitro [31], we 
cannot formally exclude a synergistic effect of residual sub-therapeutic chloroquine 
levels on immunological parasite clearance. However, chloroquine levels prior to 
challenge approached or fell below the lim it of detection and had no measureable 
parasitocidal effect in control volunteers. Of more importance, the longevity of 
immunological responses, both naturally-acquired and vaccine-induced, remains a 
critical issue in malaria and follow-up studies are planned to address this issue.
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We have identified pluripotent effector memory T cell responses as associated with 
protection. Undefined lymphocyte subsets with the same cytokine profile have been 
associated with the induction and maintenance of antigen-specific T cell memory in 
individuals immunized with pre-erythrocytic malaria vaccine candidates, but this study 
did not explore associations with protection [32]. The potent effector function of 
pluripotent cells, as suggested by their high cytokine content, has however been noted in 
other investigations demonstrating their protective role in other infectious diseases [33, 
34]. Further detailed investigations w ill be necessary to ascertain the longevity of this 
immunological response, its association with central memory-type T cell activity and its 
ability to serve as a true correlate of protection.
Since the magnitude of the first wave of parasitaemia is thought to directly reflect the 
burden of erupting mature liver schizonts, the step-wise decrease of such following each 
subsequent immunizing infection, culminating in the total absence of PCR-detectable 
parasitaemia following challenge, would suggest that the protection in our model is 
primarily due to pre-erythrocytic immunity. However, a component of blood-stage 
immunity, i.e. the inhibition of erythrocyte invasion and maturation of sub-PCR liver- 
derived merozoite inocula, is also possible. Indeed we found cellular responses to 
asexual blood-stage parasites (PfRBC) prior to challenge to be an excellent 
discriminative marker of exposure and protection in our volunteers and similar immune 
responses may have contributed to protection in the rodent model [35]. It must be borne 
in mind, however, that many of the best-studied P. falciparum  antigens conferring 
protective immunity are shared between sporozoite, liver-stage and blood-stage 
parasites [36, 37]. Thus it is plausible that our findings represent the response to a broad 
antigenic repertoire that transcends parasite developmental stages [38], making a 
dichotomy into pre-erythrocytic or intra-erythrocytic immunity inappropriate. At 
present the stage-specificity of the protective immune response must thus remain 
formally unresolved, although one way to further address this issue in future studies 
would be a blood-stage challenge.
Whereas the methodology described here does not itself represent a widely 
implementable vaccine strategy, the induction of sterile protection against an 
homologous malaria challenge suggests that the concept of a whole parasite malaria 
vaccine warrants further consideration. In addition, this model allows the nature of 
protective immune responses against malaria, both stage- and antigen-specific, to be 
further investigated.
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Supplementary methods
Serology - To assess antibody titers, asexual ELISA s were performed as previously 
described1. CSP ELISA s were performed with (NANP)6 NA (kind gift from G. 
Corradin) according to published methods2. AMA-1 and GLURP ELISA s were 
performed according to a standard in-house protocol2,3. In all ELISA s a plasma pool of 
8 healthy malaria-naive Dutch volunteers was used as a negative control to define 
sample positivity (above mean+2SD of negative control). A plasma pool of Tanzanian 
adults (n=100) living in a highly malaria endemic area was used as reference positive 
control, defined to contain 100 arbitrary units (AU).
Immunofluorescence assays were performed by incubating plasma at 1/320 dilution 
with air-dried whole sporozoites or at 1/40 dilution with asynchronous cultures of NF54 
strain asexual P. falciparum  parasites, as previously described3.
Cellular immunology - Cellular immune responses were assessed by in vitro stimulation 
assays. For use in these assays, Percoll-purified asynchronous asexual-stage cultures of 
NF54 strain parasites of 80-90% parasitaemia, consisting of more than 95% 
schizonts/mature trophozoites, were washed, aliquoted and cryopreserved in advance. 
Mock-cultured uninfected erythrocytes (uRBC) were obtained similarly and served as 
control. Cryopreserved PBMCs were thawed immediately prior to use in in vitro 
stimulation assays, washed and resuspended in RPM I 1640 culture medium containing 
2mM glutamine, 1mM pyruvate, 50^g/mL gentamicin and 10% pooled human AB+ 
serum (Sanquin, Nijmegen, N L), for a final concentration of 2.5x106/mL. PBMCs 
were transferred into 96-well round-bottom plates (5x105/well) and stimuli were added 
to duplicate wells. Stimuli included cryopreserved PfRBC  (5x106/mL), uRBC, PHA (10 
^g/mL) or RPM I only. PBMCs were stimulated for 24 hours at 37°C/5%CO2. 4 hours 
prior to cell harvest, 100^L/well supernatant was collected and replaced with 
100^L/well fresh culture medium containing 20^g/mL brefeldin A (Sigma). PBMCs 
from both time points per volunteer were tested simultaneously and cells from two 
vaccinees and one control were always tested together.
Following 24 hour in vitro stimulation, PBMCs were harvested, washed once in FACS 
buffer (0.5% BSA/PBS) and incubated for 15’ with fluorescent MAbs against cell 
surface markers. Cells were washed again and incubated for 15’ in fixation medium A 
(Caltag Laboratories, Carlsbad, CA) according to the manufacturer’s instructions, 
washed again and incubated for 15’ with fluorescent MAbs against intracellular 
cytokines in permeabilisation medium B. After a final wash step, cells were 
resuspended in FACS buffer and read on a FACScalibur flow cytometer. The following 
fluorescent MAbs were used: CD3-PerCP, CD4-PerCP, CD8-PE (BD, Breda, NL), 
IFNy-FITC, TNFa-PE, IL-2-APC, CD45RO-PE, CD62L-PeCy7, mouse IgG1-FITC & 
IgG2a-PE and rat IgG2a-APC isotype controls (all Ebioscience, Uithoorn, NL).
1Bousema JT, Roeffen W, van der KM et al. Rapid onset of transmission-reducing antibodies in 
Javanese migrants exposed to malaria in Papua, Indonesia. Am J  TropMedHyg. 2006; 74:425-31.
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immunisation with Plasmodium falciparum AMA1 induces broader allelic recognition and growth 
inhibition responses in rabbits. Infect Immun. 2008;76(6):2660-70.
3Hermsen CC, Verhage DF, Telgt DS et al. Glutamate-rich protein (GLURP) induces antibodies 
that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine. 
2007; 25:2930-40.
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Supplementary figure 1. Representative immunofluorescence assay (IFA ) images
Plasma from a vaccinee collected prior to immunization (day I-1, left) or prior to challenge (day 
C-1, right), was incubated at 1/320 dilution with whole sporozoites (above) or at 1/40 dilution 
with an asynchronous culture of asexual blood-stage parasites (below).
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Supplementary figure 2. In vitro cytokine responses to P. falciparum parasites by 
intracellular flow cytometry
a. Representative flow cytometry plots of cytokine production by PBMC isolated prior to 
immunization (day I-1, left) or prior to challenge (day C-1, right) from a vaccinee (above) and a 
control volunteer (below) and stimulated in vitro for 24 hours with PfRBC. b-d: Percentage of 
vaccinee (shaded grey) and control (unshaded) lymphocytes collected prior to immunization (day 
I-1) and prior to challenge (day C-1) producing IFNy (b), TNFa (c) and IL-2 (d), respectively, 
following in vitro stimulation with PfRBC or controls. Dotted lines represent the percentage of 
positive cells in unstimulated wells (culture medium only). Data represent mean + SEM of 
vaccinees (n=10) and control (n=5) volunteers; p-values represent differences between vaccinees 
and controls by Mann-Whitney.
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Supplementary figure 3. Lymphocyte sub-populations
Representative FACS plots (a-c) and relative proportion (d-f) of lymphocyte sub-populations in 
PBMCs isolated from vaccinees (grey bars) or control volunteers (white bars) prior to 1st 
immunization (day I-1) or prior to challenge (day C-1). a+d: Lymphocyte phenotypes: naïve T 
cells (CD3+CD45RO-, vertically lined bars), memory T-cells (CD3+CD45RO+, hashed bars) and 
non-T-lymphocytes (CD3-CD45RO-, plain bars); note that all CD45RO+ cells are also CD3+ (T- 
cells). b+e: T-cell phenotypes: T-helper cells (CD4+CD8- vertically lined bars), cytotoxic T-cells 
(CD4-CD8+, horizontally lined bars) and other lymphocytes (CD4-CD8-, plain bars). c+f: Memory 
phenotypes: naïve T-cells (CD62L+CD45RO-, vertically lined bars), central memory T-cells 
(CD62L+CD45RO+, hashed bars), effector memory T-cells (CD62L-CD45RO+, horizontally lined 
bars) and other lymphocytes (CD62L-CD45RO-, plain bars). Data represent mean + SEM of 
vaccinees (n=10) and control volunteers (n=5).
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Abstract
Introduction - Interethnic differences in susceptibility to malaria provide a unique 
opportunity to explore sorely needed immunological correlates of protection. The 
Fulani of Sahelian Africa are known for their lower susceptibility to P. falciparum  than 
surrounding tribes, yet the immunology underlying this is still poorly understood. 
Methods & Results - Here we show that mononuclear cells from Fulani individuals elicit 
over 10-fold stronger IFNy production following 24-hour in vitro co-incubation with 
asexual parasites than cells from the sympatric Dogon. This response appears specific 
for P. falciparum  amongst a panel of other human pathogens, and is independent of the 
lower number of regulatory T cell numbers in the Fulani. IFNy responses in both tribes 
were inversely correlated with peripheral parasite density as quantified by nucleic acid 
sequenced-based amplification, but Fulani responses remained significantly stronger 
than Dogons’ after adjustment for concurrent parasitaemia, suggesting hard-wired 
immunological differences underlie the observed protection.
Conclusions - These results underscore the value of early IFNy responses to P. 
falciparum  as a correlate of anti-parasite immunity, not just in this field setting but in 
the wider context of malaria, and support the development of malaria vaccines aimed at 
inducing such responses.
By permission o f  Oxford University Press
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Introduction
Studying interethnic differences in susceptibility to disease not only sheds light on the 
co-evolution of host and pathogen, but forms an important tool to investigate 
immunological correlates of protection. For no other infectious disease is this more true 
than for malaria, that has formed a major selective force on human populations in 
endemic areas, particularly sub-Saharan Africa, throughout man’s modern history [1]. 
Furthermore, such immunological insight is sorely needed in the development of a 
successful vaccine against this devastating disease.
The Fulani people of Sahelian Africa show markedly lower susceptibility to malaria 
than surrounding peoples. Interestingly, this holds true wherever this tribe is studied: 
from Mali [2] & Burkina Faso [3, 4], through to Sudan [5, 6]. Lower susceptibility is 
manifested by a lower prevalence and density of (asymptomatic) asexual P. falciparum  
parasitaemia in all age groups and by fewer per capita cases of symptomatic malaria 
infection [2, 3, 7].
Repeated investigation points to underlying differences in the immune system of the 
Fulani as being responsible, rather than behavioural factors [2, 8] or erythrocyte- 
associated genetic traits [9]. Fulani have a higher spleen rate [2, 10] and higher 
prevalence and titres of anti-P. falciparum  antibodies than sympatric tribes [11-13]. 
Interestingly, Farouk et al. found this stronger serological response was not correlated 
with an alteration in cellular Th2/Th1 ratio, with both pathways in fact appearing 
marginally more responsive in Fulani compared to Dogon [14]. Recently is was 
proposed that lower numbers of circulating regulatory T cells (Tregs) in Fulani lead 
simultaneously to more robust anti-malarial immunity and a higher incidence of 
autoimmune disease [15]. Importantly, however, neither the pathogen-specificity of 
cellular effector responses in this African population, nor their correlation with 
susceptibility to parasitaemia at an individual level, has ever been explored.
IFNy forms a crucial cytokine in both the innate and adaptive cellular immune response 
to malaria parasites. It is produced by NK cells [16] and both ap- and y5-T cells [17, 
18] within 24 hours following PfRBC stimulation in vitro and is critical in inducing 
innate and adaptive effector functions [19]. Cellular IFNy responses have been shown 
to protect volunteers in an experimental human malaria challenge model, in the absence 
of antibodies [20]. Furthermore, early IFNy responses to PfRBC correlate with clinical 
protection in both children [21] and pregnant women [22].
Here we studied early cellular responses to PfRBC in Fulani and Dogon of Mali, 
focussing in particular on IFNy responses. We show that Fulani mononuclear cells 
produce a markedly stronger IFNy response to in vitro stimulation with P. falciparum, 
but not other common pathogens, and that this response is independent of regulatory T 
cell numbers, but strongly associated with lower parasite densities.
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Materials & methods
Inclusion - The study site has been described in detail elsewhere [2]; briefly, the Dogon 
valley of Mali is a rural Sahelian area with intense seasonal malaria transmission during 
the rainy season (June-September), with very little transmission at other times of the 
year. Dogon and Fulani inhabit this area in sympatric villages. Samples for this study 
were collected in 4 separate inclusion sessions: two during the rainy season (September 
2005 and September 2006) and two during the dry season (April 2007 and February 
2008). The study included both healthy adult male volunteers and all patients presenting 
to the local health centre with symptoms of uncomplicated malaria. A thick blood slide 
was made from each volunteer, stained in 3% Giemsa and examined for the presence of 
P. falciparum  parasites; parasites were enumerated per 300 leukocytes and parasite 
densities calculated assuming a leukocyte count of 7.5x106/mL. Axillary temperature 
was measured in all patients and symptomatic malaria was defined as fever (>37.5°C), 
or history of fever, plus the presence of any density of parasites in the blood by 
microscopy [2]. No symptomatic malaria patients were expected or were recruited 
during either of the two dry season inclusions. Based on recruitment experience during 
the pilot study in 2005, we aimed to include roughly 50 healthy volunteers and 25 
patients per tribe during the 2006 study and 25 healthy volunteers per tribe during the 
2007 study; actual enrolment numbers within the available time differed only slightly. 
Another 10 healthy volunteers per tribe were recruited for more detailed immunological 
analysis during the 2008 study. Full clinical and immunological data is presented for all 
enrolled donors as far as possible; in 2006, however, PBMC stimulation assays and 
Treg enumeration (see below) could not be performed in all donors for logistical 
(mainly transportation) reasons; actual numbers of data available per assay are stated in 
the respective tables and figures in the Results section. Both community and individual 
informed consent was obtained in all cases, in the case of minors from parents or 
guardians [23]. Approval for this ongoing study was provided by the institutional 
review boards of the University of Stockholm (National Ethical Committee no. 03 536) 
and the University of Bamako (N°0527/FMP0S).
Blood collection - 10mL venous whole blood was collected into lithium heparin 
vacutubes (BD) from all healthy volunteers and symptomatic patients for whom this 
was considered clinically responsible. 500^L of whole blood was first removed for full 
blood count and parasite quantification by NASBA. Tubes were then centrifuged for 
10’ at 1700rpm, plasma collected & stored at -80C and the cell pellet reconstituted to 
the original volume with RPMI. PBMCs were isolated by centrifugation over Ficoll- 
Hypaque and washed three times in cold PBS.
PBMC stimulations - PBMCs were cultured in U-96 well plates at a final concentration 
of 2.5x106/mL in RPMI containing 2mM glutamine, 1mM pyruvate, 50^g/mL 
gentamicin and 10% pooled human AB+ serum (Sanquin, Nijmegen, NL) and 
stimulated in duplicate wells for 24 hours at 37°C with PfRBC or uRBC or with a
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variety of control stimuli. Following stimulation, supernatants were harvested and 
stored at -80°C until measurement of cytokine production by ELISA.
In some experiments, whole PBMC were first depleted of regulatory T cells by 
magnetic beads specific for CD25 (Miltenyi Biotech, Utrecht, NL) according to the 
manufacturer’s instructions. Depleted PBMCs were resuspended for culture at a 
concentration equating to 2.5x106 whole PBMC/mL. Mock-depleted control PBMCs in 
these experiments were treated similarly, i.e. also passed over a magnetic column. 
Efficiency of CD25hlF0XP3+ lymphocyte depletion was assessed in all samples by flow 
cytometry and did not differ between Dogon and Fulani (93.8±0.86 and 92.4±1.57 
respectively, p=0.86).
Stimuli - Preparations of mature NF54 strain Plasmodium falciparum-infected red blood 
cells (PfRBC) and mock-cultured uninfected erythrocytes (uRBC) were obtained by 
routine methods as described previously [24] and cryopreserved at 150x106/mL in 15% 
glycerol/PBS. Cryopreserved PfRBC form almost as strong a stimulus as fresh PfRBC 
and have identical stimulatory characteristics. Their use in large experiments has 
logistical advantages, in addition to reducing confounding due to inter-batch variation. 
One single large batch of cryopreserved PfRBC was used for each individual field study 
described above, at a final concentration of 5x106/mL. Phytohaemaglutinin (Sigma) 
and M. tuberculosis sonicate (RIVM, Bilthoven, NL) were used at a final concentration 
of 10^g/mL; heat-killed C. albicans conidia, S. aureus and S. typhi were used at a final 
concentration of 106/mL.
Flow cytometry - For regulatory T cell enumeration, isolated PBMC were washed twice 
in PBS containing 2% foetal calf serum (PBS-FCS) followed by a FACS buffer 
containing PBS-FCS and 0.1% sodium azide and blocked with 5^l mouse serum (5 
minutes at 4°C). Subsequently cells were incubated in 50^l of FACS buffer containing 
diluted PerCP-, FITC-, and APC-conjugated monoclonal antibodies with specificity for 
human CD3, CD4, and CD25 (clones CK7, RPA-T4, & 2A3, respectively, all Becton- 
Dickinson Biosciences). For intra-nuclear staining of F0XP3 the PE anti-human Foxp3 
Staining set (Ebioscience), was used according to manufacturer's instructions. For 
lymphocyte subset characterization, PBMCs were stained with CD3-PerCP and CD56- 
PE (clone MEM188, Ebioscience). Stained and fixed PBMCs were stored in FACS 
buffer and counted on a FACSCalibur flow cytometer (Becton-Dickinson). For each 
measurement the same settings were used. CellQuestPro software was used for analysis.
Cytokine ELISA - IFNy, IL-4 and IL-10 production in culture supernatants were 
measured by commercially available sandwich ELISA according to the manufacturers’ 
instructions (Sanquin, Amsterdam, NL), with lower detection limits of 3, 5 and 3 
pg/mL, respectively.
Serology - Total IgG reactivity against soluble whole P. falciparum  asexual parasite 
extract was measured by standard ELISA methodology, as described previously [25].
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QT-NASBA - Quantitative Nucleic Acid Sequence-based Amplification quantification of 
parasitaemia in venous blood was performed as described previously [26]. Briefly, 50 
^L of whole blood was lysed in high molar guanidium (L6) buffer, following which 
nucleic acids were adsorbed to silica particles and stored at -80°C. Nucleic acids were 
extracted according the Boom method and P. falciparum  18S ribosomal RNA was 
quantified by QT-NASBA according to the manufacturer’s instructions (bioMerieux, 
Boxtel, NL). QT-NASBA has a detection limit of 20 parasites/^L, i.e. a 1000-fold 
higher sensitivity than blood smear microscopy
Statistics - Statistical analysis performed in SPSS 16.0. Differences in continuous 
clinical parameters and responses between tribes were analyzed by Mann-Whitney U 
test; paired observations (Fig 3.c) were compared by the Wilcoxon signed-ranks test. 
Categorical variables were compared by x2 test or Fisher’s Exact test. Associations 
between continuous variables were assessed by Pearson’s correlation. Linear regression 
models were used to assess which factors were independently associated with log10- 
transformed IFNy response. The models included the dichotomous variables tribe, 
season, fever & age (cut-off 12 yrs) and the continuous variables anti-asexual IgG level 
(OD), logi0-transformed percentage of regulatory T cells and logi0-transformed asexual 
parasite density. Factors with a p-value <0.05 in univariate models were included in a 
multivariate model and retained if the adjusted p<0.05. Unless otherwise stated, 
statistical analyses were performed on data adjusted for background reactivity, i.e. 
responses to PfRBC subtracted by responses to uRBC; negative values were set to zero. 
P-values <0.05 were considered statistically significant in all analyses.
Results
Study population
Characteristics of the study populations are presented in Table 1. Symptomatic malaria 
cases presented only during the rainy season and were significantly (p<0.001) younger 
than asymptomatic volunteers, with higher temperatures, more enlarged spleens and 
higher parasite densities. Although the current study was not specifically designed to 
assess such differences, fewer symptomatic Fulani than Dogon presented during the 
inclusion periods. Consistent with previous findings in these populations, spleen rates 
in both asymptomatic and symptomatic Fulani were significantly higher than in 
respective Dogon, whereas parasite prevalence in thick blood slides was lower. When 
measured by the more sensitive NASBA technique, both the prevalence of parasitaemia 
in asymptomatic individuals and the parasite density in asymptomatic and clinical 
individuals during the transmission season was significantly lower in Fulani than in 
Dogon (Table 1).
Furthermore, we confirmed the Fulani’s stronger serological responses against the 
asexual blood-stage forms of Plasmodium falciparum  (Table 1).
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Table 1. Study population___________________________________________
wet season w et season dry season
asymptomatic symptomatic asymptomatic
Dogon Fulani p-
value
Dogon Fulani p-
value
Dogon Fulani p-
value
Na 79 85 35 23 34 34
age in years, median 23 19 0.56 11 9 0.39 26 15 0.17
(IQR) (13-36) (13-29) (8-16) (7-27) (15-46) (11-26)
sex, % m ale (95% 100 97.6 0.50 68.6 52.2 0.21 100 100 1.0
CI) (95.4- (91.8- (50.7- (30.6- (89.7- (89.7-
100) 99.7) 83.1) 73.1) 100) 100)
temp in  °C, median 36.5 36.3 0.03 38.6 37.2 <0.001 36.5 36.3 0.07
(IQR) (36.1- (36.1- (38.1- (36.5- (36.3- (36.0-
36.8) 36.5) 39.2) 38.0) 36.9) 36.9)
spleen, 0.0 23.5 <0.001 20.0 69.6 <0.001 0.0 17.6 0.03
% Hackett >1 (95% (0.0- (15.0- (12.5- (56.3- (0.0- (6.8-
CI) 4.6) 34.0) 43.3) 92.5) 10.3) 34.5)
anti-asexual IgG OD 1.95 2.41 <0.001 1.85 2.36 <0.001 1.98 2.28 <0.001
at 450nm, median (1.72- (2.31- (1.65- (2.27- (1.75- (2.18-
(IQR)b 2.30) 2.48) 2.09) 2.47) 2.18) 2.34)
P f  parasitaem ia:
% slide-positive 29.1 21.2 0.24 100 100 - 0.0 0.0 1.0
(95% CI) (19.4- (13.1- (90.0- (85.2- (0.0- (0.0-
40.4) 31.4) 100) 100) 10.3) 10.3)
% NASBA-positive 82.3 58.8 0.001 100 100 - 29.2 29.2 1.0
(95% CI) (72.1- (47.2- (90.0- (85.2- (12.6- (12.6-
90.0) 69.6) 100) 100) 51.1) 51.1)
par. density in 4.0 1.8 0.003 6.2 5.5 0.042 0.0 0.0 0.75
log10/mL, median (2.3- (0.0- (5.3- (2.9- (0.0- (0.0-
(IQR) 5.6) 4.9) 7.0) 6.3) 11) 2.1)
aField studies included: September 2005 (66 asymptomatic + 14 symptomatic), September 2006 
(98 asymptomatic + 44 symptomatic), April 2007 (48 asymptomatic), February 2008 (20 
asymptomatic). Clinical characteristics did not differ significantly within groups between 
inclusion years.
bSerological data is from 2006, 2007 and 2008 studies only.
Cellular responses to PfRBC
Next, we assessed cellular responses to P. falciparum-infected erythrocytes (PfRBC) in 
Fulani and Dogon, stratified by parasitological (NASBA) and clinical presentation (Fig. 
1). IFNy responses to PfRBC were markedly stronger in uninfected Fulani than Dogon 
donors (p<0.001). Indeed, almost all Fulani donors were stronger responders than any 
Dogon; i.e., roughly two-thirds of Dogon donors could be characterised as low 
producers (<100 pg/mL) and one-third as intermediate producers (100-1000 pg/mL),
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whereas two-thirds of Fulani were intermediate producers and one-third high producers 
(>1000 pg/mL). Similar interethnic differences in IFNy response were visible in both 
asymptomatic parasite carriers (p=0.061) and symptomatic donors (p=0.026) (Fig. 1.A). 
IL-10 responses to PfRBC were also significantly higher in uninfected Fulani than 
Dogon (p=0.005), though by a lesser factor, and IL-10 responses did not differ between 
asymptomatic (p=0.69) or symptomatic (p=0.40) Dogon and Fulani (Fig. 1.B). The 
resultant IFNy/IL-10 ratio was significantly more pro-inflammatory in uninfected Fulani 
than Dogon (p=0.001), with a similar trend in asymptomatic (p=0.064) and 
symptomatic (p0.062) donors (Fig. 1.C). These striking findings indicate that the 
Fulani consistently produce markedly stronger cellular responses against malaria 
parasites than the Dogon.
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Figure 1. Cytokine responses to PfRBC by 
Dogon and Fulani
PBMC isolated from uninfected (parasite', 
fever'), asymptomatic (parasite+, fever') and 
symptomatic (parasite+, fever+) donors were 
stimulated in vitro for 24 hours with PfRBC. 
IFNy (A) and IL-10 (B) were measured in the 
supernatant by ELISA; C. IFNy/ IL-10 ratio. 
Data represent all individual Dogon (open 
symbols) and Fulani (filled symbols) from
2006 and 2007 inclusions combined, from 
whom sufficient PBMCs were available for the 
assay; number of volunteers for whom data 
was available are indicated under each column. 
No significant differences in cytokine response 
were observed per group between the 2006 and
2007 inclusions. Median responses to PfRBC 
are indicated by solid lines. Median responses 
to uRBC (individual values not shown) are 
indicated by dashed lines and did not differ 
significantly between tribes; Mann-Whitney U 
test p-values for the comparison between tribes 
are given on data adjusted for background 
reactivity to uRBC.
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Cellular responses to other microorganisms
We next investigated whether this strong IFNy production is specific to P. falciparum, 
by incubating PBMCs with PHA as well as a panel of pathogenic organisms 
representing a spectrum of Gram-negative and -positive bacteria, mycobacteria and 
fungi (Fig. 2). Whereas responses to P. falciparum  were again stronger in Fulani than 
Dogon (p<0.001), IFNy responses to other microorganisms did not differ significantly 
between tribes, but appeared, if anything, stronger in Dogon (Fig. 2.A) . IL-10 
responses in contrast tended to be stronger in Fulani for most stimuli (Fig. 2.B). Th2- 
type IL-4 responses to most stimuli were poorly measurable above background in all 
volunteers (Fig. 2.C). The potent cellular Thl-type anti-P. falciparum  response by 
Fulani thus appears specific for this microorganism.
A
IFNy
10000-1
1000­
100­
10­
1
p<0.001 
•  •  
u
%
Oo
o Dogon (n=10) 
•  Fulani (n=10)
?  ° | *  6 9 •* 0 • oy o • °o
p=0.095
«P.
o— 
o  _ o * :
*
■ m
%>:
<D
° = i
00»
B
S . /
IL-10
10000­
1000­
100­
10
1
V
J*V
O p=0.051 
°cp
C IL-4
stimulus
Figure 2. Cytokine responses against 
other common pathogens
PBMC isolated from Dogon (white 
bars, n=10) or Fulani (black bars, n=10) 
were stimulated in vitro for 24 hours 
with a panel of pathogenic micro­
organisms. IFNy (A), IL-10 (B) and IL- 
4 (C) production were measured in the 
supernatant by ELISA. Data represent 
mean+SEM of all 10 donors per tribe 
during the 2008 inclusion; all Mann­
Whitney U test p-values <0.10 are 
shown.
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Haematology
Since these observations might be due to interethnic differences in total leukocyte count 
or in the relative prevalence of lymphocyte subsets known to be capable of IFNy 
production, we explored this in the PBMCs of Fulani and Dogon (Table 2). However, 
no significant differences in WBC count were observed between tribes for either 
asymptomatic (p=0.80) or symptomatic donors (p=0.75). Nor was there any interethnic 
difference in leukocyte differential count amongst asymptomatic donors, although 
symptomatic Dogon were characterised by a more pronounced granulocytosis than 
symptomatic Fulani. Moreover, FACS analysis of lymphocyte subsets revealed that 
asymptomatic Dogon and Fulani do not differ in the relative abundance of T, NKT or 
NK cells (Table 2).
Table 2. Haematology
asymptomatic symptomatic
Dogon Fulani p-
value
Dogon Fulani p-
value
Hb 14.3 12.7 0.005 12.0 11.3 0.17
(g/dL)a (12.7-15.3) (11.3-14.8) (11.0-13.3) (10.3-12.1)
WBC 6.5 6.5 0.80 11.0 11.0 0.75
(x106/mL)a (4.9-9.4) (5.2-8.2) (7.6-14.4) (6.0-14.4)
neutrophils 36 33 0.28 64 46 0.003
(% WBC)a (28-47) (27-42) (57-73) (32-62)
lymphocytes 60 58 0.20 28 49 0.018
(% WBC)a (48-65) (48-64) (22-43) (27-63)
T cells (% 64 74 0.075 - - -
lymphocytes)b (59-70) (70-75)
NKT cells (% 5.6 3.3 0.11 - - -
lymphocytes)b (3.5-7.5) (2.5-5.3)
NK cells (% 8.7 6.2 0.32 - - -
lymphocytes)b (4.9-13.1) (4.0-9.4)
aData represent median (IQR) of all volunteers from 2005 (n=43 Dogon, n=37 Fulani), 2006 
(n=71 Dogon, n=71 Fulani) and 2008 (n=10 Dogon, n=10 Fulani), p-values by Mann-Whitney U 
test. Data from 2007 were unavailable.
^Data represent mean±SD of all volunteers from 2008 (n=10 per tribe). Lymphocyte subsets were 
defined as follows: T cells CD3+CD56'; NKT cells CD3+CD56+; NK cells CD3'CD56+.
Regulatory T cells
Next, we investigated the role of regulatory T cells (Tregs) in the immune response of 
Fulani and Dogon to P. falciparum, since these cells have been implicated in the 
suppression of cellular immunity, including IFNy production [27]. Overall, Fulani 
donors harboured fewer circulating CD4+CD25hiFoxp3+ Tregs than Dogon donors 
(0.58±0.93% vs. 0.76±0.62%, p=0.001). However, uninfected donors showed no 
difference in Treg numbers were observed between Dogon and Fulani (p=0.20), while
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Treg numbers in asymptomatic parasite carriers and symptomatic cases were clearly 
lower in Fulani than in Dogon (Fig 3.A). Furthermore, circulating Treg numbers were 
not significantly correlated with IFNy responses, either within the study population as 
whole (p=0.16) or within the Dogon (p=0.87) or Fulani (p=0.97) separately (Fig 3.B).
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Figure 3. Quantification and 
functionality of regulatory T cells in 
Dogon and Fulani
A. Quantification of CD4+CD25hiFoxp3+ 
regulatory T cells in the PBMC 
populations of asymptomatic Dogon and 
Fulani. Donors were stratified by 
parasitological and clinical status as in 
Figure 1. Median values are indicted by 
solid lines; p-values by Mann-Whitney U 
test. B. Correlations between circulating 
Treg numbers and IFNy responses to 
PfRBC, stratified by tribe. R2 and p- 
values were calculated by Pearson’s 
correlation. Data in A+B represent all 
individual Dogon (open symbols) and 
Fulani (filled symbols) from 2006 and
2007 inclusions combined, for whom data 
was available; no significant differences in 
Treg numbers were observed per group 
between the 2006 and 2007 inclusions.
C. PBMC isolated from Dogon (white 
bars) or Fulani (black bars) were depleted 
of CD25+ cells and stimulated in vitro for 
24 hours with PHA or PfRBC. IFNy 
production by remaining cells is presented 
as a percentage of total production by 
undepleted PBMC (absolute values in 
Dogon and Fulani respectively 3350±309 
and 3807±1004, p=0.74 for PHA and 
167±69 pg/mL and 881±314 pg/mL, 
p=0.002 for PfRBC); responses to RPMI 
and uRBC were below the detection limit 
of the assay (3.1 pg/mL). Data represent 
mean+SEM of all 10 donors per tribe 
during the 2008 inclusion; p-values vs. 
undepleted PBMCs by Wilcoxon paired 
sample signed-rank test.
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In order to further assess any functional role of these Tregs in the response to PfRBC, 
we performed stimulations with PBMCs depleted of CD25+ cells from asymptomatic 
donors. As expected from the higher frequency of Tregs in Dogon, depletion of CD25+ 
cells in these donors led to a more significant increase in the response to the polyclonal 
stimulant PHA than it did in Fulani. However, depletion of CD25+ cells had no effect 
on the 24-hour IFNy response to PfRBC in either tribe (Fig 3.C). Interestingly, 
following 24-hour in vitro stimulation of undepleted PBMCs, both Fulani and Dogon 
demonstrated a similar up-regulation Foxp3+ Treg numbers (not shown). Thus, while a 
difference in numbers of circulating regulatory T cells does exist between parasitaemic 
Dogon and Fulani, this difference does not apparently underlie the marked interethnic 
difference in early IFNy response to PfRBC .
Other factors associated with IFNy response
In order to assess potential confounding factors, we explored associations between IFNy 
responses and a number of donor characteristics in linear regression models (Table 3). 
As could be deduced from the stratified data in Figure 1, overall IFNy responses were 
negatively correlated with parasite density (by NASBA) in both Dogon (p=0.002) and 
Fulani (p=<0.001) (see also Figure 4.A). Similarly, IFNy responses were negatively 
associated with the presence of fever in the donor and with sampling in the wet 
compared to the dry season. Furthermore, IFNy responses were also positively 
associated with serological responses to asexual parasites and were lower in individuals 
<12 years of age (Table 3). However, limited inclusion numbers prevented a more 
detailed assessment of the age-dependency of IFNy responses in childhood.
Table 3. Linear regression model of factors associated with IFNy responses“______
Univariate Multivariateb
Estimate (se) p-value Estimate (se) p-value
Tribe Dogon 0.0 (ref )
Fulani +1.12 (0.17) p<0.001 +0.94 (0.16) p<0.001
Season Wet 0.0 (ref )
Dry +0.55 (0.19) p=0.004
Fever Absent 0.0 (ref )
Present -0.82 (0.22) p<0.001
Agec Under 12 yrs 0.0 (ref )
12 yrs and over +0.55 (0.20) p=0.009
P.f. density (log10/mL) -0.19 (0.03) p<0.001 -0.14 (0.03) p<0.001
anti-asexual IgG (OD) +0.97 (0.30) p=0.002
Treg no. (log10 %) -0.39 (0.33) p=0.230
aData from 2006 and 2007 inclusions.
bAll independent factors showing significant (p<0.05) univariate association with IFNy responses 
were entered in a multivariate model and retained if the adjusted p-value remained <0.05. 
cThe cut-off of 12 years was determined to be the strongest discriminator of IFNy response 
between the ages of 8-20 (not shown).
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In a multiple linear regression model, only tribe (p<0.001) and parasite density 
(p<0.001) were independently associated with IFNy response, whereas fever, season, 
anti-asexual IgG levels(all p>0.1) and even age (p=0.062) were not and furthermore did 
not confound the relation between tribe and IFNy response (Table 3). The Fulani’s 
stronger IFNy response to malaria parasites appears thus to be independent of 
continuous exposure, but strongly associated with control of parasitaemia.
Factors associated with parasite density
Finally, in a similar set of analyses, we explored factors predictive of parasite density. 
As described above, IFNy response to PfRBC was significantly negatively correlated 
with parasitaemia in both tribes (Figure 4.A). In contrast, regulatory T cell numbers 
were significantly associated with parasitaemia, but only in the Dogon (p=0.014) and 
not in the Fulani (p=0.32, Figure 4.B). Anti-asexual IgG levels were not significantly 
associated with parasitaemia in either tribe (p=0.26 and p=0.80, respectively, Figure 
4.C). Not surprisingly, higher parasite densities were positively associated with the 
presence of fever (p<0.001) and the timing of sampling during the high-transmission 
wet season (p<0.001), and negatively associated with age (p<0.001).
A parasitaemia vs. IFNy
parasitaemia (log /mL)
B parasitaemia vs T regs
parasitaemia (log /mL)
C parasitaemia vs. IgG
parasitaemia (log /mL)
Figure 4. Cellular and humoral immune 
responses vs. parasitaemia
Shown are correlations between donors’ 
parasite density (as measured by NASBA) and 
IFNy responses to PfRBC (A), circulating 
Treg numbers (B), or anti-asexual IgG OD (C) 
stratified by tribe. Data represent all 
individual Dogon (open symbols) and Fulani 
(filled symbols) from 2006 and 2007 
inclusions combined, for whom data was 
available. R2 and p-values were calculated by 
Pearson’s correlation, fit-lines are shown for 
significant (p<0.05) associations only.
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Discussion
The relatively lower susceptibility of the Fulani to malaria compared to sympatric tribes 
is by now well-established, yet the immunological mechanisms underlying this 
protection are still far from being understood. Here we show that the Fulani develop 
markedly stronger cellular responses to the parasite, in particular a very robust early 
IFNy production. Importantly, this response appears specific to P. falciparum, amongst 
a panel of other common pathogens. The strength of these IFNy responses was strongly 
negatively correlated with parasite density, but independent of circulating regulatory T 
cell numbers, age and season.
Others [28] have proposed regulatory T cells to underlie interethnic differences in the 
ability to control parasitaemia, since Fulani in the neighbouring country of Burkina Faso 
have fewer and less suppressive Tregs than the more susceptible Mossi. Furthermore, 
depletion of Tregs in Mossi, but not Fulani, restored lymphocyte proliferation in long­
term (5 day) co-incubation assays with PfRBC. However, caution should be applied 
when interpreting such results, since regulatory T cells not only permit, but are 
themselves also induced by parasitaemia [29, 30]. In support of the latter interpretation, 
we found interethnic differences in Treg numbers only between parasitaemic Dogon and 
Fulani, which correlate with the higher parasite densities in those Dogon. In contrast, 
no difference in Treg numbers was observed between uninfected Dogon and Fulani 
during either wet or dry season, making selection bias unlikely. Furthermore, although 
we could confirm that Treg depletion can increase IFNy responses to PfRBC in long­
term stimulations (unpublished observations), we show here that the early IFNy 
response to PfRBC is neither effected by Treg depletion, nor associated with circulating 
Treg numbers. It therefore appears unlikely that regulatory T cells underlie the 
observed interethnic differences in IFNy response to malaria parasites. Finally, the 
finding that these interethnic differences in immune response appear P. falciparum - 
specific would be difficult to explain mechanistically by genetic differences in (total) 
Treg numbers. Instead, we propose that differences within the effector response itself 
underlie interethnic susceptibility to parasitaemia, and that uncontrolled chronic 
infection in turn leads to reactive increases in Treg numbers in susceptible populations. 
One of the first immunological ‘correlates of protection’ discovered in the Fulani was 
their higher titre of anti-P. falciparum  IgG and IgE [2, 3, 31-35]. We too measured 
higher anti-asexual IgG levels in Fulani compared to Dogon, but similar to Farouk et al. 
[36] we found no correlation between IgG and IFNy responses once stratified by tribe 
(Table 3); nor were IgG levels correlated with regulatory T cell numbers (p=0.88, not 
shown). Thus it would appear that cellular and humoral immune responses against P. 
falciparum  are independently regulated. Furthermore, corroborating an observation by 
others [37], we found no significant association between anti-asexual IgG levels and 
parasite density amongst individuals in either tribe (Figure 4.C), suggesting that 
humoral responses play a subordinate role, if any, in protection against parasitaemia in 
this study population.
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In marked contrast, the robust inverse correlation between IFNy response and parasite 
density, which remained statistically significant even after correction for other 
explanatory factors, strongly suggests a protective effect of cellular immunity against 
parasitaemia, corroborating findings in other studies [20, 38, 39]. Although the inverse 
mechanism, i.e. a suppressive effect of parasitaemia on IFNy responses [40], may 
simultaneously be operative, the persistent interethnic difference in IFNy responses 
across seasons and in both NASBA-negative volunteers and clinical malaria patients 
would tend to favour the former explanation. Interestingly also, this IFNy production 
appears to be an acquired response that waxes during childhood in both tribes, but 
plateaus earlier and higher in Fulani than in Dogon (not shown) and thereafter remains 
stable independent of seasonal changes in transmission intensity; specific longitudinal 
studies in children would be required to explore this hypothesis.
An important but unanswered question remains furthermore whether susceptibility to 
parasitaemia, as we have measured here, forms a proxy of susceptibility to (severe) 
disease and death, or rather the opposite. Pro-inflammatory cytokines may after all 
contribute to immunopathology in addition to controlling parasitaemia, thus 
representing a double-edged sword which is still poorly understood [41].
In conclusion, we show that the lower susceptibility of the Fulani to parasitaemia, 
relative to sympatric populations, is strongly associated with a robust early IFNy 
response against asexual P. falciparum  parasites. We argue that this insight can be 
extrapolated to define early IFNy responses as a useful correlate of protection against 
malaria in other populations [20, 42, 43], supporting the further development of whole 
parasite and recombinant vaccines aimed at inducing such responses.
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Abstract
Background - The full-length (L-) variant of caspase-12 is believed to predispose to 
sepsis. It has been replaced in the genome of most human populations by the (S-) 
variant, which leads to premature termination of translation. Strikingly, the L-allele is 
still widely prevalent in African populations, presumably due to a counterbalancing 
selective force specific to this continent, for which malaria is a prime candidate. 
Methods: We investigated associations between caspase-12 genotype and malarial 
parameters in three West-African populations, in studies encompassing immunological, 
clinical and obstetric data.
Results - The caspase-12 L-allele was found at frequencies of 11-34%. Plasmodium  
falciparum-stimulated mononuclear cells from S/L heterozygote donors produced 
stronger interferon- y and interleukin-10 responses than S/S homozygotes (p=0.011 and 
p=0.023 in respectively uninfected and infected donors). Nevertheless, we found no 
association between caspase-12 genotype and either the presentation of severe malaria 
or individual clinical parameters in sick children. Amongst pregnant women, caspase-12 
genotype influenced neither peripheral or placental malaria infection, nor basic obstetric 
parameters. Interestingly, perinatal mortality was more frequent in children of both S/S 
and L/L than S/L mothers, independent of placental P. falciparum- infection. 
Conclusions - We find little clinical or epidemiological evidence that malaria has 
contributed to the persistence of functional caspase-12 in Africa, suggesting either that 
alternative selective forces are at work or that genetic drift underlies its current global 
distribution.
Reproduced with permission from  John Libbey Eurotext.
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Caspase-12 is a member of the large family of cysteine proteases involved in apoptotic 
and inflammatory pathways [1], although it has limited proteolytic activity of its own 
[2]. Recently, caspase-12 has been implicated in the regulation of the pro-inflammatory 
cytokine IL-1P, through the inhibition of caspase-1 mediated cleavage of pro-IL-1p to 
IL-1P [3] and through the inhibition of NOD/RIP signalling [4]. Mice lacking the 
caspase-12 gene generated a stronger pro-inflammatory response than wild type animals 
[5]. In man, two allelic forms of the caspase-12 locus exist, the long (L-) and short (S-) 
variant. The former encodes for a full-length protein, whereas the latter encodes for a 
product that is prematurely terminated during translation. The emergence of the S- 
variant forms a relatively recent event in human evolution, since this variant is not 
found in chimpanzee populations [6]. Clinical studies associated the L-variant of 
caspase-12 with an increased risk of sepsis [7]. Whereas in Caucasian populations 
exclusively the S-variant of caspase-12 is found, in African populations the L-variant is 
still common [8].
The distinct global distribution of caspase-12 alleles on the one hand suggests selection 
of the inactive S-variant outside of Africa, presumably due to its protective role in 
sepsis [9]. On the other hand, maintenance of the functional L-variant in sub-Saharan 
Africa implies a comparative advantage of this allele against some major selective force 
specific to this continent.
Malaria still remains responsible for high morbidity and mortality in large parts of the 
developing world, but nowhere more so than in sub-Saharan Africa, that suffers by far 
the highest transmission intensities. This burden, combined with its target of 
particularly young, pre-pubescent children, means that the disease has exerted a strong 
selective pressure on human populations for at least the last 10.000 years. Such 
selective pressure is visible today in the genetic make-up of humans from malaria- 
endemic areas, more specifically in the presence of allelic variants or other genetic 
polymorphisms that confer some measure of protection against malaria [10]. Indeed 
some of the oldest and best-studied human genetic variations, those of the haemoglobin 
genes, including the HbS and HbC variants and a-and P-thalassaemias are found in 
African populations as a result of selection by malaria [11]. In addition to red blood cell 
phenotypes, malaria has also exerted strong selective pressure on genes involved in both 
the adaptive [12, 13] and innate immune response [14-18].
The strong selective pressure malaria is known to have exerted on other genes, 
particularly in African populations, suggests it may also have played a role in the 
maintenance of full-length caspase-12 on this continent. In the present paper we have 
combined caspase-12 genotype data from three separate studies investigating 
susceptibility to malaria in different African populations, and we assessed associations 
with immunological, clinical and obstetrical data.
Introduction
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Materials &  Methods
Mali study - Blood samples for functional assays were collected in the Koro district of 
Mali as part of investigational studies into interethnic differences in susceptibility to 
malaria. This study site has been described in detail elsewhere [19]. Briefly, it is a rural 
Sahelian area with intense malaria transmission exclusively during the rainy season 
(June-September). Samples for this study were collected both during the 2006 rainy 
season (September) and the 2007 dry season (April). The study included healthy Dogon 
or Fulani adult male volunteers and patients with symptoms of uncomplicated malaria. 
A thick blood film was made from each participant; slide-negative patients were 
excluded from the study. No positive blood films were recorded during the April 2007 
inclusion. Approval for the study was provided by the institutional review boards of the 
University of Stockholm (National Ethical Committee no. 03 536) and the University of 
Bamako (N°0527/FMP0S).
Cameroon study - This was a hospital-based study, set up to investigate inflammatory 
parameters in relation to clinical severity of malaria, details of which are published 
elsewhere [20]. Briefly, the samples for this study were collected from children aged 
between 8 months and 14 years (mean age 5.8) presenting to the outpatient clinic or 
admitted to the Central Hospital of Yaounde, Cameroon, with symptoms of malaria. 
Based on a positive thick blood smear for Plasmodium falciparum  and a complete 
physical examination, patients were classified by clinical presentation according to the 
2000 World Health Organization (WHO) standard [21] as uncomplicated or 
complicated/severe malaria. The number of patients categorised as suffering from mild 
and complicated/severe disease was 100 and 38, respectively. Clinical parameters at 
admission, including temperature, heart rate and respiratory rate were recorded and 
venous whole blood was collected for a complete blood count. Informed consent was 
provided in all cases by a parent or guardian.
Ghana study - This study on diagnosis and manifestation of placental malaria in 
pregnancy has been described in detail [22]. The study area is characterized by 
perennial and hyper- to holoendemic malaria transmission. Briefly, 889 women 
attending the Presbyterian Mission Hospital in Agogo, Ghana, for delivery were 
recruited after informed written consent was obtained. Peripheral venous blood and, 
following delivery, placental intervillous blood were collected and examined for P. 
falciparum  by microscopy, immuno-chromatographic test (ICT Malaria P.f/P.v, Becton 
Dickinson, Germany ) and nested PCR assays [23]. Haemoglobin (Hb) was measured 
by a HemoCue photometer (Ângelholm, Sweden) and anaemia defined as Hb <11 g/dL. 
Crude birth weight and gestational age were assessed within 24 hours after delivery. 
Low birth weight (LBW) was defined as <2500 g and preterm delivery (PD) as 
gestational age <37 weeks applying the Finnstrom score [24]. The study protocol was 
reviewed and approved by the Committee on Human Research Publications and Ethics, 
School of Medical Sciences, University of Science and Technology, Kumasi.
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Cytokine stimulation assay - In the Mali study, venous blood was collected from healthy 
volunteers and patients into lithium heparin vacutainers. Further manipulations took 
place in Bandiagara, approximately three hours from the study sites; all samples were 
worked-up on the day of collection. Peripheral blood mononuclear cells (PBMCs) were 
isolated by density gradient centrifugation on Ficoll, washed 3x in cold RPMI, 
enumerated and resuspended in complete culture medium (RPMI 1640 containing 2mM 
glutamine, 1mM pyruvate, 50^g/mL gentamicin and 10% pooled human AB+ serum 
(Sanquin, Nijmegen, NL)) for a final concentration of 2.5x106/mL. PBMCs were 
transferred into 96-well round-bottom plates and were immediately stimulated in 
duplicate wells with either cryopreserved NF54 strain P. falciparum -infected 
erythrocytes (PfRBC) or uninfected erythrocytes (uRBC) at 5x106/mL final, or RPMI 
only. Cells were incubated for 21 hours at 37°C, following which cell supernatants were 
collected and stored at -80°C for subsequent cytokine measurement by ELISA. Cell 
supernatants were analysed for cytokine production by commercially available ELISA 
kits according to the manufacturers’ instructions: IFNy, IL-10 (Sanquin, Nijmegen, NL) 
and IL-1P (R&D, Abingdon, UK).
Caspase-12 genotyping - DNA was extracted from whole blood using either the 
Puregene isolation kit (Gentra Systems, Minneapolis, MN) or the QIAmp blood mini kit 
(Qiagen, Hilden, Germany). Primers flanking the T125C polymorphism region and 
methodology was adopted as described by Saleh et al. [25]. Sequencing was performed 
on either a 48-capillary 3730 sequencer (Applied Biosystems) or a Lightcycler 480 
(Roche). Genotypes were analysed using the software 4Peaks by A. Griekspoor and 
Tom Groothuis (mekentosj.com).
Statistics - Data were analysed in SPSS; differences in genotype distributions between 
populations were assessed by x2-test or Fisher’s exact test. Differences in clinical 
parameters between groups were analysed by Kruskal-Wallis test. Differences in 
cytokine responses to PfRBC between groups were analysed by Mann-Whitney after 
subtracting the response to uRBC; negative values were set to zero. P-values <0.05 
were considered statistically significant in all analyses.
Results
Distribution of caspase-12 alleles in African populations 
Table 1 presents the varying caspase-12 genotype- and allele-frequencies amongst the 
African populations studied. Frequencies of the L-allele as high as 34% were observed. 
None of the populations studied showed evidence for violation of Hardy-Weinberg 
equilibrium. Caspase-12 genotype-frequencies differed significantly (p<0.05) between 
all populations studied except Cameroon and Dogon (p=0.13); similarly allele- 
frequencies differed between all populations except Ghana and Dogon (p=0.12).
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Table 1. Distribution of caspase-12 genotypes and allele-frequencies in the 
populations studied________________________________________________________
Population N Caspase-12 genotypea Allele frequency
S/Sb S/Lb L/Lb S L
Cameroon 138 81 (58.7%) 53 (38.4%) 4 (2.9%) 0.78 0.22
Ghana 885 699 (79.0%) 172 (19.4%) 14 (1.6%) 0.89 0.11
Mali Dogon 81 56 (69.1%) 25 (30.9%) 0 (0%) 0.85 0.15
Mali Fulani 91 42 (46.2%) 37 (40.7%) 12 (13.2%) 0.66 0.34
aAll populations are in Hardy-Weinberg equilibrium
bS - truncated variant, L - full-length variant. Data represent n (%).
Mali study -  cytokine profile amongst caspase-12 genotypes
During the malaria transmission season, parasite prevalence differed between caspase- 
12 genotypes within the Fulani ethnic group (S/S, 13/31 [41.9%]; S/L, 11/26 [42.3%]; 
L/L, 10/11 [90.9%]; p=0.012) but not within the sympatric Dogon (S/S, 20/42 [47.6%]; 
S/L, 9/15 [60.0%]; p=0.41). Irrespective of ethnicity, no effect of caspase-12 genotype 
was found on clinical parameters, including parasite density or haemoglobin (Hb) levels 
(data not shown).
Ex vivo stimulation assays were performed with PBMCs of 33 uninfected and 31 P. 
falciparum-infected donors in September 2006 and a further 38 uninfected volunteers in 
April 2007. Cytokine production by volunteers’ peripheral blood mononuclear cells 
(PBMCs) stimulated ex vivo with P. falciparum-infected erythrocytes (PfRBC) is 
presented in Figure 1. Interferon-y (IFNy) and interleukin-10 (IL-10) responses to 
uninfected-red blood cells (uRBC) or to medium alone were generally below the 
detection limit of the assay (IFNy, 3.1pg/mL; IL-10, 4.7pg/mL). IFNy, but not IL-10, 
responses to PfRBC were significantly stronger in uninfected than in infected volunteers 
(p<0.001 and p=0.29, respectively), and therefore cytokine responses were analysed 
separately by infection status; cytokine responses did not differ between uninfected 
volunteers in the rainy and dry season. IFNy responses to PfRBC were stronger in 
caspase-12 S/L carriers than in S/S carriers for the infected group (p=0.011) but not for 
the uninfected group, although the pattern remained similar (Figure 1). IL-10 responses 
were higher in S/L than in S/S carriers among uninfected donors (p=0.023) but not 
among infected donors, although again the pattern remained similar. These patterns 
were furthermore observed individually in both Fulani and Dogon populations and 
during both the transmission- and non-transmission seasons (data not shown). Cytokine 
data was only available for 3 infected L/L carriers; both IFNy and IL-10 appeared 
slightly lower than in S/L carriers. We also analysed the IFNy /IL-10 ratio as an 
estimate of the overall pro/anti-inflammatory balance. This ratio was lower in S/L than 
in S/S carriers for both uninfected and infected donors, although not significantly so. 
Interleukin-1p (IL-1P) production was also assessed, but responses to PfRBC were 
barely measurable above the detection limit of the assay (40 pg/mL) (data not shown).
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Figure 1.
Peripheral blood mononuclear cells from 
uninfected (left) and P. falciparum-infected 
Malian donors (right) were stimulated for 
21 hours with 5x106 PfRBC/mL and 
cytokine production in the supernatant was 
measured by ELISA (A -  IFNy; B - IL-10; 
C - IFNy/IL-10 ratio). Donors were 
stratified by caspase-12 genotype and data 
represent mean+SEM for each group of 
volunteers (number for whom cytokine data 
was available is indicated under each bar). 
Dashed lines indicate mean responses to 
uninfected red blood cells. P-values for 
differences between caspase-12 genotypes 
by Mann-Whitney.
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Cameroon study -  clinical presentation amongst caspase-12 genotypes 
Table 2 presents the distribution of caspase-12 genotypes amongst Cameroonian 
children with uncomplicated or severe malaria. Amongst the 38 patients with severe 
malaria, most had symptoms of cerebral malaria (31 were in coma [Blantyre score <3] 
and 10 suffered repeated convulsions), nine were in severe respiratory distress and one 
had severe anaemia (Hb <5g/dL); not unexpectedly, a number of patients presented with 
two or more symptoms of severe malaria. However, no association was found between 
caspase-12 genotype and disease severity overall (p=0.86), nor between caspase-12 
genotype and individual manifestations of severe malaria (Table 2). Furthermore, there 
was no evident effect of caspase-12 genotype on individual clinical parameters among 
either uncomplicated or severe cases (Table 2).
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Table 2. Cameroon study: clinical presentation amongst caspase-12 genotypes
Caspase-12 genotype p-
N S/S S/L value
Overall genotype frequency, n (%) 138 81 (58.7%) 53 (38.4%) 4 (2.9%)
Clinical presentation:
Uncomplicated malaria, n (%) 100 60 (74.1%) 37 (69.8%) 3 (75.0%)
Severe malaria (all forms), n (%) 38 21 (25.9%) 16 (30.2%) 1 (25.0%) 0.86 a
Individual forms of severe malariab:
Coma (Blantyre score <3), n (%) 31 16 (76.2%) 14 (87.5%) 1 (100%) 0.66 c
Repeated convulsions, n (%) 10 6 (28.6%) 4 (25.0%) 0 (0.0%) 0.80 c
Respiratory distress, n (%) 9 6 (28.6%) 3 (18.8%) 0 (0.0%) 0.80 c
Severe anaemia (Hb <5g/dL), n (%) 1 1 (4.8%) 0 ( 0.0%) 0 (0.0%) 0.70 c
Clinical parameters uncomplicated cases (N=100):
Gender, male d 36 (60%) 19 (53%) 0 (0%) 0.11
Age, years e 4.8±3.5 5.2±3.8 6.3±5.0 0.79
Temperature, oC e 39.2±1.1 38.3±6.7 39.2±a0.6 0.89
Parasitaemia, log10/^L e 4.4±0.9 4.5±1.1 4.7±1.8 0.61
Heamoglobin, g/dL e 8.9±2.0 9.0±1.7 7.3±3.4 0.45
Leukocytes, x106/mL e 8.7±3.9 9.8±5.2 8.4±1.2 0.60
Heart rate, /min e 126±22 127±23 127±11 0.92
Respiratory rate, /min e 37±9 39±14 36±7 0.99
Clinical parameters severe cases (N=38):
Gender, male d 11 (55%) 7 (47%) 1 (100%) 0.56
Age, years e 3.3±2.2 3.3±2.2 7.8 0.31
Temperature, oC e 39.1±1.2 38.7±1.2 39.0 0.57
Parasitaemia, log10/^L e 4.4±1.3 4.6±1.0 5.1 0.89
Haemoglobin, g/dL e 8.7±1.9 9.3±1.5 9.4 0.52
Leukocytes, x106/mL e 11.2±5.2 14.3±7.7 11.9 0.37
Heart rate, /min e 137±27 130±44 160 0.57
Respiratory rate, /min e 43±13 45±18 32 0.69
aP-value by %2-test for the difference in prevalence of severe disease between caspase-12 
genotypes (within the total population).
bPatients could present with more than one symptom of severe malaria.
cP-values by %2-test for the difference in prevalence of specific symptoms between caspase-12 
genotypes (within the severe disease population).
dData represent number of cases (%), p-values by %2-test. Data on the gender of 1 uncomplicated 
and 2 complicated case were unavailable.
eData represent mean±standard deviation, p-values by Kruskal-Wallis test.
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Ghana study -  pregnancy outcome amongst caspase-12 genotypes 
Table 3 shows the distribution of caspase-12 genotypes amongst 885 women attending 
antenatal clinics at Agogo District Hospital, Ghana for whom genetic data was 
available. Overall, neither prevalence of P. falciparum  by PCR nor parasite density was 
found to vary significantly between caspase-12 genotypes (Table 3). In a sub-group 
analysis of primigravidae (n=315), the prevalence of peripheral (but not placental) 
parasitaemia by PCR was slightly higher in S/L than S/S mothers (70.8 vs 56.9%, 
p=0.04) and this association remained stable adjusting for age, presence of 
pyrimethamine in plasma, and wet season (adjusted odds ratio, 1.89; 95%CI, 1.03-3.46; 
p=0.04). Peripheral parasite densities in these S/L mothers were, if anything, lower (2.6 
vs. 3.1 log10/^L, p=0.09).
Table 3. Ghana study: pregnancy outcome amongst caspase-12 genotypes________
Caspase-12 genotype p-value
S/S S/S S/L
over-
S/S S/L L/L
a ir
vs.
S/Lb
vs.
L/Lb
vs.
L/Lb
Overall genotype freq., n  (%) 699 (79.0%) 172 (19.4%) 14 (1.6%)
Data o f  all 885 women:
Age o f m other in years (mean) 26.3± 6.2 26.4± 6.8 27.8± 4.9 0.57
Primigravidae, n (%) 246 (35.5%) 65 (38.2%) 4 (28.6%) 0.68
M aternal fever, n (%) 22 (3.2%) 6 (3.5%) 0 (0.0%) 0.77
M aternal anemia, n (%) 262 (37.5%) 58 (33.7%) 1 (7.1%) 0.048 0.36 0.020 0.04
Perinatal m ortalityc, n (%) 19 (2.7%) 0 (0.0%) 2 (14.3%) 0.001 0.020 0.06 0.005
amongst inf.d (N=516), n (%) 9 (2.2%) 0 (0.0%) 0 (0.0%) 0.28 0.22 1.0 -
amongst uninf. (N=368), n (%) 9 (3.1%) 0 (0.0%) 2 (33.3%) <0.001 0.22 0.017 0.006
Parasite prevalence (by PCR):
peripheral blood, n (%) 363 (51.9%) 92 (53.5%) 6 (42.9%) 0.73
placental blood, n (%) 405 (57.9%) 104 (60.5%) 8 (57.1%) 0.82
Geometric mean parasite density:
peripheral blood, log10/^L 2.79 2.69 2.24 0.58
placental blood, log1o/100 fields 1.91 1.81 2.43 0.36
Data o f  live singleton deliveries:
Preterm deliverye, n (%) 119/647
(18.4%)
31/168
(18.5%)
4/12
(33.3%)
0.42
Low birth weightf, n (%) 105/653
(16.1%)
27/169
(16.0%)
1/12
(8.3%)
0.77
a%2-test or Kruskal Wallis test, bx2-test or Fisher’s exact test 
cChild born dead or died within 24 hours
dAs defined by placental P. falciparum infection detected by PCR. Data on placental infection
was unavailable for one delivery.
eData available for N=827, fdata available for N=834
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The mother’s caspase-12 genotype was not associated with fever, preterm delivery, or 
LBW (Table 3). In L/L mothers, anaemia appeared to occur at a reduced rate but this 
marginal association (p=0.04) was lost after stratification for malaria. Also, 
stratification into infected and non-infected women did not change the observed absence 
of effect of caspase-12 genotypes on maternal and foetal morbidity (data not shown). 
Interestingly, the incidence of perinatal mortality was lower in infants of S/L mothers 
(0/172) than of either S/S mothers (19/699, p=0.02) or L/L mothers (2/14, p=0.005). 
This effect could not be ascribed to malaria, however, since the majority of all such 
cases occurred in mothers without placental parasitaemia by PCR (Table 3). Although 
the precise cause of death could not always be defined, LBW appeared to contribute in a 
majority (58%) of recorded cases. Furthermore, perinatal mortality was associated with 
a history of complicated labour (47% of cases), often requiring caesarean section (47% 
of cases). Finally, 52% of cases involved either still birth or poor delivery outcome (10’ 
Apgar score <7).
Discussion
The striking global distribution of caspase-12 alleles brings the question of what 
evolutionary pressures have shaped this pattern. Humans are the only mammals, apart 
from rabbits and cows, to have lost a functional caspase-12 gene, indicating relatively 
recent and species-specific selective pressure[26]. The proposed evolutionary benefit of 
an untranslated caspase-12 gene is in protection against sepsis [27], although to our 
knowledge no further studies have yet confirmed this. In any case, estimates on the 
genetic age of the caspase-12 S-variant point to fixating pressure starting as late as 60 
thousand years ago [28].
In line with this previous report, we confirm the presence of L-variant caspase-12 in 
African populations, at allele frequencies of up to 34%. Whatever the selective force 
which has eliminated the functional L-variant outside of Africa, within Africa it must 
have been counter-balanced by a factor acting with an opposite effect, in order to 
explain the continued high frequencies of this functional allele in populations on this 
continent. Malaria, given its strong selective effect, specifically in Africa, would appear 
to be a prime candidate for this role.
However, in none of the three studies did we find any convincing evidence for an effect 
of the functional caspase-12 L allele on either the prevalence or density of parasitaemia 
or the clinical severity of malaria. Furthermore, caspase-12 genotypes did not directly 
affect most individual obstetric parameters, including prevalence or density of placental 
parasitaemia, fever, preterm delivery or LBW. Nor was there any robust effect on Hb 
levels or anaemia in delivering women (or either of the other two study populations). 
One limitation that must be borne in mind when considering these findings, is the low 
number of data on L/L homozygotes, limiting the characterisation of their phenotype. 
However, although L/L homozygotes may arguably show a more pronounced
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phenotype than heterozygous individuals, as for any recessive genetic trait this 
difference would not be expected to be greater than the observed (lack of) difference 
between S/L heterozygotes and S/S homozygotes, since both L/L homozygotes and S/L 
heterozygotes express some full-length protein whereas S/S homozygotes do not 
express any caspase-12 protein at all.
The full-length caspase-12 protein has been proposed to reduce pro-inflammatory 
cytokine production through inhibition of caspase-1 mediated activation of IL-1P [29]. 
To test this hypothesis, we measured cytokine responses to P. falciparum -infected 
erythrocytes by PBMCs from healthy and parasitaemic African volunteers. Although 
IL-1P production was too weak to draw meaningful conclusions, we were able to 
measure robust IFNy responses. IFNy is induced downstream of IL-18, which itself 
requires activation by caspase-1 in a manner similar to IL-1P [30, 31]. Remarkably, 
IFNy production in caspase-12 S/L-heterozygotes tended to be stronger than in S/S 
individuals. However, S/L donors also elicited stronger anti-inflammatory IL-10 
responses than S/S homozygotes and, overall, the IFNy/IL-10 ratio was lower in 
heterozygotes. For diseases in which inflammation contributes significantly to 
pathology, such as is the case for various presentations of severe malaria [32], a 
relatively stronger anti-inflammatory balance may actually provide a survival 
advantage. IL-10 production has been shown to reduce susceptibility to severe malaria 
in animal models [33, 34], but in humans the role of IL-10 is less well established. 
Clinical and post-mortem studies have shown elevated levels of both pro-inflammatory 
cytokines and IL-10 in most forms of severe malaria [35-37]. However, the ratios of 
pro-inflammatory cytokines (IFNy, TNFa, IL-6) to IL-10 are usually increased in severe 
malaria patients [38-41], suggesting that enhanced anti-inflammatory responses protect 
against severe manifestations of malaria. In particular, high IL-10 levels appear to 
attenuate severe anaemia [42, 43]. It remains unclear, however, by what pathway a full- 
length caspase-12 might lead to stronger IL-10 production.
Finally, the observed association between maternal caspase-12 genotype and infant 
perinatal mortality risk, although potentially coincidental, remains intriguing. This 
effect could not be ascribed to malaria, or specifically to other infections. Rather, 
perinatal death was associated with LBW and complicated labour requiring caesarean 
section, possibly implying a role of caspase-12 in the physiology of pregnancy. 
Nevertheless, this finding may represent a balanced evolutionary force acting on 
caspase-12 alleles. Bearing in mind sampling error, the observed relative selection 
against both homozygote states predict an equilibrium frequency of the L-allele of 
2.7/(2.7+14.3)=0.16 by standard population genetics theory, remarkably similar to the 
observed frequency in this population of 0.11. This alone, of course, could not explain 
the disappearance of the L-allele in Europe and Asia, which would then presumably be 
due to the superimposed effects of other infections on those continents (e.g. plague, 
influenza).
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In summary, we aimed to investigate the evolutionary pressures that maintain a full- 
length caspase-12 allele on the African continent, with an emphasis on malaria 
infection. No major effects of caspase-12 genotype on clinical or parasitological 
parameters were apparent, although functional studies assessing cytokine stimulation by 
P. falciparum -infected erythrocytes showed a slightly more anti-inflammatory profile in 
the presence of functional caspase-12. These data obtained in cross-sectional settings 
should be followed by larger prospective studies, in order to fully understand the impact 
of caspase-12 polymorphisms on malaria. Coincidentally, we found indications of an 
effect of caspase-12 genotype on perinatal mortality, which could itself represent an 
important selective pressure. Alternatively, genetic drift or other (parasitic) infections 
that could have led to the balanced evolution of caspase-12 in Africa should be 
considered.
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Abstract
Immune responses against Plasmodium parasites, the causative organisms of malaria, 
are traditionally dichotomised into pre-erythrocytic and blood-stage components. 
Whereas the central role of cellular responses in pre-erythrocytic immunity is well 
established, protection against blood stage parasites has generally been ascribed to 
humoral responses. A number of recent studies, however, have highlighted the 
existence of cellular immunity against blood-stage parasites, in particular the 
prominence of IFNy production.
Here we have undertaken to chart the contribution of this prototypical cellular cytokine 
to immunity against both pre-erythrocytic and blood-stage parasites. We summarise the 
various anti-parasitic effector functions IFNy serves to induce, discuss the activation 
and contribution of different cellular sources of IFNy production during malaria 
infection and its regulation in relation to exposure. We review an array of data on its 
protective effects and scrutinise evidence for any deleterious immunopathological 
outcome in malaria patients. We conclude that IFNy forms a central mediator of 
protective immune responses against both pre-erythrocytic and blood-stage malaria 
parasites and identify a number of implications for rational malaria vaccine 
development.
Used with permission from  the Society fo r  Leukocyte Biology.
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Interferon-gamma (IFNy) is the only type-II interferon and is the prototypical Th1 
cytokine, inducing cell-mediated immunity by promoting Th1 over Th2 differentiation 
of T cells, inducing IgG class-switching to cytophilic isotypes and activating 
phagocytes (reviewed in [1]). It is predominantly produced by lymphocytes, including 
natural killer (NK) cells, NKT cells, y5T and apT cells, but may also be produced by 
cells of the myeloid lineage [2, 3]. Its induction is largely dependent on IL-12 and IL- 
18 production by activated myeloid antigen presenting cells (APCs) [4, 5], in addition to 
signals directly activating lymphocytes themselves.
IFNy is an important mediator of the immune response against intracellular 
(myco)bacteria and some viruses [6-8], but is also involved in protection against both 
intra- and extracellular protozoan parasites such as Leishmania spp [9], Trypanosoma 
cruzi [10] and Toxoplasma gondii [11]. In this review we will focus on the involvement 
of IFNy in immune responses against malaria.
Malaria is caused by protozoan parasites of the genus Plasmodium, and P. falciparum  in 
particular has major clinical importance for human disease at a global scale. 
Plasmodium parasites have a complicated multi-stage lifecycle involving both intra- and 
extracellular stadia in an Anopheline mosquito vector and a vertebrate host (Figure 1). 
By convention, immune responses in malaria are dichotomised into pre-erythrocytic 
responses (directed against sporozoites and liver-stage parasites) and blood-stage 
responses (directed against merozoites and intra-erythrocytic parasites). Whereas 
humoral (antibody) responses against extracellular sporozoites stages are well 
documented [13, 14], pre-erythrocytic immunity is generally considered to consist 
largely of cellular responses against infected hepatocytes, which inhibit intracellular 
parasite development through the induction of reactive nitrogen intermediates (reviewed 
in [15]). In contrast, humoral responses against extracellular merozoites and intra- 
erythrocytic parasites (pRBC) have traditionally been considered the most important 
component of blood-stage immunity [16-18]. T-cell responses against pRBC remain 
less well understood, partly because erythrocytes lack MHC class I or II presentation 
capacity. Nevertheless cellular responses against pRBC have been suggested to 
contribute to protection in humans in the absence of antibodies ([19], Chapter 6). 
Finally monocyte/macrophage-mediated responses, in particular phagocytosis (e.g. [20]) 
and antibody-dependent cellular inhibition (ADCI, e.g. [21]) also form an important 
component of blood-stage immunity.
Given this range of evidence, IFNy likely forms an important component of immunity 
against both stages of malaria infection. Indeed IFNy plays a plethora of roles in 
malaria, functioning equally as an inducer and effector of both innate and adaptive 
immune responses (Table 1) throughout the parasite life-cycle (Figure 1). It could be 
argued that IFNy forms the central determinant of all immunological pathways involved 
in protection against malaria.
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Figure 1. Life-cycle of malaria parasites and effector functions of IFNy
Infective sporozoite-stage parasites are unwittingly injected into the skin of human hosts 
by blood-feeding mosquitoes, where a proportion are trapped in draining lymph nodes but 
the remainder quickly migrate to the liver. These sporozoites invade hepatocytes, in 
which they mature and multiply intracellularly over 6-7 days without causing symptoms. 
Once fully ripe, these liver-stage schizonts rupture, releasing merozoites into the 
bloodstream which immediately invade erythrocytes (RBCs). These intra-erythrocytic 
parasites multiply asexually over roughly 48 hours into blood-stage schizonts, which 
again rupture releasing a second generation of merozoites which in turn invade new 
RBCs. It is this exponential multiplication cycle that is responsible for the clinical 
symptoms and potentially severe complications of malaria. A small number of blood- 
stage parasites develop into male and female gametocyte forms which can be taken up by 
a second blood-feeding mosquito. Within the mosquito these gametes undergo sexual 
replication, eventually resulting in a new generation of infective sporozoites.
Various effector functions of IFNy, enhancing immunological recognition and elimination 
of the parasite’s different life-cycle stages, are indicated.
Figure modified from [12] with permission.
180
IFNy in immunity against malaria
Table 1: Effects of IFNy on innate and adaptive immune responses against malaria
Function References
Innate immune responses:
Increased production of reactive nitrogen species (iNOS) by liver cells 
against intrahepatic parasites 
Increased production of reactive oxygen (H2O2) and nitrogen species 
(iNOS) by monocytes against blood-stage parasites 
Enhanced phagocytosis of merozoites and pRBC 
Inhibition of gametocyte infectivity to mosquitoes
[22-24]
[25-29]
[26, 30-32] 
[33]
Interplay between innate and adaptive systems:
Pro-inflammatory priming of TLR responses Chapter 3, [34-36]
Up-regulation of MHC class I and II expression [37]
Enhanced antibody-dependent cellular inhibition (ADCI) against blood 
stage parasites
[21]
Adaptive immune responses:
Increased Th1/Th2 ratio amongst T cells
Class switching by B cells to cytophilic antibody isotypes
Enhanced induction of cellular (central) memory responses
[38]
[39]
[40, 41]
But what host and parasite factors determine those responses and what is the hard 
evidence for a protective role of IFNy responses? Most importantly: how can we 
exploit those factors to rationally design an effective malaria vaccine? In this review we 
first examine the molecular pathways underlying the induction of IFNy responses, the 
various potential cellular sources of IFNy, their differing requirements for activation and 
their relative contribution to total IFNy production during pre-erythrocytic and blood- 
stage infection. Next we consider the relationship between exposure and IFNy responses 
and discuss immunoregulation by the malaria parasite. Finally, we focus on the wealth 
of evidence for the protective role of IFNy responses and critically discuss any evidence 
for their possible immunopathological (side-) effects. We conclude by identifying a 
number of implications arising from (gaps in) our current understanding of IFNy 
responses, with particular regard to rational malaria vaccine development. Where 
possible we present direct evidence from human studies of P. falciparum infection, 
which we supplement with data from in vitro and murine malaria models.
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Induction and maintenance: host and parasite factors determine the 
magnitude of IFNy responses against malaria parasites
Involvement of PRRs in the induction of IFNy responses against pRBC
For many pathogens initial recognition takes places through innate pattern-recognition 
receptors (PRRs) on myeloid cells that recognize pathogen-associated molecular 
patterns (PAMPs). The best studied example of this is the recognition of the lipid A 
component of Gram-negative bacterial lipopolysaccharide (LPS) by Toll-like receptor 
(TLR)-4 [42]. Ligand binding to TLR-4, as for most other TLRs, leads via MyD88 (a 
common adapter molecule shared with the IL-1b and IL-18 signalling pathways [43, 
44]) to NF-kB activation and eventually pro-inflammatory cytokine production (e.g. IL- 
1b, IL-12 and TNFa) by myeloid cells. These serve to recruit and activate lymphocytes 
which in turn produce Th1-type (e.g. IFNy) or Th2-type (e.g. IL-4) cytokines.
With regards to Plasmodium, glycosylphosphatidylinositol anchors of membrane-bound 
P. falciparum  proteins are recognized by TLR-2 and to a lesser extent TLR-4 in vitro 
[45]. Furthermore, TLR-9 has been shown to recognize components of pRBC, although 
some controversy exists as to the precise ligand involved, with one group identifying 
haemozoin [46-48] and another haemozoin-associated DNA [49]. However, the above 
in vitro studies employed only transfected HEK cell lines or purified murine 
macrophages and measured upstream cytokines, e.g. TNFa; downstream IFNy or even 
IL-12 production was not assessed. In contrast, in vitro IFNy production by murine 
natural killer (NK) cells in response to pRBC was inhibited when MyD88-/- or IL-18R- 
/-, but not TLR-1-/-, TLR-2-/- or TLR-9-/- macrophages were used as APCs [50], 
suggesting the requirement of the IL-1/IL-18 signalling pathway, but not individual 
TLRs, for the IFNy response to whole parasites. A similar picture emerges from in vivo 
studies investigating the contribution of TLR-pathways to malaria susceptibility in 
murine models: these tend to show reduced serum or ex vivo IFNy production in 
MyD88- or IL-18-KO mice, but not in TLR-2-, TLR-4- or TLR-9-deficient animals 
[51], [52], [53], although elsewhere these same authors do report TLR-9-dependency for 
the ex vivo IFNy response to malaria by murine splenocytes [46, 53]. Part of these 
discrepancies may be due to differences in TLR/MyD88 pathway usage between mouse 
strains used [54]. Nevertheless, whereas the IL-1/IL-18 signalling pathway is clearly 
involved, individual TLRs, with the possible exception of TLR-9, appear thus to play 
little role in the induction of IFNy responses by pRBC in animal models. However, 
since nothing was known about the role of human Toll-like receptors in this process, we 
undertook to explore this for the first time (Chapter 2). We show that TLR-2, TLR-3 
and TLR-4 are not important in the recognition of pRBC by human PBMCs. In 
contrast, we demonstrate that human TLR-9 signalling does contribute to the IFNy 
response against pRBC. Remarkably, although not required for recognition of pRBC, 
we show in Chapter 3 that TLR-2 and TLR-4 signalling pathways are themselves 
modulated by malaria parasites towards more pro-inflammatory responses, a 
phenomenon unique amongst common human pathogens. In an interesting final twist,
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this modulation was itself shown to be IFNy-dependent [36]. The potential 
consequences hereof for parasite and host remain unresolved.
In addition to the TLRs, other PRRs are known to contribute to pathogen recognition, 
including the nucleotide-binding oligomerisation domain containing (NOD) proteins 1 
and 2, C-type lectins, mannose receptor, dectin-1 and dectin-2, amongst others. Very 
little is known about their importance in pRBC recognition, although it was recently 
shown that NOD-1 and NOD-2 contribute to cytokine production, including IFNy, in a 
murine malaria model [55]. It has furthermore been suggested that haemozoin is also 
recognized via the NALP-3 inflammasome and uric acid production [56-58]. Finally, 
the scavenger receptor CD36 has been implicated in the binding to, and recognition of, 
pRBC by APCs [59-61]. In Chapter 2 we extended our understanding of pRBC 
recognition by demonstrating the role of the mannose receptor in the induction of IFNy 
responses. Thus the pattern recognition pathways underlying the IFNy response to 
blood-stage malaria parasites are starting to be unravelled, although the overall picture 
remains incompletely elucidated. To our knowledge, what is more, no studies have yet 
described the recognition by PRRs of other parasite life-stages, e.g. sporozoites and 
gametocytes.
Cellular sources of IFNy against different parasite life-stages
AßT cells, y5T cells, NKT cells and NK cells have all variously been shown to produce 
IFNy in response to Plasmodium parasites, although mechanisms of activation differ 
amongst these lymphocyte subsets and their relative magnitude varies between parasite 
stages. Delineating these various pathways and their potential contribution to the total 
magnitude of IFNy production is an important step towards understanding protective 
cellular immunity against malaria.
Pre-erythrocytic stages - Classical ‘adaptive’ (aß)T cell responses are dependent on 
presentation of cognate antigen in the context of either MHC class I or II molecules. 
CD8+ T cells recognise parasite-infected hepatocytes in the context of MHC class I 
presentation [62], leading to IFNy production (e.g. [63]), but first require priming by 
cross-presenting DCs in skin-draining lymph nodes [64, 65]. CD4+ T-cells also 
recognise pre-erythrocytic antigen, in MHC class II context [66-68]. In addition to aßT 
cells, y5T responses have been shown to contribute to liver-stage protection [69] and 
NKT cells can inhibit intrahepatic parasite development through IFNy production [70]. 
Finally, NK cell IFNy responses have been demonstrated against both sporozoites [71] 
and parasitized hepatocytes [72, 73]. Thus considerable redundancy appears to exist 
between cellular sources of IFNy against pre-erythrocytic parasite stages, but the 
relative importance of these various lymphocyte subsets for protection in humans 
remains unresolved (reviewed in [15]).
Blood-stage - The cellular source of IFNy responses against intra-erythrocytic parasites 
at first appears to form an immunological blind-spot. Whereas CD4+ T cells recognise 
malaria antigen phagocytosed and presented on MHC II molecules by professional
183
Chapter 9
APCs, it was generally believed that CD8+ T cells cannot respond to pRBC. However, 
it was recently demonstrated in murine malaria models that blood-stage infection can 
generate parasite-specific CD8+ (cytotoxic) T cell responses, following cross­
presentation by dendritic cells [74, 75]. Intriguingly, it has been suggested that such 
blood-stage infection-induced CD8+ T cells may be involved in protection against liver- 
stage, but not blood-stage infection [76]. Furthermore, both CD4+ and CD8+ pRBC- 
responding T cell clones have been isolated from previously exposed humans [77].
Figure 2. Induction and cellular sources of IFNy against malaria parasite stages
A. NK cells directly recognise free sporozoites [71].
B. In skin-draining lymph nodes, sporozoites invade or are taken up by DCs, which in 
turn prime CD4+ T cells (presentation on MHC-II) [67] and CD8+ T cells (cross­
presentation on MHC-I) [64, 65].
C. Primed CD8+ T cells directly recognise infected hepatocytes [62, 63]; primed CD4+ T 
cells respond to antigen presented by local APCs [66-68]. NK cells are activated in a 
bystander fashion [72, 73].
D. In blood or spleen yST cells directly recognise pRBC phosphorylated antigens without 
the need for APC presentation [86, 87]. APCs (monocytes and/or mDCs) recognise 
pRBC ligands through PRRs (e.g. haemozoin [46] and/or associated parasite DNA [49] 
via TLR-9). CD4+ and CD8+ recognise pRBC antigens presented by DCs in respectively 
MHC-II [77] and (cross-presented) MHC-I context [74, 75]. NK cells directly recognise 
pRBC [92], but require help from APCs and T cells for full activation [50, 91].
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y5T cells too can recognize malaria antigens in MHC class II [78, 79] or MHC class I 
[80] context, inducing proliferation and IFNy production [81-83]. Some studies have 
suggested this response to be IL-2 dependent [80, 84, 85], implying a crucial accessory 
role for CD4+ T cells. However, the ySTCR is also capable of directly recognising non­
peptide antigens, particularly phosphoantigens, without MHC presentation. Thus in 
contrast to apT cells and NK cells, y5T cells can respond to pRBC in the absence of 
APCs [86, 87], although supplementation with APC-derived cytokines, e.g. IL-12, can 
further augment y5T cell IFNy production. (Reviewed in [88]).
NK cells are considered innate lymphocytes as the first line of defence (reviewed in 
[89]) and potent early producers of IFNy in response to pRBC in vitro, for which they 
are dependent on IL-12 and IL-18 [90]. Myeloid antigen-presenting cells presumably 
form the source of the required IL-12 and IL-18, since the presence of these cells is 
required for IFNy response by NK cells in vitro; exactly which APC subsets are 
required remains somewhat unclear with some authors reporting that only monocytes 
suffice [50] while others also demonstrate this ability in myeloid dendritic cells (mDCs) 
are also capable [91], with the requirement of contact-dependent signals between APCs 
and NK cells in addition to soluble (cytokine) signals [91]. Besides these accessory 
signals, NK cells must make direct cell-contact with pRBC for an IFNy response [92, 
93]. Intriguingly, heterogeneity in killer cell Ig-like (KIR) receptors appears to correlate 
with NK IFNy responses to pRBC [92, 94], although this does not necessarily mean 
these receptors interact directly with pRBC, which lack MHC class I molecules. More 
recently it was also proposed that NK cells recognise the parasite surface protein 
PfEMP-1 via another NKR, NKp30 [95]. Finally, IFNy induction by pRBCs in NK 
cells is also IL-2 dependent [91] and we (Chapter 4) and others [96] have recently 
demonstrated the absolute dependency of NK cells on additional helper signals from 
CD3+ T-cells, bringing into doubt their status as ‘innate’ responders in malaria. An 
overview of the various cellular pathways to IFNy against different parasite stages is 
provided in Figure 2.
The relative contribution of these different lymphocyte subsets to total IFNy production 
in response to pRBC needs to be further explored, however. In in vitro stimulation 
experiments with PBMC from malaria-naïve donors, the majority of IFNy-producing 
cells have respectively been identified as NK cells [50, 90], apT cells [85, 97, 98] and 
y5T cells [82] including intriguing NK-like y5T cells [83]. Whether these 
inconsistencies represent differences between donors or in experimental setups is not 
fully clear, although it is evident that in most donors all three subsets do contribute to 
the total response. Less still is known about in vivo sources of IFNy during malaria 
infection in humans or in re-call responses from previously-exposed donors. Plasma 
samples taken from malaria-naïve volunteers undergoing experimental malaria infection 
revealed soluble granzyme induction in addition to IFNy and other cytokines, 
suggesting an early role of NK cells [99] and in C hapter 5 we show that during and 
following infection not just apT cells, but also y5T cells and NK cells contributed to the 
overall increase in in vitro IFNy responses against pRBC. In a naturally-exposed
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healthy paediatric populations the majority of IFNy producing lymphocytes in vitro 
were NK-like y5T cells [100] and amongst children recovering from malaria y5T cells 
were also the foremost ex vivo producers of IFNy [101].
Genetic variability in IFNy responses
The burden of malaria has exerted strong selective pressure on the genetic make-up of 
humans from malaria-endemic areas [102]. We and others have shown that malaria has 
in particular helped to shape both the adaptive [103] and innate immune response [104­
106] of endemic populations. Genetic variation continues to influence susceptibility to 
malaria to this day (reviewed extensively elsewhere [107, 108]). The review here will 
limit itself to genetic polymorphisms affecting the IFNy response against malaria 
parasites.
In Chapter 7 we show that IFNy responses can differ at not only the individual, but also 
at the ethnic level, strongly suggesting genetic regulation, although the chromosomal 
loci underlying these differences have not yet been elucidated.
Prime candidates would be polymorphisms in the IFNy gene itself, but only few have 
been described. A CA microsatellite repeat polymorphism in the gene’s first intron 
[109] linked to a single nucleotide polymorphism (SNP) (+874T/A) that coincides with 
a putative NF-kB binding site [110] has been associated with enhanced IFNy production 
potential [111, 112], but in the only study to assess this, no association with in vitro 
IFNy production against malaria antigen was found [113]. A polymorphism in the 
promoter region of IFNy (-183G/T) that creates a putative additional AP-1 binding site 
and also increases gene transcription [114, 115], was associated with protection from 
cerebral malaria, as were higher circulating IFNy levels [116], although no direct 
correlation was assessed between genotype and plasma IFNy in this study.
Genetic variability in upstream inducers of IFNy may also affect cytokine responses. 
Two non-coding loci in the gene encoding the p40 sub-unit of IL-12 (an A/C SNP at 
position +16974 in the 3’UTR associated with lower IL-12 expression [117] and IL- 
12Bpro, a complex GC/CTCTAA indel polymorphism in the promotor region believed 
to result in lower IL12p40 and subsequently lower IL12 production in heterozygotes 
[118-120] - although the picture may be more complex still [121-123]) have both been 
associated with cerebral malaria in most [124-127] but not all [124] populations tested, 
although no direct effect on parasitaemia was found [128]. Interestingly, in the only 
study in which this was assessed, these polymorphisms were associated with inverse 
effects on circulating IL12p40 and IFNy [127]. Caspase-12 exists in two allelic forms: 
whereas the S-variant is prematurely terminated during translation, the L-variant 
encodes a full-length protein, thought to inhibit caspase-1 mediated activation of IL-18 
[129-131], itself another upstream inducer of IFNy. In Chapter 8 we show that caspase-
12 S/L heterozygotes surprisingly produce stronger in vitro IFNy responses than S/S 
homozygotes. However, S/L heterozygotes also produce stronger IL-10 responses and 
overall their IFNy /IL-10 ratio tends to be lower. The significance of the persistence of 
the L-variant in African populations nevertheless remains uncertain, since caspase-12 
genotype is not associated with susceptibility to malaria (Chapter 8).
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Retracing one step further, genetic diversity in parasite recognition pathways can effect 
subsequent IFNy induction. SNPs in TLR-9 of children with cerebral malaria were 
associated with serum IFNy levels, for example [132]. Whereas variation in killer 
immunoglobulin-like receptors KIR has been shown to effect innate IFNy responses by 
NK cells [92, 94], little association was found between MHC-II alleles and IFNy 
production (by T cells) in naturally-exposed populations [133]. Despite potentially 
affecting opsonisation, neither RBC surface expression of complement receptor-1 (CR- 
1), nor SNPs in CR-1 were associated with plasma IFNy levels in malaria patients 
[134]. Finally, stronger in vitro IFNy responses against malaria antigen were seen in 
HbAS (sickle cell trait) carriers than in wildtype HbAA patients during infection, which 
the authors speculated was associated with lower parasitaemia in this group [135].
Although genetic diversity in downstream pathways signalling pathways will not affect 
IFNy expression per sé, it may modulate responses to IFNy production. An SNP in the 
promoter of the IFNy receptor-1 (-56T/C) reduces its expression [136] and was 
associated with protection from cerebral malaria in heterozygote carriers in one [137] 
but not two other [136, 138] studies. A second polymorphism in the IFNy receptor-1 
promoter (a TT deletion at -470/471) has cell-specific effects on its expression [139] 
and may also protect against CM [137]. Finally interferon regulatory factor 1, an 
upstream inducer of type I  interferon production, it is itself induced by IFNy; 
polymorphisms in IRF-1 were associated with parasite density and disease severity in 
one [140] but not three other African populations [141].
Dynamics of IFNy responses in relation to exposure
A major factor affecting the magnitude of IFNy responses against malaria is their 
modulation in relation to exposure. Low-level IFNy responses to pRBC have been 
repeatedly demonstrated in malaria-naïve donors [60, 83, 90, 98, 142, 143] and have 
variously been ascribed to innate responses, non-specific polyclonal responses to super­
antigens, or cross-reactive responses by T cells primed by environmental antigens 
(discussed in [144]). In contrast, re-call responses are markedly increased in malaria 
patients following even a first clinical episode [145-148]. Indeed, even sub-clinical 
infections are sufficient to induce robust IFNy responses to pRBC in previously naïve 
donors ([19, 41], Chapter 6).
In general, immune responses to malaria are commonly believed to be short-lived 
following exposure, based mainly on the short half-life of specific antibodies [149-151] 
(reviewed in [152]), an explanation which is often offered for the slow development of 
immunity. It would appear that IFNy responses to individual antigens are indeed either 
relatively short-lived, i.e. declining within a few years of exposure [153, 154], or at least 
unstable [155-159]. However, even before the characterisation of IFNy, Wyler & 
Oppenheim demonstrated that cellular proliferative responses to crude whole parasite 
antigen could be detected in donors up to 15 years following a single malaria infection 
[145]. More recently, Todryk et al found undiminished IFNy effector responses at 3 
months post-infection in previously naïve volunteers [41] and in C hapter 5 we show
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that such IFNy recall responses to whole pRBC remain practically undiminished at least
13 months post-infection. Thus, although responses to individual antigens or epitopes 
may be unstable, possibly representing in vivo fluctuations in individual T cell clones, 
the total IFNy response to pRBC can remain remarkably long-lived.
It comes somewhat of a surprise therefore to find that adult residents of highly endemic 
regions produce markedly lower IFNy responses against pRBC than residents of low- 
endemic regions or indeed even non-exposed donors [147, 160] and that plasma IFNy 
levels during clinical malaria episodes are relatively lower in semi-immune than in non­
immune patients [161, 162]. Depressed responses in highly-exposed individuals can be 
rescued by supplementation of exogenous IL-2 [163]. Furthermore, these defective 
responses appear to be antigen-specific [147, 160], suggesting either clonal elimination 
or specific suppression by regulatory T cells [164, 165]. In either case, down-regulation 
of pro-inflammatory responses has been proposed to be a beneficial adaptation by the 
host to avoid immunopathology due to repeated or chronic malaria infections [166], 
although as we shall see there is limited evidence to support this hypothesis with 
regards to IFNy in humans.
Modulation of IFNy responses by the parasite
Various mechanisms by which malaria parasites may actively suppress cellular immune 
responses have been reviewed elsewhere [166, 167]. Suppression of (protective) pro- 
inflammatory responses may be an active strategy pursued by malaria parasites in order 
to prolong their own survival in the host. Indeed, suppression of proliferation (e.g. 
[168-170]) and IFNy production [146, 171] during clinical malaria episodes is a 
common, although not universal [172], finding. Although it is possible that this may in 
part reflect an in vitro artefact due to in vivo sequestration of parasite-specific 
lymphocytes during acute infection [173-175], remaining cells also appear generally 
hyporesponsive [101, 176]. Evidence that repeated or chronic parasitaemia also 
suppresses IFNy responses has arisen from longitudinal field studies [157] and long­
term chemoprophylaxis studies [177]. Thus it appears that down-regulation of cellular 
responses in general, and IFNy in particular, not only is an active strategy pursued by 
the parasite, but that this strategy is so central to its survival that it has evolved multiple 
mechanisms by which to achieve it.
Given this generalisation, it comes as somewhat of a surprise that malaria parasites are 
also capable of pro-inflammatory modulation of innate (TLR-mediated) cytokine 
responses both in vivo and in vitro and even of in vitro IFNy responses to pRBC 
(Chapter 3). Interestingly, this priming appears itself to be IFNy-dependent [36]. 
Presumably this represents a temporary state early during infection before chronic 
parasitaemia establishes anti-inflammatory countermeasures, since TLR responses tend 
to be down-regulated at later time points [178]. Alternatively, inflammation at these 
early time points may be relatively beneficial to the parasite, e.g. by upregulating 
endothelial cell adhesion molecules needed for sequestration [179-181].
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Due to distinct biological, immunological and pathological characteristics for each stage 
(Figure 1), most research on immunological correlates of protection in malaria has 
focussed either on pre-erythrocytic or erythrocytic stages separately. A wealth of data 
on both stages exists from both murine malaria models and human studies. Here we 
will briefly discuss the consensus derived from murine immunological studies and focus 
primarily on human data, including experimental malaria infections, cross-sectional and 
longitudinal field studies and efficacy data from vaccine studies.
Pre-erythrocytic stages
Pre-erythrocytic protection can be induced in murine malaria models by various 
immunisation strategies including irradiated sporozoites, recombinant peptide or 
nucleic-acid vaccines. Although immunological effector mechanisms vary slightly 
between approaches and between inbred mouse strains e.g. [23, 62, 72, 76, 182-184], 
the core elements tend to consist of CD8+ and/or CD4+ T cell and IFNy-mediated 
responses against infected hepatocytes (reviewed in [15]), a large but definable 
threshold of which is predictive of protection [185]. Indeed, protection against pre- 
erythrocytic malaria in naïve mice, rats and monkeys can also be induced by simply 
injecting exogenous IFNy [22, 186] or IL-12 [187, 188].
Some of the most compelling evidence for the protective role of IFNy responses in 
humans comes from experimental malaria infections. The strength of these studies lies 
in the tight control exercised over previous exposure, timing and measure of infection, 
factors which often confound field-based studies. Following a primary infection, high 
IFNy responses are associated with reduced asexual parasite multiplication rates, 
although eventually all volunteers do develop patent parasitaemia [189].
Since the days of malaria therapy, however, sterile immunity against malaria can be 
induced in previously unexposed humans. The best-studied approach has been through 
inoculation of irradiated sporozoites by repeated mosquito bite [190]. These radiation- 
attenuated sporozoites arrest during the liver-stage and induce both humoral (e.g. [191]) 
and CD8+ [192] and CD4+ [68] cytotoxic T cell and IFNy responses against sporozoite 
and liver-stage antigens [193, 194]. Nevertheless, multiple rounds of immunisation, 
equating to at least 1000 infected mosquito bites, are required to generate sterile 
protection in >90% of the volunteers.
In an attempt to improve upon this protocol, we immunised volunteers with patent 
sporozoites under cover of the blood schizonticidal drug chloroquine, which leaves 
development of liver stages unaffected (Chapter 6). This approach exposes volunteers’ 
immune systems to the full course of intrahepatic development in addition to the first 
cycle of intra-erythrocytic development. Following 3 rounds of immunisation (totalling 
36-45 infectious bites), sterile protection against subsequent patent sporozoite challenge 
was achieved in all volunteers, none of whom developed detectable blood-stage 
parasitaemia. Interestingly, robust cellular responses were detected in all immunised
Evidence for protection
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volunteers, consisting of pluripotent effector memory T cells which produced IFNy in 
addition to TNFa and IL-2 in response to pRBC in vitro, suggesting an important role 
for stage-transcending cellular immunity. In contrast, antibody responses against pre- 
erythrocytic and blood-stage antigens were detectable at low titres in only 8/10 and 3/10 
volunteers respectively (Chapter 6).
Many field studies in malaria-endemic areas have sought to correlate (cellular) immune 
responses with protection against malaria. The most robust of these have included 
multiple assay points and a prospective follow-up, while cross-sectional surveys and 
other single-point measurements can suffer from the commonly observed temporal 
variability in individual immune responses to malaria [155-159]. Furthermore, it can 
sometimes prove difficult to differentiate between pre-erythrocytic and blood-stage 
protection, particularly in clinical studies.
Initial studies measuring only plasma IFNy levels in malaria patients found a correlation 
with protection against reinfection [195], but results from subsequent studies remained 
equivocal, either failing [196-198] or succeeding [199-202] to demonstrate an 
association between clinical protection and IFNy responses to selected pre-erythrocytic 
antigens. The explanation for these discrepancies may be related to obvious differences 
in setting, endemicity, age and assay techniques. Alternatively this outcome may 
represent an insufficiently measurable effect of such individual responses amidst the full 
spectrum of anti-parasite immune reactivity. Simple ex vivo assays, representing 
effector (memory) responses, may be less representative of in vivo protection than 
cultured assays representing central memory responses, as has been shown for the 
vaccine candidate TRAP ([156] vs. [203], respectively) and CSP [202].
Associations between IFNy responses to individual pre-erythrocytic antigens and 
clinical protection have also been studied in phase IIa and phase IIb malaria vaccine 
trials, in particular in the context of RTS,S, a pre-erythrocytic vaccine candidate 
containing epitopes from the circumsporozoite (CS) protein coupled to hepatitis B 
surface antigen (HBsAg) particles in a proprietary oil-in-water adjuvant [204]. In an 
initial phase IIa trial prolonged IFNy responses by CD4+ and CD8+ T cells against the 
CSP associated with protection upon experimental challenge [205]. Although in 
another study only a trend was seen for higher CSP-specific ex vivo and cultured 
ELISPOT IFNy responses in PBMC from protected volunteers [206], a review of 
subsequent phase IIa trials confirmed that higher IFNy ELISPOT counts were 
consistently observed in protected volunteers [207]. Results from phase IIb field studies 
have been slightly less forthcoming, but nevertheless PBMC cultured IFNy ELISPOT 
responses to one CSP epitope were associated with protection in Gambian adults [202] 
and a trend was seen for higher CD8+ IFNy responses to CSP in protected Mozambican 
infants [208].
A phase IIa trial of LSA-1 [209] in a similar adjuvant system induced robust IFNy recall 
responses, but unfortunately failed to induce protection against challenge in malaria- 
naïve volunteers. More success has been achieved with the vaccine candidate ME-
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TRAP, administered in the form of prime-boost regimens with attenuated vaccinia and 
adenoviral vectors. This vaccine has been shown to induce protection against challenge 
in a proportion of naïve volunteers, which correlates with IFNy responses by cultured, 
but not ex vivo, ELISPOT [210, 211].
Thus sufficiently strong IFNy responses against selected pre-erythrocytic antigens are 
associated with protection against (clinical) malaria episodes.
Blood-stage
Cellular responses including IFNy are also important in controlling blood-stage 
parasites in murine models (reviewed in [212, 213]). Perhaps the most clear-cut 
evidence for this arises from infections in IFNy -/- [27, 214, 215] and IFNy-receptor 
(IFGR)-/- mice [216], who fail to control the initial wave of parasite multiplication 
following blood-stage challenge and rapidly succumb to hyperparasitaemia. A similar 
failure to control parasitaemia is observed in immunocompetent animals in which IFNy 
is depleted during infection [217-219].
In order to assess blood-stage-specific protection in human volunteers, Pombo and 
colleagues [19] repeatedly infected volunteers with sub-microscopic inocula of blood- 
stage parasites which were subsequently drug-cleared before they became patent. These 
inoculations induced strong CD4+ T cell-mediated responses against pRBC, including 
proliferation and IFNy production, but no measurable antibody responses. The 
volunteers were subsequently found to be protected against a similar blood-stage 
challenge. This landmark study was thereby the first to demonstrate a protective effect 
of cell-mediated immune responses against blood-stage malaria parasites in humans 
[19], although a concomitant effect of residual circulating antimalarial drug 
concentrations could not be excluded [220].
Several field studies have also assessed cellular correlates of protection against blood- 
stage malaria by measuring IFNy production to whole parasites (i.e. live pRBC or 
pRBC lysate) in whole blood or PBMC assays. With the exception of one small 
retrospective study [221], other prospective studies have consistently found pRBC- 
induced IFNy responses to be associated with reduced risk of fever and clinical malaria 
episodes [100, 222, 223]. Similarly, we found pRBC-specific IFNy responses to 
correlate with protection against parasitaemia at both an ethnic and individual level 
(Chapter 7). Associations between protection and IFNy responses to individual 
(vaccine candidate) blood stage antigens are not conclusive: whilst most studies failed 
[224-229], two other studies did show such associations [199, 230].
In conclusion, broad anti-parasite IFNy responses, but not necessarily responses to 
individual blood-stage antigens, are associated with protection against (clinical) malaria 
episodes.
Evidence for IFNy in inflammation and immunopathology
Clinical malaria is characterised by strong pro-inflammatory responses, in particular the 
production of IL-10, IL-6 and TNFa endogenous pyrogens which induce the disease’s
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characteristic of high fever. Over-production of these cytokines has also been 
implicated in the immunopathology underlying various forms of severe malaria, in 
particular cerebral malaria [104, 231-234]. IFNy in itself is not a pyrogen, but can 
induce downstream pyrogenic cytokines, in addition to its many other 
immunomodulatory functions (Table 1). IFNy has been shown to be involved in many 
[215, 235-238], but not all [239-242] murine models of cerebral malaria and similar 
discrepancies exists for other forms of severe disease in rodent models [243-245]. What 
then is the evidence that IFNy contributes to pyrexia and more importantly, to 
immunopathology in human malaria? Studies in malaria-naive volunteers have indeed 
indicated (temporal) correlations between IFNy responses and fever during 
experimental infection [189, 246]. Most [161, 247-250] (but not all [162, 251, 252]) 
case-control studies have similarly measured higher plasma IFNy levels in symptomatic 
malaria patients compared to healthy or uninfected controls. Furthermore, ex vivo IFNy 
responses to blood-stage exoantigens [225], but not whole pRBC [222], have 
prospectively been associated with susceptibility to pyretic malaria episodes. Thus it 
seems likely that IFNy does indeed contribute to inflammation and fever in malaria. 
However, the evidence is less clear-cut for an association between IFNy responses per 
se (as opposed to TNFa and other pro-inflammatory cytokines) and manifestations of 
severe malaria. Whereas several case-control studies found higher plasma IFNy levels 
in severe malaria (SM) compared to uncomplicated malaria (UM) patients [127, 253­
258], various similar studies have found higher plasma levels of TNFa [248, 259-262], 
IL-2R [263], IL-6 [259, 264], IL-1a [260] or IL-10 [262], but not IFNy in SM 
compared to UM patients. Furthermore, plasma levels of IL-12 [262, 265-268] and IL- 
18 [266-268], which both induce IFNy, have been found to be lower in SM than UM 
patients. Finally, a higher proportion of children with UM registered ex vivo IFNy 
responses to malaria antigens, although absolute cytokine concentrations did not differ 
between UM and SM groups [199].
Any association between IFNy and specific manifestations and outcome of severe 
malaria remains similarly unclear: whereas plasma levels of IFNy were lower in Indian 
patients with cerebral malaria than in patients with either other forms of severe malaria 
or uncomplicated malaria [262], no such difference was seen in Burundi [269]. Post­
mortem studies have both identified [270, 271] and failed to identify [270, 272] elevated 
IFNy in the brains of cerebral malaria victims. The largest study to date in 287 
Vietnamese patients with severe disease, found plasma levels of TNFa and IL-6 and IL- 
10, but not IFNy, to be positively correlated with the risk of death. Amongst patients 
with various manifestations of severe disease, high plasma IFNy levels were particularly 
associated with hyperparasitaemia and to a lesser extent with jaundice and shock, but 
not with renal failure, and negatively correlated with cerebral malaria [273]. Similarly, 
amongst Malian children with cerebral malaria, plasma IFNy levels, and the prevalence 
of the IFNy promoter polymorphism -183G/T (which increases IFNy gene transcription 
[114, 115]), were lower than in matched UM controls [116].
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Similarly, whereas some studies have found elevated plasma levels IFNy associated 
with (severe) malarial anaemia [274, 275], other studies found no such association [222, 
276] or even an inverse relationship between IFNy responses and anaemia [277]. 
Finally, IFNy has been associated with adverse pregnancy outcome [278, 279], 
particularly in primigravidae, but again this has not been a universal finding [280, 281]. 
Some caution must be exercised when interpreting these findings, as cross-sectional 
immunological measurements, in particular plasma cytokine levels during infection, 
may represent both cause and effect of clinical presentation. Thus, although IFNy 
responses appear to be correlated with symptomatic infection, the relationship between 
IFNy responses and manifestations of severe disease appears to be much more complex 
and will require further dissection. Nevertheless, the greater part of evidence from 
human studies would at least suggest a negative association between IFNy responses 
and cerebral malaria.
Implications for vaccine development
Given this evidence for the protective effect of IFN y against parasitaemia, developing a 
malaria vaccine aimed at reproducing such IFNy responses would appear to be 
desirable. Whether ‘the stronger, the better’ in terms of IFNy responses should be the 
ultimate goal of malaria vaccine development, must eventually depend on a more 
precise understanding of the complex relationship between IFNy and manifestations of 
severe disease. Nevertheless, in designing any such vaccine strategy, a number of 
lessons can be drawn from what we currently understand about what determines the 
magnitude of IFNy responses against malaria.
Induce multiple cellular pathways and a broad IFNy response
In addition to traditional apT cells, NK cells and y5T cells form important tappable 
sources of IFNy. Their IFNy response against malaria parasites is induced through 
distinct pathways which can be exploited in vaccine design, i.e. by the inclusion of 
phosphoantigens to activate y5T or whole parasites to activate IFNy production by NK 
cells. Although generally considered ‘innate’ lymphocytes, we (Chapter 4) and others 
[282, 283] have clearly demonstrated ‘memory-like’ patterns in the IFNy responses of 
these cells, supporting their rational inclusion in vaccine design. Exploiting such 
alternative cellular pathways furthermore bypasses parasite-mediated inhibition of DC 
function and its concomitant suppression of IFNy responses in apT cells.
The problem of short-lived or erratic responses to individual antigens can be partially 
overcome by inducing a broader response, e.g. by whole parasite-based vaccines. These 
expose the host’s immune system to the full palette of parasite antigens, ideally also 
inducing IFNy against multiple life-stages. Furthermore, whole parasites contain ‘built- 
in adjuvant’, further augmenting overall IFNy responses [46]. Indeed whole parasite- 
based vaccines induce robust IFNy responses in humans ([19, 190], Chapter 6) and 
have generally proven more successful than sub-unit vaccines [284-287].
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Prevent exposure-mediated suppression of IFNy responses
Since suppression of IFNy responses in relation to exposure does not seem to serve the 
host, but rather appears solely a survival strategy by the parasite, the question arises 
whether/how such suppression can be avoided in the context of vaccine-induced IFNy 
responses. In other words, does suppression of IFNy responses automatically follow 
from repeated exposure and can we design strategies to bypass it? Further field studies 
addressing the mechanism(s) underlying immune suppression in relation to exposure 
will be necessary, but are complicated by the fact that in endemic settings the effect of 
exposure cannot readily be distinguished from the effect of age [288]. Infants’ and 
children’s immune systems function differently from adults’, both quantitatively and 
qualitatively (e.g. [289-291]), and it could be hypothesised that the basis for life-long 
suppressed IFNy responses against malaria is laid in the immature immune systems of 
infants in highly endemic areas [292]. However, only very little is understood about the 
effect of age on (cellular) immune responses to malaria from rodent models [293-295] 
and although IFNy responses against malaria in human children growing up in endemic 
areas tend to be weaker than in adults [159, 201, 296-298], the effect of prior exposure 
in these studies is again hard to distinguish from that of age per se.
One potential approach to answering these related questions would be to study IFNy 
responses in people who become highly exposed to malaria only later in childhood or in 
adulthood, e.g. transmigrants, as has been performed for humoral responses in Javanese 
transmigrants to Irian Jaya [299-301], or in settings of epidemic or resurgent malaria 
such as Madagascar [302].
Concluding remarks
In this review we have shown how IFNy forms a critical component of immune 
responses against both pre-erythrocytic and blood-stage malaria parasites. A wealth of 
evidence supports its protective efficacy against clinical malaria episodes, whereas the 
evidence associating IFNy responses with immunopathology remains equivocal and will 
require further investigation. In the meantime, striving for strong and long-lasting IFNy 
production appears justified as a malaria vaccine strategy and in order to achieve this, 
such vaccines should be designed to induce a broad response via multiple cellular 
pathways. Additionally, the mechanism by which repeated exposure leads to 
suppression of such responses needs to be resolved.
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Summary
Despite welcome signs of reduction in the incidence of malaria in some parts of the 
world since the dawn of the new millennium, P. falciparum  infection in particular 
remains responsible for an intolerable global burden of morbidity and mortality. 
Although the success of rejuvenated vector-control and improved case-management has 
renewed the prospect of ultimately eliminating malaria, it is clear that an effective 
vaccine would not only prevent a great number of cases in the short term but will 
probably also be necessary for optimal control in the long term. However, malaria 
vaccine development has in the past been and still is hampered by an incomplete 
understanding of what constitutes protective immunity against P. falciparum  infection 
in humans (Chapter 1).
Such immunity develops in both naturally-exposed populations and experimentally 
infected volunteers, although the respective mechanisms may differ. Immunity can be 
directed against each of the parasite’s different life-cycle stages (pre-erythrocytic, 
blood-stage and transmission stages), although in practice such sub-divisions may be 
less distinct. Whereas the importance of humoral immune responses against both pre- 
erythrocytic and blood-stage parasites has long-since been delineated, the protective 
role of cellular responses against blood-stage infection in particular is only recently 
starting to be recognised. Central to cellular immunology in general is the cytokine 
IFNy, a master-activator of both innate (e.g. monocyte & natural killer cell) and 
adaptive (T cell) responses. However, many crucial issues in cellular immune responses 
against malaria remain incompletely understood, including: 1. the molecular pathways 
by which parasites are first recognised and lead to cytokine production; 2. the induction, 
persistence and cellular source of IFNy responses following infection; and most 
importantly 3. correlations between such responses and clinical immunity to malaria.
Molecular pathways for recognition of malaria parasites
Pathogenic micro-organisms are first recognised by cells of the innate immune system 
through pattern-recognition receptors (PRRs), such as Toll-like receptors (TLRs). 
Although the potential of variously TLR-2, TLR-4 and TLR-9 to recognise blood-stage 
parasite (pRBC) ligands has been demonstrated in in vitro or animal models, the 
contribution of these and other PRRs to the recognition of whole pRBC and 
downstream cytokine production by human peripheral blood mononuclear cells 
(PBMCs) has not previously been determined. In C hapter 2 we show that human TLR- 
2, TLR-3 and TLR-4 are not important for pRBC recognition by human PBMCs in 
vitro; in contrast, TLR-9 signalling does contribute to IFNy responses against pRBC. In 
addition, we find evidence for the first time of the involvement of another PRR, the 
macrophage mannose receptor, in recognition of pRBCs by human PBMCs.
Signalling through TLR pathways generally leads to negative feedback on those same 
pathways, a phenomenon first described as endotoxin tolerance. In C hapter 3 we 
explore whether a similar down-regulation of TLR signalling occurs following 
recognition of pRBC. Surprisingly, we find instead evidence of the opposite
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phenomenon: the pro-inflammatory priming of TLR responses by malaria parasites, 
both in vitro and in vivo. This priming affects all TLR pathways investigated, but 
particularly TLR-4, and is independent of duration or dose of stimulation. Such pro- 
inflammatory priming of innate immune responses, shown since by others to be IFNy- 
dependent, is a trait unique amongst common human pathogens and may explain to 
some extent the characteristic systemic inflammation associated with clinical malaria 
infection. Whether this phenomenon represents an inevitable consequence of 
haematological infection or a deliberate survival strategy by malaria parasites remains 
to be determined.
Induction, duration & cellular source of IFNy following malaria infection
The slow development of immunity in persons naturally exposed to malaria has led to 
the assumption that protective immune responses against these parasites are either 
difficult to induce or quick to wane. Testing these theories in endemic settings has 
proved problematic, however, due to the inability to control for timing and intensity of 
natural exposure. Experimental human malaria infections (EHMIs) are a safe and well- 
characterised model, in which the measure of exposure can be precisely defined. In 
C hapter 4 we employ this model to explore the development of cellular IFNy responses 
against pRBC following a single clinical malaria infection in previously naive human 
volunteers. We show that such responses are readily induced in all volunteers and are 
produced by both T cells and NK cells. Interestingly, not just ‘adaptive’ T cells, but also 
‘innate’ NK cells appear to exhibit a classical immunological re-call response following 
exposure. However, we show that this memory-like behaviour by NK cells turns out to 
reflect their absolute dependency on T cell help for full activation by pRBC. This 
dependency is mediated in part by IL-2 and calls into question the status of NK cells as 
true ‘innate’ responders in malaria.
In C hapter 5 we extend these findings by exploring IFNy responses induced by single 
or multiple experimental malaria infections in further detail. We demonstrate that 
responses against both blood-stage (pRBC) and pre-erythrocytic (sporozoite) parasites 
are readily induced and long-lived following infection, persisting almost undiminished 
more than a year post-challenge. Not just NK cells and ordinary apT cells, but also 
‘semi-innate’ y5T cells contribute to the overall increase in IFNy production following 
infection, through different mechanisms, but only apT and to a lesser extent y5T 
independently carry true immunological memory. We furthermore identify the 
induction and persistence of pluripotent IFNy- and IL-2-producing effector memory T 
cell populations, believed to be important contributors to protective immune responses. 
The demonstration that cellular immunological responses against malaria parasites are 
both readily induced and persistent in naive volunteers following experimental 
infection, raises important questions about the common absence of such responses in 
naturally exposed populations.
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Evidence for IFNy in protection against malaria
The question furthermore remains, to what extent such cellular re-call responses 
constitute genuine protective immunity. In C hapter 6 we describe a novel method of 
immunisation against malaria in previously unexposed human volunteers. Following 
exposure to three rounds of sporozoite inoculation under chloroquine prophylaxis, a 
drug which permits liver-stage but interrupts blood-stage infection, these volunteers 
were sterilely protected against a subsequent patent malaria infection. Such robust 
protection against malaria is remarkable and has never previously been achieved so 
readily in humans. Analysis of immunological correlates of protection indicated that 
little to no antibody responses were induced by immunisation, but that protection was 
strongly associated with the ability of volunteers’ effector memory T cells to produce 
IFNy in combination with TNFa and/or IL-2 against pRBC in vitro prior to challenge. 
An alternative approach to identifying immunological correlates of protection is by 
studying interethnic differences in susceptibility to disease. The Fulani people of 
Sahelian Africa have long been known to be less susceptible to malaria than other 
sympatric populations. In Chapter 7 we show that this resistance, in particular their 
ability to control parasitaemia, is correlated with robust IFNy responses against PfRBC 
by PBMCs in vitro, both at an ethnic and an individual level. These responses are 
specific to P. falciparum  amongst a panel of common human pathogens and are 
independent of regulatory T cell responses.
The strength of immune responses in general, and IFNy production in particular, can be 
influenced by many host genetic factors. In C hapter 8 we explore the role of one of 
these, caspase-12, an enzyme believed to modulate IFNy production through its effect 
on IL-18 activation. Although we find evidence for preserved heterogeneity in this gene 
in African populations, this simultaneously affects both IFNy and counteracting 
cytokine responses against PfRBC and overall does not clearly influence their balance. 
More importantly, no correlation is observed between caspase-12 genotype and 
susceptibility to malaria in any of three different clinical settings, indicating that factors 
other malaria have presumably maintained this diversity in African populations.
Having demonstrated in two independent settings the strong correlation between cellular 
IFNy responses against PfRBC and clinical protection against malaria, we discuss these 
results in the light of published literature on the topic (Chapter 9). Our review 
highlights the central role of IFNy in cellular immune responses against malaria and 
summarises its various effector functions on both the innate and adaptive immune 
system. Whereas the molecular pathways underlying pRBC recognition by the innate 
immune system are only recently starting to be elucidated, much more is known about 
the contribution of apT cells, y5T cells and NK cells to IFNy responses and their 
respective activation requirements. Although cellular immunity against malaria 
parasites in naive human volunteers appears not only to be readily inducible but also 
persistent following infection, IFNy responses in naturally-exposed populations tend to 
be much weaker. This may reflect an immunoregulatory effect of repeated or chronic 
parasitaemia and is believed to be a strategy evolved by the parasite to down-modulate
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its host’s immune response for enhanced survival. A wealth of evidence from animal 
models and human studies links IFNy to suppression of both pre-erythrocytic and 
blood-stage parasite infection. Furthermore, although conflicting data exists on whether 
excessive IFNy may contribute to immunopathology and some forms of severe disease, 
cerebral malaria in humans at least appears to be averted by IFNy. We conclude that 
striving for robust and long-lasting IFNy responses forms a justified goal in malaria 
vaccine development and end by proposing a number of rational strategies to achieve 
this, in particular the promotion of attenuated-whole-parasite-based immunisation.
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Samenvatting
Ondanks aangename aanwijzingen voor een daling in het vóórkomen van malaria in 
sommige delen van de wereld sinds het begin van het nieuwe millennium, blijft met 
name P. falciparum  infectie wereldwijd verantwoordelijk voor een ondraagbare last aan 
ziekte en sterfte. Hoewel het succes van hernieuwde vector-bestrijdingsprogramma’s en 
verbeterde behandelstrategieën opnieuw vooruitzicht bieden op de uiteindelijke 
uitroeiing van malaria, is het duidelijk dat een effectief vaccin niet alleen op de korte 
termijn een groot aantal slachtoffers zou kunnen voorkomen maar waarschijnlijk ook 
nodig zal zijn voor optimale controle van de ziekte op de langere termijn. De 
ontwikkeling van een malaria vaccin werd en wordt echter belemmerd door een 
onvolledig begrip van wat beschermende afweer tegen P. falciparum  infectie bij mensen 
inhoudt (Hoofdstuk 1).
Zulke immuniteit ontwikkelt zich zowel in op-natuurlijke-wijze blootgestelde 
bevolkingen en in experimenteel-geïnfecteerde vrijwilligers, hoewel de respectievelijke 
mechanismen wellicht verschillen. Immuniteit kan zich richten tegen ieder van de 
verschillende levenscyclus stadia van de parasiet (pre-erythrocytair stadium, bloed- 
stadium en transmissie stadia), hoewel in de praktijk zulk onderscheid minder duidelijk 
kan zijn. Terwijl het belang van antilichaamreacties tegen zowel pre-erythrocytaire als 
bloed-stadium parasieten al jaren bekend is, wordt de beschermende rol van cellulaire 
reacties in de afweer tegen met name bloed-stadium parasieten pas recentelijk 
onderkend. Van centraal belang voor cellulaire immunologie in het algemeen is de 
cytokine interferon-gamma (IFNy), één van de voornaamste aandrijvers van zowel 
aangeboren (bijvoorbeeld monocyt & NK cel) als verworven (T cel) reacties. Vele 
cruciale zaken rondom cellulaire afweer tegen malaria worden echter onvolledig 
begrepen, waaronder: 1. de moleculaire herkenning van parasieten die leidt tot cytokine 
productie; 2. de opwekking, het onderhoud en de cellulaire bron van IFNy responsen bij 
infectie; en van grootste belang 3. correlaties tussen zulke responsen en klinische 
immuniteit tegen malaria.
Moleculaire herkenning van malaria parasieten
Pathogene micro-organismen worden aanvankelijk herkend door cellen van het 
aangeboren afweersysteem via patroon-herkenningsreceptoren (PRRs), zoals Toll-like 
receptors (TLRs). Hoewel van TLR-2, TLR-4 en TLR-9 in vitro of in diermodellen is 
aangetoond dat ze in staat zijn om individuele liganden afkomstig van bloed-stadium 
parasieten (pRBC) te herkennen, is het belang van deze en andere PRRs voor de 
herkenning van intacte pRBC en de daaropvolgende cytokine productie door primaire 
humane witte bloedcellen (PBMCs) niet eerder onderzocht. In Hoofdstuk 2 tonen wij 
aan dat humane TLR-2, TLR-3 and TLR-4 niet betrokken zijn bij de herkenning van 
pRBC door humane PBMCs in vitro; signalering via TLR-9 draagt daarentegen wel bij 
aan IFNy responsen tegen pRBC. Daarnaast vinden wij voor het eerst bewijs voor de rol 
van een andere PRR, de macrofaag mannose receptor, in de herkenning van pRBC door 
PBMCs.
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Signalering via TLRs leidt in het algemeen tot negatieve terugkoppeling op diezelfde 
signaleringsroute, een fenomeen dat voor het eerst werd beschreven bij endotoxine- 
tolerantie. In Hoofdstuk 3 onderzoeken we of een vergelijkbare afzwakking van TLR 
signalering ontstaat na herkenning van pRBC. Verrassenderwijs vinden we echter 
bewijs voor het omgekeerde fenomeen: dat TLR responsen door herkenning van malaria 
parasieten meer ontstekingsgericht worden, zowel in vitro als in vivo. Dit effect wordt 
gezien bij alle onderzochte TLRs, maar vooral TLR-4, en is onafhankelijk van de 
tijdsduur of dosis van stimulatie. Zulke pro-inflammatoire beïnvloeding van aangeboren 
afweerreacties, inmiddels door anderen aangetoond als zijnde IFNy-afhankelijk, is een 
unieke eigenschap van P. falciparum  onder ziekteverwekkers en verklaart mogelijk ten 
dele de kenmerkende lichaamsbrede ontstekingsverschijnselen van klinische malaria. Of 
dit fenomeen een onafwendbaar gevolg is van een bloedbaan infectie, of een 
doelbewuste overlevingsstrategie van de malaria parasiet betreft, moet vooralsnog 
vastgesteld worden.
Opwekking, onderhoud & cellulaire bron van IFNy bij malaria infectie
De langzame ontwikkeling van immuniteit in personen die op natuurlijke wijze aan 
malaria worden blootgesteld, heeft geleid tot de aanname dat beschermende 
afweerreacties tegen deze parasieten hétzij moeilijk op te wekken zijn, hétzij snel weer 
afzwakken. Het uittesten van deze theorieën in endemische gebieden is echter 
problematisch gebleken, voornamelijk door gebrek aan grip op de tijdsduur en mate van 
natuurlijke blootstelling. Experimentele humane malaria infecties (EHMIs) vormen een 
veilig en goed-beschreven model, waarin de mate van blootstelling precies vastgesteld 
kan worden. In Hoofdstuk 4 bestuderen we met behulp van dit model de ontwikkeling 
van cellulaire IFNy responsen tegen pRBC na een enkele malaria infectie in 
vrijwilligers die nooit eerder waren blootgesteld. We tonen aan dat zulke responsen vrij 
gemakkelijk opgewekt worden in alle vrijwilligers en afkomstig zijn van zowel T cellen 
als NK cellen. Merkwaardigerwijs lijken na infectie niet alleen ‘verworven’ T cel 
reacties, maar ook ‘aangeboren’ NK cel reacties een klassiek patroon van 
afweergeheugen te vertonen. We tonen echter aan dat deze schijnbare eigenschap van 
NK cellen in feite blijkt te berusten op hun absolute afhankelijkheid van de hulp van T 
cellen voor volledige activatie door pRBC. Deze afhankelijkheid wordt gedeeltelijk 
bewerkstelligd door interleukine-2 (IL-2) en vraagt om herziening van de gedachte dat 
NK celreacties tegen malaria ‘aangeboren’ zijn.
In Hoofdstuk 5 bouwen we voort op deze bevindingen door de IFNy responsen die 
worden opgewekt na enkele en meervoudige experimentele malaria infecties in meer 
detail te onderzoeken. We tonen aan dat afweerreacties tegen zowel bloed-stadium 
(pRBC) als pre-erythrocytaire (sporozoiet) parasieten gemakkelijk opgewekt worden en 
lang onderhouden worden na blootstelling, met vrijwel onverminderde waarden meer 
dan een jaar na dato. Niet alleen NK cellen en gewone apT cellen, maar ook ‘semi- 
verworven’ y5T cellen dragen bij aan de algehele toename in IFNy productie na infectie, 
ieder via verschillende mechanismen, maar dat alleen apT en in mindere mate y5T 
cellen onafhankelijk afweergeheugen dragen. We wijzen bovendien op het ontstaan en
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onderhoud van parate, meervoudig IFNy- en IL-2-producerende geheugen T cellen, van 
welke wordt gedacht dat ze een belangrijke bijdrage leveren aan beschermende 
afweerreacties. Het bewijs dat cellulaire afweerreacties tegen malaria parasieten in niet­
eerder blootgestelde vrijwilligers na experimentele infectie zowel gemakkelijk op te 
wekken als van lange duur zijn, doet belangrijke vragen rijzen over de frequente 
afwezigheid van zulke reacties in bevolkingsgroepen die onder natuurlijke 
omstandigheden worden blootgesteld aan malaria.
Bewijs voor een rol van IFNy in bescherming tegen malaria
Bovendien resteert de vraag in hoeverre zulke cellulaire geheugenreacties werkelijk 
beschermende afweer vertegenwoordigen. In Hoofdstuk 6 beschrijven we een nieuwe 
manier van inenting tegen malaria in niet-eerder blootgestelde vrijwilligers. Na 
blootstelling aan drie inentingen van sporozoieten onder inname van chloroquine 
profylaxe, een geneesmiddel dat lever-stadium parasieten ongemoeid laat, maar bloed- 
stadium infectie onderbreekt, bleken deze vrijwilligers steriel beschermd tegen een 
volgende volwaardige proefbesmetting met malaria. Een dusdanig krachtige 
bescherming tegen malaria is opmerkelijk en is nooit eerder zo gemakkelijk bereikt in 
mensen. Analyse van immunologische vertolkers van bescherming wees uit dat weinig 
tot geen antilichaamproductie werd opgewekt door inenting; daarentegen was 
bescherming bij de vrijwilligers wel sterk gerelateerd aan het vermogen van hun parate 
geheugen T cellen om voorafgaande aan de proefbesmetting in vitro IFNy in combinatie 
met tumor necrosis factor-alpha (TNFa ) en/of IL-2 te produceren in reactie op pRBC. 
Een alternatieve aanpak om immunologische correlaten van bescherming vast te stellen, 
is het bestuderen van interetnische verschillen in vatbaarheid voor ziekte. De Fulani 
stam van de Afrikaanse Sahel was al langer bekend vanwege lagere vatbaarheid voor 
malaria dan omwonende bevolkingsgroepen. In Hoofdstuk 7 tonen we aan dat deze 
weerstand, vooral het vermogen om parasitemie te bedwingen, op zowel etnisch als 
individueel niveau gerelateerd is aan robuuste IFNy responsen tegen pRBC door 
PBMCs in vitro. Deze responsen zijn specifiek tegen P. falciparum  onder 
veelvoorkomende ziekteverwekkers en zijn onafhankelijk van regulatoire T celreacties. 
De kracht van afweerreacties in het algemeen, en IFNy productie in het bijzonder, kan 
beïnvloed worden door verschillende genetische factoren van de gastheer. In Hoofdstuk 
8 onderzoeken wij in meer detail één van deze: caspase-12, een enzym dat gedacht 
wordt IFNy productie te beïnvloeden door zijn effect op IL-18 activatie. Hoewel we 
bewijs vinden voor aanhoudende heterogeniteit in dit gen in Afrikaanse 
bevolkingsgroepen, heeft dit gelijktijdig effect op zowel IFNy als antagonerende 
cytokine responsen tegen pRBC en beïnvloedt het niet duidelijk de algehele balans 
hiertussen. Van groter belang is dat er geen relatie wordt gezien tussen het genotype van 
caspase-12 en vatbaarheid voor malaria in drie verschillende klinische contexten, wat 
erop wijst dat waarschijnlijk andere factoren dan malaria deze verscheidenheid binnen 
Afrikaanse bevolkingen hebben gehandhaafd.
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Na het aantonen van de sterke relatie tussen cellulaire IFNy responsen en klinische 
bescherming tegen malaria in twee onafhankelijke humane populaties, bespreken we 
deze resultaten in de context van gepubliceerde literatuur over dit onderwerp 
(Hoofdstuk 9). Onze revue onderstreept de centrale rol van IFNy in cellulaire 
afweerreacties tegen malaria and vat haar verschillende effecten op zowel het 
aangeboren als het verworven afweersysteem samen. Terwijl de moleculaire 
mechanismen betrokken bij de herkenning van pRBC door het aangeboren 
afweersysteem pas recentelijk ontdekt beginnen te worden, is veel meer bekend over de 
bijdrage van apT cellen, y5T cellen en NK cellen aan IFNy responsen and hun 
respectievelijke behoeften voor activatie. Hoewel cellulaire afweer tegen malaria 
parasieten in niet-eerder blootgestelde vrijwilligers niet alleen gemakkelijk opwekbaar 
maar ook van lange duur lijkt na infectie, zijn IFNy responsen onder bevolkingen die 
op natuurlijke wijze worden blootgesteld in het algemeen veel zwakker. Dit kan het 
gevolg zijn van een afweer-verzwakkend effect van herhaalde of chronische 
parasitemie, wat mogelijk een strategie vertegenwoordigt van de parasiet om haar eigen 
overleving te bevorderen. Een overdaad aan bewijs uit dierenmodellen en humaan 
onderzoek onderstreept de rol van IFNy in het bedwingen van zowel pre-erythrocytaire 
als bloed-stadium parasieten. Hoewel er enige onenigheid bestaat over de vraag of 
buitensporige IFNy productie kan bijdragen aan immunopathologie en sommige vormen 
van ernstige ziekte, lijkt in ieder geval cerebrale malaria bij mensen afgewend te worden 
door IFNy. We concluderen dat het streven naar robuuste en langdurige IFNy responsen 
een verdedigbaar doel vormt bij de ontwikkeling van een vaccin tegen malaria en 
eindigen door een aantal onderbouwde strategieën voor te stellen om dit te bereiken, 
met name de bevordering van inenting op basis van intacte verzwakt-levende parasieten.
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